Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.

Overview for Request cder_mpl1r_wp169

Request ID: cder_mpl1r_wp169_nsdp_v01

Request Description: In this report we examined counts of new users of sacubitril/valsartan, angiotensin-converting enzyme inhibitors (ACEI), and other angiotensin II receptor blockers (ARB) with heart failure in the Sentinel Distributed Database (SDD).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 9.2.1

Data Source: The study period spanned from January 1, 2015 to July 31, 2019. We distributed the analytic package to 16 Data Partners (DP) on February 27, 2020. Please see Appendix A for a list of the dates of available data for each DP included in this report.

Study Design: We identified cohorts of ACEI, ARB, and sacubitril/valsartan users among cohorts who were 18 years of age or older with heart failure. This is a Type 2 analysis in the Query Request Package (QRP) documentation.

Exposures: Our exposures of interest were ACEI, ARB (other than sacubitril/valsartan), and sacubitril/valsartan. We identified the exposures of interest using outpatient pharmacy dispensing records and National Drug Codes (NDCs). Our analysis included all exposure episodes observed within an eligible member, and individuals could re-enter each of the exposure cohorts to contribute more than one qualifying (index) episode. Please see Appendix B for a list of generic and brand names of medical products used to define exposures in this request.

Cohort Eligibility Criteria: We required eligible members to be continuously enrolled in health plans with medical and drug coverage in the 183 days (6 months) prior to their index date, with a gap in coverage of up to 45 days allowed. We also required eligible members to have evidence of a heart failure diagnosis in any care setting in the 183 days prior to or on the index date of each episode. We included the following age groups in the cohort: 18-44, 45-54, 55-64, and 65+ years, based on age on the index date. See Appendix C for a list of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes used to define heart failure inclusion criteria. Other inclusion and exclusion criteria varied by cohort:

ACEI Cohorts:

1) We excluded members with evidence of a sacubitril/valsartan dispensing date or days supply in the 183 days prior to and on their index date, and members with evidence of a ACEI or ARB dispensing date or days supply in the 183 days prior to their index date.
2) We excluded members with evidence of an ACEI or ARB dispensing date or days supply in the 183 days prior to their index date.
3) No additional exclusion or inclusion criteria.

ARB Cohorts:

1) We excluded members with evidence of a sacubitril/valsartan dispensing date or days supply in the 183 days prior to and on their index date, and members with evidence of a ACEI or ARB dispensing date or days supply in the 183 days prior to their index date.
2) We excluded members with evidence of an ACEI or ARB dispensing date or days supply in the 183 days prior to their index date.
3) No additional exclusion or inclusion criteria.

Sacubitril/Valsartan Cohorts:

1) We required members to have evidence of an ACEI dispensing date or days supply in the 183 days prior to their index date. Excluded members with evidence of an ACEI dispensing date on their index date.
2) We required members to have evidence of an ARB dispensing date or days supply in the 183 days prior to their index date. Excluded members with evidence of an ARB dispensing on their index date.
3) No additional exclusion or inclusion criteria.
4) Excluded members with evidence of sacubitril/valsartan, ACEI, or ARB dispensing date or days supply in the 183 days prior to their index date.

Overview for Request cder_mpl1r_wp169

5) Excluded members with evidence of ACEI dispensing date or days supply in the 183 days prior to and on their index date. Excluded members with evidence of sacubitril/valsartan or ARB dispensing date or days supply in the 183 days prior to their index date.
6) Excluded members with evidence of ARB dispensing date or days supply in the 183 days prior to and on their index date. Excluded members with evidence of sacubitril/valsartan or ACEI dispensing date or days supply in the 183 days prior to their index date.
7) Required evidence of ACEI dispensing date or days supply in the 183 days prior to their index date. Excluded members with evidence of sacubitril/valsartan dispensing date or days supply in the 183 days prior to their index date. Excluded members with evidence of ACEI dispensing on their index date.
8) Required evidence of ARB dispensing date or days supply in the 183 days prior to their index date. Excluded members with evidence of sacubitril/valsartan dispensing date or days supply in the 183 days prior to their index date. Excluded members with evidence of ARB dispensing on their index date.

Follow-up Time: We created exposure episodes based on the cumulative days supply of consecutive dispensings, with gaps shorter than 14 days bridged between days supply exhaustion of one dispensing and the dispensing date of the next. Follow-up began on the day of the index dispensing and continued until the first occurrence of any of the following: 1) disenrollment; 2) death; 3) the end of the data provided by each DP; 4) exposure discontinuation.

Baseline Characteristics: We assessed the following characteristics on the index date of exposure episodes: age, year, and sex. We assessed the following characteristics in the 183 days prior to and on the index date of exposure episodes: Charlson/Elixhauser combined comorbidity score[1], health service and drug utilization, ambulatory allergy diagnosis or allergy treatment, serious allergy, ambulatory allergies or allergy treatment without evidence of serious allergy, renal disorders, diabetes, ischemic heart disease, and angioedema, as well as use of non-steroidal anti-inflammatory drugs (NSAIDs), sirolimus, everolimus, ACEI, ARB, sacubitril/valsartan, beta blockers, and aliskiren. We also assessed the number of ACEI and ARB dispensings at baseline for sacubitril/valsartan users. We identified ambulatory allergy in the ambulatory care setting, serious allergy in the inpatient hospital or emergency department settings, and angioedema in the inpatient hospital, ambulatory, or emergency department settings. The other characteristics were identified in any care setting. Baseline characteristics were defined using ICD-9-CM and ICD-10-CM diagnosis codes, Healthcare Common Procedure Coding System (HCPCS) codes, and NDCs. Please see Appendix D for generic and brand names of medical products, and Appendix E for a list of diagnosis and procedure codes used to define baseline characteristics in this request.

Please see Appendix F for the specifications of parameters used in this request.

Limitations: Algorithms to define exposures, inclusion and exclusion criteria, and baseline characteristics may not be validated, and members identified in this query are subject to misclassification. Therefore, data should be interpreted with these limitations in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (https://dev.sentinelsystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse).

[1] Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759

Sentinel

Table of Contents

Table of Contents

Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

- **Ambulatory Visit (AV) -** includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.
- **Emergency Department (ED) -** includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.
- **Inpatient Hospital Stay (IP) -** includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.
- **Non-Acute Institutional Stay (IS) -** includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.
- **Other Ambulatory Visit (OA) -** includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a “continuously enrolled” sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module*

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregated Baseline Characteristics of Sacubitril/Valsartan (SV) Users with Baseline Heart Failure and Angiotensin-Converting Enzyme Inhibitor (ACEI) Use in the Sentinel Distributed Database (SDD) from January 1, 2015 to July 31, 2019

	Exclusion criteria: ACEI on Index Date		Exclusion criteria: SV -183 to -1, ACEI on index date	
Characteristic[1]	**Number**	**Percent**	**Number**	**Percent**
Number of unique patients	59,913		58,141	
Number of episodes	79,627		58,524	
Demographics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**
Mean Age (in years)	69.9	11.3	70.1	11.2
	Number	**Percent**	**Number**	**Percent**
Age (in years)				
18-44 years	2,925	3.7%	2,091	3.6%
45-54 years	6,162	7.7%	4,366	7.5%
55-64 years	13,191	16.6%	9,573	16.4%
65+ years	57,349	72.0%	42,494	72.6%
Sex				
Male	41,478	69.2%	40,218	69.2%
Race[2]				
Unknown	9,098	15.2%	8,793	15.1%
American Indian or Alaska Native	203	0.3%	197	0.3%
Asian	699	1.2%	675	1.2%
Black or African American	8,216	13.7%	7,906	13.6%
Native Hawaiian or Other Pacific Islander	69	0.1%	68	0.1%
White	41,628	20.10%	40,502	69.7%
Hispanic Origin	1,266	2.1%	1,218	2.1%
Year				
2015	1,621	2.0%	1,508	2.6%
2016	15,010	18.9%	11,627	19.9%
2017	26,182	32.9%	18,824	32.2%
2018	29,981	37.7%	21,543	36.8%
2019	6,833	8.6%	5,022	8.6%
Recorded History of:	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**
Charlson/Elixhauser Combined Comorbidity Score[3]	5.3	2.7	5.3	2.7
	Number	**Percent**	**Number**	**Percent**
Angioedema	104	0.1%	87	0.1%
Ambulatory Allergy or Allergy Treatments	39,174	49.2%	29,043	49.6%
Serious Allergy	9,001	11.3%	6,805	11.6%
Ambulatory Allergy or Allergy Treatment and not Serious Allergy	33,195	41.7%	24,520	41.9%
Diabetes	40,690	51.1%	29,734	50.8%
Ischemic Heart Disease	62,899	79.0%	46,371	79.2%
ACEI	79,627	100.0%	58,524	100.0%
ARB (not including sacubitril/valsartan)	7,199	9.0%	5,843	10.0%

Table 1a. Aggregated Baseline Characteristics of Sacubitril/Valsartan (SV) Users with Baseline Heart Failure and Angiotensin-Converting Enzyme Inhibitor (ACEI) Use in the Sentinel Distributed Database (SDD) from January 1, 2015 to July 31, 2019

	Exclusion criteria: ACEI on Index Date		Exclusion criteria: SV -183 to -1, ACEI on index date	
Beta Blockers	76,516	96.1%	56,231	96.1%
Everolimus	15	0.0%	12	0.0%
Nonsteroidal Anti-Inflammatory Drugs	8,852	11.1%	6,520	11.1%
Sirolimus	*****	*****	*****	*****
Aliskiren	28	0.0%	23	0.0%
Renal Disorders	31,510	39.6%	23,166	39.6%
Sacubitril/Valsartan	79,627	100.0%	58,524	100.0%
Number of ACEI Dispensings at Baseline				
0	11,782	14.8%	4,935	8.4%
1	22,376	28.1%	14,914	25.5%
2	26,348	33.1%	22,280	38.1%
3	6,770	8.5%	5,422	9.3%
4	4,542	5.7%	3,769	6.4%
5+	7,809	9.8%	7,204	12.3%
Number of ARB Dispensings at Baseline				
0	73,265	92.0%	53,233	91.0%
1	2,825	3.5%	2,209	3.8%
2	1,870	2.3%	1,623	2.8%
3	728	0.9%	612	1.0%
4	425	0.5%	375	0.6%
5+	514	0.6%	472	0.8%
Health Service Utilization Intensity:	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**
Mean number of ambulatory encounters	18.3	14	18.2	13.8
Mean number of emergency room encounters	0.7	1.5	0.7	1.5
Mean number of inpatient hospital encounters	0.8	1.2	0.8	1.2
Mean number of non-acute institutional encount	0.2	0.8	0.2	0.8
Mean number of other ambulatory encounters	8.2	12	8.4	12.1
Mean number of unique drug classes	11.5	4.6	11.6	4.6
Mean number of generics	13.3	5.3	13.4	5.3
Mean number of filled prescriptions	32.3	19.8	32.3	20.2

[1]All metrics are based on total number of episodes per group, except for sex, race, and hispanic origin which are based on total number of unique patients

[2]In the SDD, race information is not well populated and there are substantial proportions of "unknown" race and Hispanic indicator values. Specifically, two commercial Data Partners do not provide any race or ethnicity data.

[3]The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1b. Aggregated Baseline Characteristics of Sacubitril/Valsartan (SV) Users with Baseline Heart Failure and Angiotensin II Receptor Blocker (ARB) Use in the Sentinel Distributed Database (SDD) from January 1, 2015 to July 31, 2019

	Exclusion criteria: ARB on Index Date		Exclusion criteria: SV -183 to -1, ARB on index date	
Characteristic[1]	**Number**	**Percent**	**Number**	**Percent**
Number of unique patients	42,960		41,351	
Number of episodes	57,284		41,719	
Demographics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**
Mean Age (in years)	72.1	10.9	72.3	10.8
	Number	**Percent**	**Number**	**Percent**
Age (in years)				
18-44 years	1,509	2.6%	1,008	2.4%
45-54 years	3,388	5.9%	2,338	5.6%
55-64 years	7,300	12.7%	5,212	12.5%
65+ years	45,087	78.7%	33,161	79.5%
Sex				
Male	26,374	61.4%	25,335	61.3%
Race[2]				
Unknown	6,437	15.0%	6,200	15.0%
American Indian or Alaska Native	122	0.3%	114	0.3%
Asian	998	2.3%	966	2.3%
Black or African American	6,349	14.8%	6,034	14.6%
Native Hawaiian or Other Pacific Islander	56	0.1	53	0.1%
White	28,998	20.10%	27,984	67.7%
Hispanic Origin	1,073	2.5%	1,017	2.5%
Year				
2015	1,123	2.0%	1,040	2.5%
2016	10,042	17.5%	7,714	18.5%
2017	17,816	31.1%	12,916	31.0%
2018	22,586	39.4%	15,965	38.3%
2019	5,717	10.0%	4,084	9.8%
Recorded History of:	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**
Charlson/Elixhauser Combined Comorbidity Score[3]	5.4	2.7	5.4	2.7
	Number	**Percent**	**Number**	**Percent**
Angioedema	80	0.1%	55	0.1%
Ambulatory Allergy or Allergy Treatments	30,941	54.0%	22,675	54.4%
Serious Allergy	7,346	12.8%	5,458	13.1%
Ambulatory Allergy or Allergy Treatment and not Serious Allergy	25,891	45.2%	18,919	45.3%
Diabetes	31,006	54.1%	22,434	53.8%
Ischemic Heart Disease	44,762	78.1%	32,801	78.6%
ACEI	7,122	12.4%	5,776	13.8%
ARB (not including sacubitril/valsartan)	57,284	100.0%	41,719	100.0%

Table 1b. Aggregated Baseline Characteristics of Sacubitril/Valsartan (SV) Users with Baseline Heart Failure and Angiotensin II Receptor Blocker (ARB) Use in the Sentinel Distributed Database (SDD) from January 1, 2015 to July 31, 2019

	Exclusion criteria: ARB on Index Date		Exclusion criteria: SV -183 to -1, ARB on index date	
Beta Blockers	54,386	94.9%	39,603	94.9%
Everolimus	15	0.0%	14	0.0%
Nonsteroidal Anti-Inflammatory Drugs	6,573	11.5%	4,781	11.5%
Sirolimus	*****	*****	*****	*****
Aliskiren	55	0.1%	46	0.1%
Renal Disorders	24,936	43.5%	18,140	43.5%
Sacubitril/Valsartan	57,284	100.0%	41,719	100.0%
Number of ACEI Dispensings at Baseline				
0	51,656	90.2%	36,999	88.7%
1	2,699	4.7%	2,192	5.3%
2	1,615	2.8%	1,373	3.3%
3	601	1.0%	517	1.2%
4	346	0.6%	305	0.7%
5+	367	0.6%	333	0.8%
Number of ARB Dispensings at Baseline				
0	7,567	13.2%	2,947	7.1%
1	16,006	27.9%	10,378	24.9%
2	19,166	33.5%	16,056	38.5%
3	5,073	8.9%	4,016	9.6%
4	3,308	5.8%	2,728	6.5%
5+	6,164	10.8%	5,594	13.4%
Health Service Utilization Intensity:	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**
Mean number of ambulatory encounters	19.6	14.9	19.5	14.6
Mean number of emergency room encounters	0.6	1.4	0.6	1.4
Mean number of inpatient hospital encounters	0.8	1.2	0.8	1.2
Mean number of non-acute institutional encount	0.2	0.8	0.2	0.8
Mean number of other ambulatory encounters	8.4	11.9	8.5	11.9
Mean number of unique drug classes	12.1	4.8	12.2	4.8
Mean number of generics	14	5.5	14.2	5.5
Mean number of filled prescriptions	33.6	20.9	33.6	21.5

[1]All metrics are based on total number of episodes per group, except for sex, race, and hispanic origin which are based on total number of unique patients

[2]In the SDD, race information is not well populated and there are substantial proportions of "unknown" race and Hispanic indicator values. Specifically, two commercial Data Partners do not provide any race or ethnicity data.

[3] The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1c. Aggregated Baseline Characteristics of Sacubitril/Valsartan (SV) Users with Baseline Heart Failure in the Sentinel Distributed Database (SDD) from January 1, 2015 to July 31, 2019

	Exclusion criteria: None		Exclusion criteria: SV/ACEI/ARB -183 to -1		Exclusion criteria: ACEI -183 to 0, SV/ARB -183 to -1		Exclusion criteria: ARB -183 to 0, SV/ACEI -183 to -1	
Characteristic[1]	**Number**	**Percent**	**Number**	**Percent**	**Number**	**Percent**	**Number**	**Percent**
Number of unique patients	131,491		30,572		30,557		30,547	
Number of episodes	237,112		31,546		31,529		31,518	
Demographics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**
Mean Age (in years)	70.7	11.7	71.8	11.8	71.9	11.8	71.9	11.8
	Number	**Percent**	**Number**	**Percent**	**Number**	**Percent**	**Number**	**Percent**
Age (in years)								
18-44 years	8,636	3.6%	1,086	3.4%	1,086	3.4%	1,082	3.4%
45-54 years	17,539	7.4%	2,144	6.8%	2,141	6.8%	2,141	6.8%
55-64 years	35,158	14.8%	4,220	13.4%	4,214	13.4%	4,211	13.4%
65+ years	175,779	74.1%	24,096	76.4%	24,088	76.4%	24,084	76.4%
Sex								
Male	86,769	66.0%	19,822	64.8%	19,808	64.8%	19,808	64.8%
Race[2]								
Unknown	19,651	14.9%	4,241	13.9%	4,238	13.9%	4,234	13.9%
Alaska Native	430	0.3%	104	0.3%	104	0.3%	104	0.3%
Asian	2,010	1.5%	381	1.2%	381	1.2%	380	1.2%
African American	18,756	14.3%	4,257	13.9%	4,254	13.9%	4,253	13.9%
Other Pacific Islander	146	0.1%	28	0.1%	28	0.1%	28	0.1%
White	90,498	20.10%	21,561	70.5%	21,552	70.5%	21,548	70.5%
Hispanic Origin	2,811	2.1%	541	1.8%	540	1.8%	539	1.8%
Year								
2015	3,068	1.3%	431	1.4%	431	1.4%	430	1.4%
2016	32,585	13.7%	4,253	13.5%	4,250	13.5%	4,248	13.5%
2017	71,874	30.3%	9,637	30.5%	9,633	30.6%	9,630	30.6%
2018	102,334	43.2%	13,414	42.5%	13,407	42.5%	13,401	42.5%
2019	27,251	11.5%	3,811	12.1%	3,808	12.1%	3,809	12.1%
Recorded History of:	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**
Charlson/Elixhauser Combined Comorbidity Score[3]	5.2	2.7	5.6	2.8	5.6	2.8	5.6	2.8
	Number	**Percent**	**Number**	**Percent**	**Number**	**Percent**	**Number**	**Percent**
Angioedema	223	0.1%	31	0.1%	31	0.1%	31	0.1%
Ambulatory Allergy or Allergy Treatments	116,379	49.1%	15,680	49.7%	15,674	49.7%	15,669	49.7%
Serious Allergy	26,439	11.2%	4,166	13.2%	4,166	13.2%	4,164	13.2%
Ambulatory Allergy or Allergy Treatment and not Serious Allergy	98,764	41.7%	12,972	41.1%	12,966	41.1%	12,963	41.1%
Diabetes	119,219	50.3%	14,964	47.4%	14,956	47.4%	14,950	47.4%

Table 1c. Aggregated Baseline Characteristics of Sacubitril/Valsartan (SV) Users with Baseline Heart Failure in the Sentinel Distributed Database (SDD) from January 1, 2015 to July 31, 2019

	Exclusion criteria: None		Exclusion criteria: SV/ACEI/ARB -183 to -1		Exclusion criteria: ACEI -183 to 0, SV/ARB -183 to -1		Exclusion criteria: ARB -183 to 0, SV/ACEI -183 to -1	
Ischemic Heart Disease	180,618	76.2%	24,191	76.7%	24,176	76.7%	24,176	76.7%
ACEI	80,262	33.8%	17	0.1%	0	0.0%	17	0.1%
ARB (not including sacubitril/valsartan)	57,944	24.4%	28	0.1%	28	0.1%	0	0.0%
Beta Blockers	220,632	93.0%	27,308	86.6%	27,293	86.6%	27,284	86.6%
Everolimus	45	0.0%	*****	*****	*****	*****	*****	*****
Nonsteroidal Anti-Inflammatory Drugs	24,804	10.5%	3,102	9.8%	3,100	9.8%	3,101	9.8%
Sirolimus	24	0.0%	*****	*****	*****	*****	*****	*****
Aliskiren	129	0.1%	36	0.1%	36	0.1%	36	0.1%
Renal Disorders	96,389	40.7%	14,178	44.9%	14,168	44.9%	14,169	45.0%
Sacubitril/Valsartan	237,112	100.0%	31,546	100.0%	31,529	100.0%	31,518	100.0%
Number of ACEI Dispensings at Baseline								
0	168,711	71.2%	--	--	--	--	--	--
1	22,508	9.5%	--	--	--	--	--	--
2	26,520	11.2%	--	--	--	--	--	--
3	6,824	2.9%	--	--	--	--	--	--
4	4,599	1.9%	--	--	--	--	--	--
5+	7,950	3.4%	--	--	--	--	--	--
Number of ARB Dispensings at Baseline								
0	186,849	78.8%	--	--	--	--	--	--
1	16,141	6.8%	--	--	--	--	--	--
2	19,325	8.2%	--	--	--	--	--	--
3	5,128	2.2%	--	--	--	--	--	--
4	3,371	1.4%	--	--	--	--	--	--
5+	6,298	2.7%	--	--	--	--	--	--
Health Service Utilization Intensity:	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**
Mean number of ambulatory encounters	18	15	18.4	17	18.4	17	18.4	17
Mean number of emergency room encounters	0.6	1.4	0.7	1.3	0.7	1.3	0.7	1.3
Mean number of inpatient hospital encounters	0.7	1.1	0.8	1.1	0.8	1.1	0.8	1.1
Mean number of non-acute institutional encounters	0.2	0.8	0.3	0.9	0.3	0.9	0.3	0.9
Mean number of other ambulatory encounters	7.7	12	9.3	14	9.3	14	9.3	14

Table 1c. Aggregated Baseline Characteristics of Sacubitril/Valsartan (SV) Users with Baseline Heart Failure in the Sentinel Distributed Database (SDD) from January 1, 2015 to July 31, 2019

	Exclusion criteria: None		Exclusion criteria: SV/ACEI/ARB -183 to -1		Exclusion criteria: ACEI -183 to 0, SV/ARB -183 to -1		Exclusion criteria: ARB -183 to 0, SV/ACEI -183 to -1	
Mean number of unique drug classes	11.3	4.7	11.1	4.9	11.1	4.9	11.1	4.9
Mean number of generics	12.5	5.4	11.8	5.5	11.8	5.5	11.8	5.5
Mean number of filled prescriptions	30.8	19.7	27.6	20.9	27.6	20.9	27.6	20.9

[1]All metrics are based on total number of episodes per group, except for sex, race, and hispanic origin which are based on total number of unique patients

[2]In the SDD, race information is not well populated and there are substantial proportions of "unknown" race and Hispanic indicator values. Specifically, two commercial Data Partners do not provide any race or ethnicity data.

[3] The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1d. Aggregated Characteristics of Angiotensin-Converting Enzyme Inhibitor (ACEI) Users with Baseline Heart Failure in the Sentinel Distributed Database (SDD) from January 1, 2015 to July 31, 2019

	Exclusion criteria: Sacubitril Valsartan (SV) - 183 to 0, ACEI and Angiotenisn II Receptor Blocker (ARB) -183 to -1		Exclusion criteria: ACEI/ARB -183 to -1		Exclusion criteria: None	
Characteristic[1]	**Number**	**Percent**	**Number**	**Percent**	**Number**	**Percent**
Number of unique patients	703,848		707,248		1,650,477	
Number of episodes	740,703		744,727		2,767,592	
Demographics	**Mean**	**Standard Deviation**	**Mean**	**Standard Devation**	**Mean**	**Standard Deviation**
Mean Age (in years)	72.6	12.7	72.5	12.7	72.3	12.6
	Number	**Percent**	**Number**	**Percent**	**Number**	**Percent**
Age (in years)						
18-44 years	24,556	3.3%	24,693	3.3%	84,772	3.1%
45-54 years	50,935	6.90%	51,261	6.9%	195,226	7.1%
55-64 years	106,199	14.3%	106,860	14.3%	420,139	15.2%
65+ years	559,013	75.5%	561,913	75.5%	2,067,455	74.7%
Sex						
Male	357,076	50.7%	359,405	50.8%	825,391	50.0%
Race[2]						
Unknown	94,171	13.4%	94,616	13.4%	206,722	12.5%
American Indian or Alaska Native	4,640	0.7%	4,655	0.7%	11,066	0.7%
Asian	9,723	1.4%	9,756	1.4%	22,011	1.3%
Black or African American	95,368	13.5%	95,836	13.6%	243,282	14.7%
Islander	1,268	0.2%	1,271	0.2%	2,914	0.2%
White	498,678	20.10%	501,114	70.9%	1,164,482	70.6%
Hispanic Origin	17,386	2.5%	17,463	2.5%	44,447	2.7%
Year						
2015	190,120	25.7%	190,130	25.5%	736,190	26.6%
2016	183,274	24.7%	183,632	24.7%	692,959	25.0%
2017	172,918	23.3%	174,158	23.4%	640,080	23.1%
2018	159,384	21.5%	161,321	21.7%	575,739	20.8%
2019	35,007	4.7%	35,486	4.8%	122,624	4.4%
Recorded History of:	**Mean**	**Standard Deviation**	**Mean**	**Standard Devation**	**Mean**	**Standard Deviation**
Charlson/Elixhauser Combined Comorbidity Score[3]	5.7	3	5.8	3	5.6	3
	Number	**Percent**	**Number**	**Percent**	**Number**	**Percent**
Angioedema	799	0.1%	805	0.1%	3,635	0.1%
Ambulatory Allergy or Allergy Treatments	359,196	48.5%	361,316	48.5%	1,346,176	48.6%
Serious Allergy	114,950	15.5%	115,601	15.5%	394,326	14.2%
Ambulatory Allergy or Allergy Treatment and not Serious Allergy	287,235	38.8%	288,922	38.8%	1,093,088	39.5%
Diabetes	347,345	46.9%	349,476	46.9%	1,473,723	53.2%
Ischemic Heart Disease	462,462	62.4%	465,731	62.5%	1,710,747	61.8%

Table 1d. Aggregated Characteristics of Angiotensin-Converting Enzyme Inhibitor (ACEI) Users with Baseline Heart Failure in the Sentinel Distributed Database (SDD) from January 1, 2015 to July 31, 2019

	Exclusion criteria: Sacubitril Valsartan (SV) - 183 to 0, ACEI and Angiotenisn II Receptor Blocker (ARB) -183 to -1		Exclusion criteria: ACEI/ARB -183 to -1		Exclusion criteria: None	
ACEI	740,703	100.0%	744,727	100.0%	2,767,592	100.0%
ARB (not including sacubitril/valsartan)	878	0.1%	882	0.1%	169,251	6.1%
Beta Blockers	558,389	75.4%	562,180	75.5%	2,125,049	76.8%
Everolimus	208	0.0%	208	0.0%	501	0.0%
Nonsteroidal Anti-Inflammatory Drugs	93,867	12.7%	94,298	12.7%	383,025	13.8%
Sirolimus	240	0.0%	240	0.0%	698	0.0%
Aliskiren	462	0.1%	463	0.1%	1,452	0.1%
Renal Disorders	305,773	41.3%	307,924	41.3%	1,170,350	42.3%
Sacubitril/Valsartan	0	0.0%	4,024	0.5%	10,187	0.4%
Health Service Utilization Intensity:	**Mean**	**Standard Deviation**	**Mean**	**Standard Devation**	**Mean**	**Standard Deviation**
Mean number of ambulatory encounters	17.1	19.6	17.1	19.6	17.4	19.2
Mean number of emergency room encounters	0.9	1.8	0.9	1.8	0.9	1.9
Mean number of inpatient hospital encounters	1	1.2	1	1.2	0.9	1.2
Mean number of non-acute institutional encounters	0.4	1.1	0.4	1.1	0.4	1.1
Mean number of other ambulatory encounters	12.9	17.9	12.9	17.9	12.6	17.6
Mean number of unique drug classes	10.8	5	10.8	5.1	11.2	4.9
Mean number of generics	11.6	5.7	11.6	5.7	12.1	5.7
Mean number of filled prescriptions	27	22.9	27	22.9	30.8	22.1

[1]All metrics are based on total number of episodes per group, except for sex, race, and hispanic origin which are based on total number of unique patients

[2]In the SDD, race information is not well populated and there are substantial proportions of "unknown" race and Hispanic indicator values. Specifically, two commercial Data Partners do not provide any race or ethnicity data.

[3] The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1e. Aggregated Baseline Characteristics of Angiotensin II Receptor Blocker (ARB) Users in the Sentinel Distributed Database (SDD) from January 1, 2015 to July 31, 2019

	Exclusion criteria: Sacubitril Valsartan (SV) -183 to 0, Angiotenin-Converting Enzyme Inhibitor (ACEI) and ARB -183 to -1		Exclusion criteria: ACEI/ARB -183 to -1		Exclusion criteria: None	
Characteristic[1]	**Number**	**Percent**	**Number**	**Percent**	**Number**	**Percent**
Number of unique patients	318,588		322,767		1,099,562	
Number of episodes	333,809		338,358		1,821,210	
Demographics	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**
Mean Age (in years)	73.8	12.1	73.8	12.1	74.3	11.8
	Number	**Percent**	**Number**	**Percent**	**Number**	**Percent**
Age (in years)						
18-44 years	8,593	2.6%	8,712	2.6%	38,039	2.1%
45-54 years	18,318	5.5%	18,590	5.5%	93,383	5.1%
55-64 years	40,546	12.1%	41,179	12.2%	212,185	11.7%
65+ years	266,352	79.8%	269,877	79.8%	1,477,603	81.1%
Sex						
Male	140,195	44.0%	142,815	44.2%	459,473	41.8%
Race[2]						
Unknown	41,389	13.0%	41,971	13.0%	139,926	12.7%
American Indian or Alaska Native	1,930	0.6%	1,944	0.6%	5,546	0.5%
Asian	8,997	2.8%	9,074	2.8%	28,678	2.6%
Black or African American	53,295	16.7%	53,900	16.7%	177,481	16.1%
Islander	668	0.2%	672	0.2%	2,293	0.2%
White	212,309	66.6%	215,206	66.7%	745,638	67.8%
Hispanic Origin	9,826	3.1%	9,917	3.1%	33,981	3.1%
Year						
2015	67,190	20.10%	67,199	19.9%	419,155	23.0%
2016	73,891	22.1%	74,215	21.9%	427,363	23.5%
2017	82,000	24.6%	83,222	24.6%	435,034	23.9%
2018	91,983	27.6%	94,415	27.9%	443,978	24.4%
2019	18,745	5.6%	19,307	5.7%	95,680	5.3%
Recorded History of:	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**
Charlson/Elixhauser Combined Comorbidity Score[3]	5.7	2.9	5.7	2.9	5.6	2.9
	Number	**Percent**	**Number**	**Percent**	**Number**	**Percent**
Angioedema	688	0.2%	706	0.2%	5,690	0.3%
Treatments	174,010	52.1%	176,403	52.1%	968,490	53.2%
Serious Allergy	51,992	15.6%	52,590	15.5%	270,938	14.9%
Ambulatory Allergy or Allergy Treatment and not Serious Allergy	139,741	41.9%	141,711	41.9%	785,554	43.1%
Diabetes	173,539	52.0%	175,923	52.0%	1,008,101	55.4%
Ischemic Heart Disease	202,268	60.6%	205,789	60.8%	1,104,662	60.7%

Table 1e. Aggregated Baseline Characteristics of Angiotensin II Receptor Blocker (ARB) Users in the Sentinel Distributed Database (SDD) from January 1, 2015 to July 31, 2019

	Exclusion criteria: Sacubitril Valsartan (SV) -183 to 0, Angiotenin-Converting Enzyme Inhibitor (ACEI) and ARB -183 to -1		Exclusion criteria: ACEI/ARB -183 to -1		Exclusion criteria: None	
ACEI	878	0.3%	882	0.3%	304,854	16.7%
sacubitril/valsartan)	333,809	100.0%	338,358	100.0%	1,821,210	100.0%
Beta Blockers	244,147	73.1%	248,366	73.4%	1,365,087	75.0%
Everolimus	112	0.0%	112	0.0%	406	0.0%
Nonsteroidal Anti-Inflammatory Drugs	43,298	13.0%	43,741	12.9%	261,891	14.4%
Sirolimus	151	0.0%	152	0.0%	563	0.0%
Aliskiren	778	0.2%	780	0.2%	2,398	0.1%
Renal Disorders	152,729	45.8%	154,914	45.8%	820,076	45.0%
Sacubitril/Valsartan	0	0.0%	4,549	1.3%	11,393	0.6%
Health Service Utilization Intensity:	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**	**Mean**	**Standard Deviation**
Mean number of ambulatory	20	22.4	20	22.3	19.4	20.6
Mean number of emergency room encounters	0.8	1.7	0.8	1.7	0.8	1.6
Mean number of inpatient hospital encounters	0.8	1.2	0.8	1.2	0.8	1.2
Mean number of non-acute institutional encounters	0.4	1	0.4	1	0.4	1
Mean number of other ambulatory encounters	11.8	17.3	11.8	17.3	11.5	16.5
Mean number of unique drug classes	11.2	5.1	11.2	5.1	11.6	5
Mean number of generics	12	5.8	12	5.8	12.7	5.7
Mean number of filled prescriptions	27.8	22	27.9	22	31.4	21.5

[1]All metrics are based on total number of episodes per group, except for sex, race, and hispanic origin which are based on total number of unique patients

[2]In the SDD, race information is not well populated and there are substantial proportions of "unknown" race and Hispanic indicator values. Specifically, two commercial Data Partners do not provide any race or ethnicity data.

[3] The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (index date).

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019

Exclusion Criteria	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
ACEI Users				
SV -183 to 0, ACEI/ARB -183 to -1	703,848	740,703	4,983,025	141.25
ACEI/ARB -183 to -1	707,248	744,727	5,039,614	140.34
None	1,650,477	2,767,592	8,778,332	188.02
ARB Users				
SV -183 to 0, ACEI/ARB -183 to -1	318,588	333,809	4,983,025	63.93
ACEI/ARB -183 to -1	322,767	338,358	5,039,614	64.05
None	1,099,562	1,821,210	8,778,332	125.26
SV Users with Baseline History of ACEI				
ACEIs on Index Date	59,913	79,627	3,687,116	16.25
SV -183 to -1, ACEI on index date	58,141	58,524	3,682,553	15.79
SV Users with Baseline History of ARBs				
ARBs on Index Date	42,960	57,284	2,467,719	17.41
SV -183 to -1, ARBs on index date	41,351	41,719	2,463,134	16.79
SV Users				
ACEI -183 to 0, SV/ARB -183 to -1	30,557	31,529	4,960,882	6.16
ARB -183 to 0, SV/ACEI -183 to -1	30,547	31,518	4,973,106	6.14
SV/ACEI/ARB -183 to -1	30,572	31,546	4,983,316	6.13
None	131,491	237,112	8,778,332	14.98

[1]Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

Table 3. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Sex

Exclusion Criteria/Sex	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
ACEI Users				
SV -183 to 0, ACEI/ARB -183 to -1				
Female	346,756	363,960	2,716,606	127.64
Male	357,076	376,727	2,266,283	157.56
Other	16	16	136	117.65
ACEI/ARB -183 to -1				
Female	347,827	365,240	2,734,631	127.19
Male	359,405	379,471	2,304,846	155.93
Other	16	16	137	116.79
None				
Female	825,039	1,375,042	4,744,050	173.91
Male	825,391	1,392,472	4,034,050	204.61
Other	47	78	232	202.59
ARB Users				
SV -183 to 0, ACEI/ARB -183 to -1				
Female	*****	*****	*****	65.67
Male	140,195	146,788	2,266,283	61.86
Other	*****	*****	*****	36.76
ACEI/ARB -183 to -1				
Female	*****	*****	*****	65.80
Male	142,815	149,615	2,304,846	61.96
Other	*****	*****	*****	36.50
None				
Female	640,069	*****	4,744,050	134.92
Male	459,473	747,847	4,034,050	113.90
Other	20	*****	232	86.21
SV Users with Baseline History of ACEIs				
ACEIs on Index Date				
Female	*****	*****	*****	10.06
Male	41,478	54,969	1,854,049	22.37
Other	*****	*****	*****	10.42
SV -183 to -1, ACEI on Index Date				
Female	*****	*****	*****	9.78
Male	40,218	40,497	1,850,828	21.73
Other	*****	*****	*****	10.53
SV Users with Baseline History of ARBs				
ARBs on Index Date				
Female	*****	*****	*****	11.45
Male	26,374	35,067	1,019,272	25.88

Table 3. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Sex

Exclusion Criteria/Sex	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
Other	*****	*****	*****	52.63
SV -183 to -1, ARBs on Index Date				
Female	*****	*****	*****	11.07
Male	25,335	25,549	1,016,213	24.93
Other	*****	*****	*****	35.09
SV Users				
SV/ACEI/ARB -183 to -1				
Female	*****	*****	*****	3.96
Male	19,822	20,454	2,266,457	8.75
Other	*****	*****	*****	7.35
ACEI -183 to 0, SV/ARB -183 to -1				
Female	*****	*****	*****	3.97
Male	19,808	20,439	2,254,201	8.79
Other	*****	*****	*****	7.35
ARB -183 to 0, SV/ACEI -183 to -1				
Female	*****	*****	*****	3.96
Male	19,808	20,438	2,261,740	8.76
Other	*****	*****	*****	7.35
None				
Female	*****	*****	*****	9.43
Male	86,769	156,111	4,034,050	21.51
Other	*****	*****	*****	21.55

[1]Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 4. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Race

Exclusion Criteria/Race[1]	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[2] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
ACEI Users				
SV -183 to 0, ACEI/ARB -183 to -1				
American Indian or Alaska Native	4,640	4,951	25,062	185.14
Asian	9,723	10,229	79,183	122.79
Black or African American	95,368	102,919	585,584	162.86
Native Hawaiian or Other Pacific Islander	1,268	1,345	6,786	186.86
Unknown	94,171	98,193	651,536	144.54
White	498,678	523,066	3,634,874	137.19
ACEI/ARB -183 to -1				
American Indian or Alaska Native	4,655	4,970	25,238	184.44
Asian	9,756	10,269	80,031	121.90
Black or African American	95,836	103,500	593,560	161.46
Native Hawaiian or Other Pacific Islander	1,271	1,348	6,838	185.87
Unknown	94,616	98,722	660,529	143.24
White	501,114	525,918	3,673,418	136.42
None				
American Indian or Alaska Native	11,066	21,867	42,034	263.26
Asian	22,011	34,761	154,749	142.24
Black or African American	243,282	479,699	1,053,058	231.02
Native Hawaiian or Other Pacific Islander	2,914	4,944	13,719	212.41
Unknown	206,722	333,945	1,144,189	180.67
White	1,164,482	1,892,376	6,370,583	182.79
ARB Users				
SV -183 to 0, ACEI/ARB -183 to -1				
American Indian or Alaska Native	1,930	2,099	25,062	77.01
Asian	8,997	9,562	79,183	113.62
Black or African American	53,295	57,009	585,584	91.01
Native Hawaiian or Other Pacific Islander	668	715	6,786	98.44
Unknown	41,389	43,074	651,536	63.53
White	212,309	221,350	3,634,874	58.41
ACEI/ARB -183 to -1				
American Indian or Alaska Native	1,944	2,114	25,238	77.03
Asian	9,074	9,643	80,031	113.38
Black or African American	53,900	57,699	593,560	90.81

Table 4. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Race

Exclusion Criteria/Race[1]	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[2] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
Native Hawaiian or Other Pacific Islander	672	719	6,838	98.27
Unknown	41,971	43,712	660,529	63.54
White	215,206	224,471	3,673,418	58.58
None				
American Indian or Alaska Native	5,546	10,185	42,034	131.94
Asian	28,678	46,086	154,749	185.32
Black or African American	177,481	340,220	1,053,058	168.54
Native Hawaiian or Other Pacific Islander	2,293	3,934	13,719	167.14
Unknown	139,926	226,008	1,144,189	122.29
White	745,638	1,194,777	6,370,583	117.04
SV Users with Baseline History of ACEI				
ACEIs on Index Date				
American Indian or Alaska Native	203	281	20,291	10.00
Asian	699	874	49,138	14.23
Black or African American	8,216	11,783	468,006	17.56
Native Hawaiian or Other Pacific Islander	69	91	6,179	11.17
Unknown	9,098	11,680	455,861	19.96
White	41,628	54,918	2,687,641	15.49
SV -183 to -1, ACEI on Index Date				
American Indian or Alaska Native	197	197	20,280	9.71
Asian	675	684	49,076	13.75
Black or African American	7,906	7,984	467,365	16.92
Native Hawaiian or Other Pacific Islander	68	68	6,176	11.01
Unknown	8,793	8,831	454,883	19.33
White	40,502	40,760	2,684,773	15.09
SV Users with Baseline History of ARBs				
ARBs on Index Date				
American Indian or Alaska Native	122	159	10,058	12.13
Asian	998	1,260	70,742	14.11
Black or African American	6,349	9,175	337,266	18.82
Native Hawaiian or Other Pacific Islander	56	74	4,897	11.44
Unknown	6,437	8,360	319,267	20.16
White	28,998	38,256	1,725,489	16.81

Table 4. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Race

Exclusion Criteria/Race[1]	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[2] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
SV -183 to -1, ARBs on index date				
American Indian or Alaska Native	114	115	10,042	11.35
Asian	966	976	70,638	13.68
Black or African American	6,034	6,108	336,552	17.93
Native Hawaiian or Other Pacific Islander	53	54	4,891	10.84
Unknown	6,200	6,240	318,347	19.48
White	27,984	28,226	1,722,664	16.24
SV Users				
None				
American Indian or Alaska Native	430	819	42,034	10.23
Asian	2,010	3,163	154,749	12.99
Black or African American	18,756	38,640	1,053,058	17.81
Native Hawaiian or Other Pacific Islander	146	262	13,719	10.64
Unknown	19,651	32,963	1,144,189	17.17
White	90,498	161,265	6,370,583	14.21
SV/ACEI/ARB -183 to -1				
American Indian or Alaska Native	104	107	25,062	4.15
Asian	381	394	79,194	4.81
Black or African American	4,257	4,473	585,620	7.27
Native Hawaiian or Other Pacific Islander	28	29	6,786	4.13
Unknown	4,241	4,339	651,573	6.51
White	21,561	22,204	3,635,081	5.93
ACEI -183 to 0, SV/ARB -183 to -1				
American Indian or Alaska Native	104	107	24,936	4.17
Asian	381	394	78,811	4.83
Black or African American	4,254	4,470	583,142	7.29
Native Hawaiian or Other Pacific Islander	28	29	6,721	4.17
Unknown	4,238	4,336	647,169	6.55
White	21,552	22,193	3,620,103	5.95
ARB -183 to 0, SV/ACEI -183 to -1				
American Indian or Alaska Native	104	107	25,030	4.16
Asian	380	393	78,804	4.82
Black or African American	4,253	4,467	584,250	7.28
Native Hawaiian or Other Pacific Islander	28	29	6,761	4.14

Table 4. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Race

Exclusion Criteria/Race[1]	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[2] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
Unknown	4,234	4,332	649,519	6.52
White	21,548	22,190	3,628,742	5.94

[1]In the SDD, race information is not well populated and there are substantial proportions of "unknown" race and Hispanic indicator values. Specifically, two commercial Data Partners do not provide any race or ethnicity data.

[2]Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

Table 5. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Age Group

Exclusion Criteria/Age Group	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
ACEI Users				
SV -183 to 0, ACEI/ARB -183 to -1				
18-44 years	23,072	24,556	150,854	152.94
45-54 years	48,029	50,935	279,902	171.59
55-64 years	100,646	106,199	603,197	166.85
65+ years	534,194	559,013	4,060,380	131.56
ACEI/ARB -183 to -1				
18-44 years	23,177	24,693	152,867	151.62
45-54 years	48,304	51,261	284,555	169.75
55-64 years	101,186	106,860	613,280	164.99
65+ years	536,712	561,913	4,103,183	130.80
None				
18-44 years	45,473	84,772	213,671	212.82
45-54 years	108,149	195,226	471,720	229.27
55-64 years	240,883	420,139	1,100,137	218.96
65+ years	1,278,465	2,067,455	7,257,906	176.15
ARB Users				
SV -183 to 0, ACEI/ARB -183 to -1				
18-44 years	8,101	8,593	150,854	53.70
45-54 years	17,347	18,318	279,902	61.98
55-64 years	38,725	40,546	603,197	64.20
65+ years	255,082	266,352	4,060,380	62.82
ACEI/ARB -183 to -1				
18-44 years	8,199	8,712	152,867	53.63
45-54 years	17,588	18,590	284,555	61.81
55-64 years	39,307	41,179	613,280	64.09
65+ years	258,358	269,877	4,103,183	62.97
None				
18-44 years	21,089	38,039	213,671	98.70
45-54 years	53,403	93,383	471,720	113.21
55-64 years	126,249	212,185	1,100,137	114.76
65+ years	909,868	1,477,603	7,257,906	125.36
SV Users with Baseline History of ACEI				
ACEIs on Index Date				
18-44 years	2,176	2,925	80,811	26.93
45-54 years	4,548	6,162	213,958	21.26
55-64 years	9,892	13,191	517,537	19.11
65+ years	43,498	57,349	2,984,111	14.58

Table 5. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Age Group

Exclusion Criteria/Age Group	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
SV -183 to -1, ACEI on Index Date				
18-44 years	2,087	2,091	80,542	25.91
45-54 years	4,335	4,366	213,343	20.32
55-64 years	9,495	9,573	516,295	18.39
65+ years	42,243	42,494	2,980,708	14.17
SV Users with Baseline History of ARBs				
ARBs on Index Date				
18-44 years	1,055	1,509	36,182	29.16
45-54 years	2,489	3,388	102,245	24.34
55-64 years	5,471	7,300	264,474	20.69
65+ years	34,069	45,087	2,119,779	16.07
SV -183 to -1, ARBs on Index Date				
18-44	996	1,008	35,991	27.67
45-54	2,325	2,338	101,773	22.84
55-64	5,171	5,212	263,477	19.63
65+	32,871	33,161	2,116,251	15.53
SV Users				
None				
18-44	4,408	8,636	213,671	20.63
45-54	9,406	17,539	471,720	19.94
55-64	19,827	35,158	1,100,137	18.02
65+	99,240	175,779	7,257,906	13.67
SV/ACEI/ARB -183 to -1				
18-44	1,039	1,086	150,862	6.89
45-54	2,056	2,144	279,931	7.34
55-64	4,083	4,220	603,239	6.77
65+	23,422	24,096	4,060,599	5.77
ACEI -183 to 0, SV/ARB -183 to -1				
18-44	1,039	1,086	149,824	6.93
45-54	2,053	2,141	277,826	7.39
55-64	4,078	4,214	599,456	6.80
65+	23,414	24,088	4,044,683	5.79
ARB -183 to 0, SV/ACEI -183 to -1				
18-44	1,036	1,082	150,490	6.88
45-54	2,054	2,141	279,223	7.36
55-64	4,075	4,211	601,796	6.77
65+	23,410	24,084	4,052,768	5.78

[1]Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

Table 6. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database between January 1, 2015 and July 31, 2019 by Year

Exclusion Criteria/Year	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
ACEI Users				
SV -183 to 0, ACEI/ARB -183 to -1				
2015	189,491	190,120	2,059,705	92.00
2016	182,616	183,274	2,103,023	86.83
2017	172,365	172,918	2,134,196	80.76
2018	158,926	159,384	2,146,459	74.04
2019	35,007	35,007	1,210,886	28.91
ACEI/ARB -183 to -1				
2015	189,501	190,130	2,059,808	92.00
2016	182,972	183,632	2,111,643	86.65
2017	173,599	174,158	2,167,365	80.10
2018	160,848	161,321	2,208,858	72.82
2019	35,486	35,486	1,268,851	27.97
None				
2015	561,587	736,190	4,152,754	135.23
2016	534,811	692,959	4,235,475	126.27
2017	501,502	640,080	4,294,041	116.79
2018	461,798	575,739	4,333,710	106.56
2019	119,304	122,624	2,742,619	43.50
ARB Users				
SV -183 to 0, ACEI/ARB -183 to -1				
2015	66,986	67,190	2,059,705	32.52
2016	73,676	73,891	2,103,023	35.03
2017	81,773	82,000	2,134,196	38.32
2018	91,758	91,983	2,146,459	42.75
2019	18,745	18,745	1,210,886	15.48
ACEI/ARB -183 to -1				
2015	66,995	67,199	2,059,808	32.52
2016	73,999	74,215	2,111,643	35.04
2017	82,986	83,222	2,167,365	38.29
2018	94,181	94,415	2,208,858	42.64
2019	19,307	19,307	1,268,851	15.22
None				
2015	323,131	419,155	4,152,754	77.81
2016	333,858	427,363	4,235,475	78.82
2017	344,151	435,034	4,294,041	80.15
2018	359,684	443,978	4,333,710	83.00
2019	93,219	95,680	2,742,619	33.99

Table 6. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database between January 1, 2015 and July 31, 2019 by Year

Exclusion Criteria/Year	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
SV Users with Baseline History of ACEI				
ACEIs on Index Date				
2015	1,514	1,621	1,710,352	0.89
2016	12,282	15,010	1,689,265	7.27
2017	20,983	26,182	1,648,159	12.73
2018	24,479	29,981	1,581,181	15.48
2019	6,608	6,833	915,769	7.22
SV -183 to -1, ACEI on index date				
2015	1,508	1,508	1,710,289	0.88
2016	11,622	11,627	1,686,999	6.89
2017	18,812	18,824	1,639,340	11.48
2018	21,530	21,543	1,568,865	13.72
2019	5,022	5,022	904,135	5.55
SV Users with Baseline History of ARBs				
ARBs on Index Date				
2015	1,042	1,123	1,028,885	1.01
2016	8,161	10,042	1,087,910	7.50
2017	14,399	17,816	1,138,122	12.65
2018	18,382	22,586	1,195,107	15.38
2019	5,528	5,717	740,469	7.47
SV -183 to -1, ARBs on Index Date				
2015	1,040	1,040	1,028,844	1.01
2016	7,712	7,714	1,086,240	7.10
2017	12,902	12,916	1,131,695	11.40
2018	15,949	15,965	1,185,022	13.46
2019	4,084	4,084	730,243	5.59
SV Users				
None				
2015	2,845	3,068	4,152,754	0.69
2016	24,493	32,585	4,235,475	5.78
2017	50,683	71,874	4,294,041	11.80
2018	71,447	102,334	4,333,710	16.49
2019	25,950	27,251	2,742,619	9.46
SV/ACEI/ARB -183 to -1				
2015	431	431	2,059,707	0.21
2016	4,244	4,253	2,103,055	2.02
2017	9,599	9,637	2,134,306	4.50
2018	13,355	13,414	2,146,670	6.22
2019	3,811	3,811	1,210,988	3.15

Table 6. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database between January 1, 2015 and July 31, 2019 by Year

Exclusion Criteria/Year	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
ACEI -183 to 0, SV/ARB -183 to -1				
2015	431	431	2,051,989	0.21
2016	4,241	4,250	2,095,114	2.02
2017	9,595	9,633	2,126,747	4.51
2018	13,348	13,407	2,139,718	6.24
2019	3,808	3,808	1,209,099	3.15
ARB -183 to 0, SV/ACEI -183 to -1				
2015	430	430	2,056,856	0.21
2016	4,239	4,248	2,099,876	2.02
2017	9,592	9,630	2,130,742	4.50
2018	13,342	13,401	2,142,600	6.23
2019	3,809	3,809	1,210,074	3.15

[1]Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
ACEI Users				
Exclusion Criteria: SV -183 to 0, ACEI/ARB -183 to -1				
2015				
January	17,052	17,052	975,571	17.48
February	15,337	15,337	959,059	15.99
March	17,286	17,286	975,241	17.72
April	16,659	16,659	979,107	17.01
May	15,399	15,399	978,607	15.74
June	15,076	15,076	983,419	15.33
July	15,751	15,751	1,034,872	15.22
August	14,832	14,832	1,038,893	14.28
September	15,332	15,332	1,033,728	14.83
October	15,808	15,808	1,044,506	15.13
November	15,223	15,223	1,028,048	14.81
December	16,365	16,365	1,041,739	15.71
2016				
January	15,797	15,797	1,014,127	15.58
February	15,892	15,892	1,004,795	15.82
March	17,087	17,087	1,016,779	16.81
April	15,561	15,561	1,005,934	15.47
May	14,999	14,999	1,006,228	14.91
June	14,826	14,826	1,011,876	14.65
July	14,248	14,248	1,059,532	13.45
August	15,156	15,156	1,073,024	14.12
September	14,766	14,766	1,063,655	13.88
October	14,951	14,951	1,071,374	13.95
November	14,713	14,713	1,063,587	13.83
December	15,278	15,278	1,063,428	14.37
2017				
January	15,653	15,653	1,032,174	15.17
February	14,337	14,337	1,026,183	13.97
March	15,957	15,957	1,044,808	15.27
April	14,165	14,165	1,039,908	13.62
May	14,758	14,758	1,049,111	14.07
June	13,921	13,921	1,054,733	13.20
July	13,372	13,372	1,100,994	12.15
August	14,617	14,617	1,114,529	13.11
September	13,490	13,490	1,098,501	12.28
October	14,498	14,498	1,109,463	13.07

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
November	14,175	14,175	1,100,851	12.88
December	13,975	13,975	1,110,819	12.58
2018				
January	14,731	14,731	1,078,501	13.66
February	13,701	13,701	1,064,278	12.87
March	14,884	14,884	1,077,649	13.81
April	13,825	13,825	1,074,733	12.86
May	13,807	13,807	1,080,473	12.78
June	12,134	12,134	1,077,441	11.26
July	12,632	12,632	1,118,061	11.30
August	13,351	13,351	1,126,082	11.86
September	11,711	11,711	1,105,746	10.59
October	13,442	13,442	1,122,593	11.97
November	12,755	12,755	1,110,770	11.48
December	12,411	12,411	1,119,401	11.09
2019				
January	12,568	12,568	1,034,682	12.15
February	10,322	10,322	901,831	11.45
March	11,057	11,057	908,108	12.18
April	338	338	20,256	16.69
May	277	277	17,883	15.49
June	233	233	18,107	12.87
July	212	212	18,606	11.39
Exclusion Criteria: ACEI/ARB -183 to -1				
2015				
January	17,052	17,052	975,571	17.48
February	15,337	15,337	959,059	15.99
March	17,286	17,286	975,241	17.72
April	16,659	16,659	979,107	17.01
May	15,399	15,399	978,607	15.74
June	15,076	15,076	983,419	15.33
July	15,751	15,751	1,034,872	15.22
August	14,832	14,832	1,038,897	14.28
September	15,333	15,333	1,033,765	14.83
October	15,809	15,809	1,044,632	15.13
November	15,228	15,228	1,028,287	14.81
December	16,368	16,368	1,042,141	15.71
2016				
January	15,800	15,800	1,014,699	15.57

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
February	15,897	15,897	1,005,649	15.81
March	17,105	17,105	1,018,053	16.80
April	15,577	15,577	1,007,769	15.46
May	15,017	15,017	1,008,749	14.89
June	14,848	14,848	1,015,162	14.63
July	14,280	14,280	1,064,007	13.42
August	15,200	15,200	1,078,653	14.09
September	14,805	14,805	1,070,380	13.83
October	14,991	14,991	1,079,413	13.89
November	14,775	14,775	1,072,860	13.77
December	15,337	15,337	1,074,353	14.28
2017				
January	15,733	15,733	1,044,145	15.07
February	14,411	14,411	1,039,580	13.86
March	16,044	16,044	1,059,948	15.14
April	14,259	14,259	1,056,704	13.49
May	14,833	14,833	1,067,807	13.89
June	14,009	14,009	1,075,342	13.03
July	13,464	13,464	1,124,670	11.97
August	14,743	14,743	1,140,417	12.93
September	13,616	13,616	1,126,021	12.09
October	14,625	14,625	1,139,250	12.84
November	14,312	14,312	1,132,511	12.64
December	14,109	14,109	1,144,879	12.32
2018				
January	14,882	14,882	1,112,673	13.37
February	13,843	13,843	1,100,075	12.58
March	15,011	15,011	1,115,317	13.46
April	13,992	13,992	1,114,555	12.55
May	13,939	13,939	1,122,530	12.42
June	12,276	12,276	1,121,569	10.95
July	12,812	12,812	1,165,842	10.99
August	13,527	13,527	1,176,364	11.50
September	11,885	11,885	1,157,712	10.27
October	13,627	13,627	1,177,180	11.58
November	12,932	12,932	1,166,829	11.08
December	12,595	12,595	1,177,983	10.69
2019				
January	12,743	12,743	1,088,255	11.71

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
February	10,484	10,484	951,042	11.02
March	11,196	11,196	958,959	11.68
April	338	338	20,574	16.43
May	278	278	18,174	15.30
June	235	235	18,408	12.77
July	212	212	18,929	11.20
Exclusion Criteria: None				
2015				
January	63,439	63,456	2,317,565	27.37
February	58,367	58,371	2,288,861	25.50
March	64,352	64,362	2,322,237	27.71
April	61,861	61,877	2,336,656	26.47
May	59,416	59,433	2,338,629	25.41
June	60,052	60,064	2,351,736	25.54
July	63,332	63,351	2,466,035	25.68
August	61,144	61,152	2,471,192	24.74
September	61,114	61,130	2,454,914	24.89
October	61,935	61,956	2,474,702	25.03
November	58,695	58,706	2,436,645	24.09
December	62,319	62,332	2,462,707	25.31
2016				
January	59,143	59,156	2,392,981	24.72
February	58,094	58,107	2,378,433	24.43
March	61,201	61,218	2,409,164	25.40
April	57,116	57,131	2,397,063	23.83
May	56,611	56,622	2,400,644	23.58
June	57,348	57,361	2,416,647	23.73
July	56,256	56,267	2,521,837	22.31
August	60,123	60,136	2,547,631	23.60
September	57,060	57,068	2,524,771	22.60
October	56,776	56,789	2,536,302	22.39
November	56,495	56,512	2,516,621	22.45
December	56,571	56,592	2,527,077	22.39
2017				
January	56,196	56,214	2,441,524	23.02
February	51,462	51,470	2,437,578	21.11
March	57,158	57,174	2,478,145	23.06
April	51,892	51,901	2,476,717	20.95
May	55,383	55,397	2,499,424	22.16

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
June	53,137	53,151	2,516,041	21.12
July	52,918	52,929	2,608,720	20.29
August	55,197	55,210	2,634,573	20.95
September	51,027	51,029	2,597,324	19.65
October	53,637	53,649	2,615,887	20.50
November	51,756	51,767	2,598,194	19.92
December	50,177	50,189	2,616,254	19.18
2018				
January	52,457	52,467	2,532,997	20.71
February	47,756	47,765	2,515,499	18.98
March	51,745	51,755	2,546,701	20.32
April	48,998	49,003	2,551,412	19.20
May	49,038	49,061	2,571,176	19.07
June	45,468	45,478	2,571,893	17.68
July	47,964	47,973	2,657,511	18.05
August	49,945	49,952	2,673,942	18.68
September	43,508	43,515	2,631,357	16.53
October	48,619	48,629	2,663,424	18.25
November	45,625	45,647	2,635,405	17.31
December	44,481	44,494	2,647,761	16.80
2019				
January	45,075	45,082	2,437,981	18.49
February	35,463	35,467	2,123,028	16.70
March	38,826	38,832	2,133,569	18.20
April	894	894	52,320	17.09
May	821	821	46,125	17.80
June	741	741	47,013	15.76
July	787	787	48,346	16.28
ARB Users				
Exclusion Criteria: SV -183 to 0, ACEI/ARB -183 to -1				
2015				
January	5,752	5,752	975,571	5.90
February	5,249	5,249	959,059	5.47
March	5,823	5,823	975,241	5.97
April	5,688	5,688	979,107	5.81
May	5,298	5,298	978,607	5.41
June	5,221	5,221	983,419	5.31
July	5,661	5,661	1,034,872	5.47
August	5,366	5,366	1,038,893	5.17

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
September	5,503	5,503	1,033,728	5.32
October	5,961	5,961	1,044,506	5.71
November	5,491	5,491	1,028,048	5.34
December	6,177	6,177	1,041,739	5.93
2016				
January	6,220	6,220	1,014,127	6.13
February	6,194	6,194	1,004,795	6.16
March	6,603	6,603	1,016,779	6.49
April	6,143	6,143	1,005,934	6.11
May	5,987	5,987	1,006,228	5.95
June	5,920	5,920	1,011,876	5.85
July	5,785	5,785	1,059,532	5.46
August	6,228	6,228	1,073,024	5.80
September	6,016	6,016	1,063,655	5.66
October	6,145	6,145	1,071,374	5.74
November	6,291	6,291	1,063,587	5.91
December	6,359	6,359	1,063,428	5.98
2017				
January	6,961	6,961	1,032,174	6.74
February	6,344	6,344	1,026,183	6.18
March	7,287	7,287	1,044,808	6.97
April	6,738	6,738	1,039,908	6.48
May	7,045	7,045	1,049,111	6.72
June	6,622	6,622	1,054,733	6.28
July	6,289	6,289	1,100,994	5.71
August	7,182	7,182	1,114,529	6.44
September	6,381	6,381	1,098,501	5.81
October	7,188	7,188	1,109,463	6.48
November	6,947	6,947	1,100,851	6.31
December	7,016	7,016	1,110,819	6.32
2018				
January	7,539	7,539	1,078,501	6.99
February	7,066	7,066	1,064,278	6.64
March	7,864	7,864	1,077,649	7.30
April	8,123	8,123	1,074,733	7.56
May	8,321	8,321	1,080,473	7.70
June	7,893	7,893	1,077,441	7.33
July	7,789	7,789	1,118,061	6.97
August	8,380	8,380	1,126,082	7.44

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
September	7,013	7,013	1,105,746	6.34
October	7,856	7,856	1,122,593	7.00
November	7,378	7,378	1,110,770	6.64
December	6,761	6,761	1,119,401	6.04
2019				
January	7,117	7,117	1,034,682	6.88
February	5,523	5,523	901,831	6.12
March	5,622	5,622	908,108	6.19
April	130	130	20,256	6.42
May	137	137	17,883	7.66
June	108	108	18,107	5.96
July	108	108	18,606	5.80
Exclusion Criteria: ACEI/ARB -183 to -1				
2015				
January	5,752	5,752	975,571	5.90
February	5,249	5,249	959,059	5.47
March	5,823	5,823	975,241	5.97
April	5,688	5,688	979,107	5.81
May	5,298	5,298	978,607	5.41
June	5,221	5,221	983,419	5.31
July	5,661	5,661	1,034,872	5.47
August	5,366	5,366	1,038,897	5.17
September	5,503	5,503	1,033,765	5.32
October	5,964	5,964	1,044,632	5.71
November	5,495	5,495	1,028,287	5.34
December	6,179	6,179	1,042,141	5.93
2016				
January	6,227	6,227	1,014,699	6.14
February	6,201	6,201	1,005,649	6.17
March	6,614	6,614	1,018,053	6.50
April	6,156	6,156	1,007,769	6.11
May	6,005	6,005	1,008,749	5.95
June	5,941	5,941	1,015,162	5.85
July	5,804	5,804	1,064,007	5.45
August	6,260	6,260	1,078,653	5.80
September	6,056	6,056	1,070,380	5.66
October	6,185	6,185	1,079,413	5.73
November	6,345	6,345	1,072,860	5.91
December	6,421	6,421	1,074,353	5.98

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
2017				
January	7,013	7,013	1,044,145	6.72
February	6,414	6,414	1,039,580	6.17
March	7,353	7,353	1,059,948	6.94
April	6,804	6,804	1,056,704	6.44
May	7,132	7,132	1,067,807	6.68
June	6,705	6,705	1,075,342	6.24
July	6,400	6,400	1,124,670	5.69
August	7,287	7,287	1,140,417	6.39
September	6,502	6,502	1,126,021	5.77
October	7,340	7,340	1,139,250	6.44
November	7,111	7,111	1,132,511	6.28
December	7,161	7,161	1,144,879	6.25
2018				
January	7,704	7,704	1,112,673	6.92
February	7,241	7,241	1,100,075	6.58
March	8,051	8,051	1,115,317	7.22
April	8,291	8,291	1,114,555	7.44
May	8,512	8,512	1,122,530	7.58
June	8,071	8,071	1,121,569	7.20
July	8,004	8,004	1,165,842	6.87
August	8,630	8,630	1,176,364	7.34
September	7,210	7,210	1,157,712	6.23
October	8,114	8,114	1,177,180	6.89
November	7,594	7,594	1,166,829	6.51
December	6,993	6,993	1,177,983	5.94
2019				
January	7,340	7,340	1,088,255	6.74
February	5,697	5,697	951,042	5.99
March	5,779	5,779	958,959	6.03
April	132	132	20,574	6.42
May	137	137	18,174	7.54
June	111	111	18,408	6.03
July	111	111	18,929	5.86
Exclusion Criteria: None				
2015				
January	35,103	35,106	2,317,565	15.15
February	32,042	32,046	2,288,861	14.00
March	36,107	36,112	2,322,237	15.55

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
April	34,784	34,793	2,336,656	14.89
May	33,569	33,576	2,338,629	14.35
June	34,753	34,760	2,351,736	14.78
July	36,205	36,211	2,466,035	14.68
August	34,794	34,801	2,471,192	14.08
September	35,435	35,443	2,454,914	14.43
October	35,975	35,989	2,474,702	14.54
November	33,925	33,929	2,436,645	13.92
December	36,382	36,389	2,462,707	14.77
2016				
January	35,329	35,331	2,392,981	14.76
February	34,506	34,508	2,378,433	14.51
March	37,108	37,118	2,409,164	15.40
April	34,353	34,360	2,397,063	14.33
May	34,850	34,856	2,400,644	14.52
June	35,568	35,571	2,416,647	14.72
July	34,509	34,513	2,521,837	13.68
August	37,773	37,781	2,547,631	14.83
September	35,548	35,555	2,524,771	14.08
October	35,845	35,849	2,536,302	14.13
November	35,832	35,843	2,516,621	14.24
December	36,069	36,078	2,527,077	14.27
2017				
January	36,249	36,251	2,441,524	14.85
February	33,535	33,539	2,437,578	13.76
March	37,888	37,894	2,478,145	15.29
April	34,556	34,559	2,476,717	13.95
May	37,481	37,491	2,499,424	15.00
June	36,478	36,483	2,516,041	14.50
July	35,924	35,929	2,608,720	13.77
August	38,160	38,164	2,634,573	14.48
September	34,844	34,850	2,597,324	13.42
October	37,621	37,624	2,615,887	14.38
November	36,454	36,464	2,598,194	14.03
December	35,781	35,786	2,616,254	13.68
2018				
January	37,339	37,340	2,532,997	14.74
February	34,471	34,474	2,515,499	13.70
March	37,830	37,834	2,546,701	14.85

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
April	37,554	37,557	2,551,412	14.72
May	38,348	38,358	2,571,176	14.91
June	36,909	36,916	2,571,893	14.35
July	38,604	38,614	2,657,511	14.53
August	40,213	40,225	2,673,942	15.04
September	34,048	34,052	2,631,357	12.94
October	37,749	37,759	2,663,424	14.17
November	36,208	36,215	2,635,405	13.74
December	34,624	34,634	2,647,761	13.08
2019				
January	34,839	34,846	2,437,981	14.29
February	27,212	27,215	2,123,028	12.82
March	30,949	30,953	2,133,569	14.51
April	729	729	52,320	13.93
May	658	658	46,125	14.27
June	620	620	47,013	13.19
July	659	659	48,346	13.63
SV Users with Baseline History of ACEI				
Exclusion Criteria: ACEIs on Index Date				
2015				
January	0	0	910,629	0.00
February	0	0	896,508	0.00
March	0	0	909,041	0.00
April	0	0	912,318	0.00
May	0	0	912,151	0.00
June	0	0	914,106	0.00
July	21	21	955,650	0.02
August	86	86	954,578	0.09
September	242	242	944,862	0.26
October	381	381	950,796	0.40
November	406	407	932,039	0.44
December	484	484	938,891	0.52
2016				
January	536	536	908,900	0.59
February	619	619	900,874	0.69
March	858	858	912,507	0.94
April	905	905	907,795	1.00
May	1,010	1,011	907,063	1.11
June	1,259	1,259	909,043	1.38

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
July	1,347	1,347	943,874	1.43
August	1,671	1,671	950,213	1.76
September	1,570	1,570	937,364	1.67
October	1,638	1,639	938,726	1.74
November	1,826	1,826	926,404	1.97
December	1,769	1,769	931,362	1.90
2017				
January	1,821	1,821	895,020	2.03
February	1,787	1,787	889,390	2.01
March	2,095	2,095	903,355	2.32
April	2,111	2,111	900,247	2.34
May	2,402	2,403	904,855	2.65
June	2,194	2,195	905,786	2.42
July	2,203	2,203	931,259	2.37
August	2,368	2,368	936,302	2.53
September	2,149	2,149	918,171	2.34
October	2,476	2,476	920,484	2.69
November	2,318	2,319	909,159	2.55
December	2,254	2,255	911,151	2.47
2018				
January	2,506	2,507	875,402	2.86
February	2,280	2,280	866,327	2.63
March	2,602	2,602	876,951	2.97
April	2,579	2,579	875,429	2.95
May	2,741	2,742	879,393	3.12
June	2,532	2,532	874,855	2.89
July	2,538	2,538	897,935	2.83
August	2,704	2,705	899,392	3.01
September	2,181	2,181	879,999	2.48
October	2,576	2,576	886,361	2.91
November	2,412	2,413	871,935	2.77
December	2,326	2,326	870,124	2.67
2019				
January	2,587	2,588	796,998	3.25
February	1,957	1,957	685,573	2.85
March	2,183	2,184	689,170	3.17
April	30	30	19,098	1.57
May	21	21	16,800	1.25
June	29	29	17,145	1.69

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
July	24	24	17,586	1.36
Exclusion Criteria: SV -183 to -1, ACEI on Index Date				
2015				
January	0	0	910,629	0.00
February	0	0	896,508	0.00
March	0	0	909,041	0.00
April	0	0	912,318	0.00
May	0	0	912,151	0.00
June	0	0	914,106	0.00
July	21	21	955,650	0.02
August	86	86	954,556	0.09
September	239	239	944,751	0.25
October	370	370	950,437	0.39
November	378	378	931,323	0.41
December	414	414	937,780	0.44
2016				
January	429	429	907,456	0.47
February	491	491	899,060	0.55
March	692	692	910,285	0.76
April	739	739	905,072	0.82
May	790	790	903,863	0.87
June	995	995	905,422	1.10
July	1,082	1,082	939,480	1.15
August	1,327	1,327	945,044	1.40
September	1,187	1,187	931,430	1.27
October	1,218	1,218	932,187	1.31
November	1,371	1,371	919,413	1.49
December	1,306	1,306	923,723	1.41
2017				
January	1,282	1,282	887,383	1.44
February	1,319	1,319	881,556	1.50
March	1,580	1,580	895,135	1.77
April	1,590	1,590	891,470	1.78
May	1,796	1,796	895,557	2.01
June	1,592	1,592	895,898	1.78
July	1,533	1,533	920,743	1.66
August	1,702	1,702	925,469	1.84
September	1,510	1,510	907,048	1.66
October	1,715	1,715	909,206	1.89

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
November	1,606	1,606	897,791	1.79
December	1,599	1,599	899,715	1.78
2018				
January	1,709	1,709	864,571	1.98
February	1,652	1,652	855,344	1.93
March	1,927	1,927	865,632	2.23
April	1,902	1,902	863,650	2.20
May	2,056	2,056	867,234	2.37
June	1,855	1,855	862,219	2.15
July	1,775	1,775	884,713	2.01
August	1,852	1,852	885,850	2.09
September	1,480	1,480	866,343	1.71
October	1,847	1,847	872,905	2.12
November	1,762	1,762	858,621	2.05
December	1,726	1,726	856,837	2.01
2019				
January	1,818	1,818	785,467	2.31
February	1,462	1,462	675,213	2.17
March	1,656	1,656	678,617	2.44
April	27	27	18,939	1.43
May	18	18	16,653	1.08
June	22	22	16,990	1.29
July	19	19	17,422	1.09
SV Users with Baseline History of ARBs				
Exclusion Criteria: ARBs on Index Date				
2015				
January	0	0	537,085	0.00
February	0	0	532,548	0.00
March	0	0	542,118	0.00
April	0	0	547,379	0.00
May	0	0	550,119	0.00
June	0	0	554,450	0.00
July	13	13	581,354	0.02
August	72	72	582,778	0.12
September	164	164	579,803	0.28
October	256	256	586,482	0.44
November	291	291	578,852	0.50
December	327	327	586,345	0.56

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
2016				
January	370	370	571,523	0.65
February	425	425	570,792	0.74
March	587	587	581,998	1.01
April	597	597	582,470	1.02
May	752	752	585,337	1.28
June	850	850	591,853	1.44
July	950	950	616,892	1.54
August	1,019	1,019	623,829	1.63
September	1,070	1,070	619,663	1.73
October	1,035	1,035	622,938	1.66
November	1,194	1,194	619,472	1.93
December	1,193	1,193	625,710	1.91
2017				
January	1,191	1,191	603,930	1.97
February	1,141	1,141	604,186	1.89
March	1,390	1,390	617,134	2.25
April	1,338	1,338	618,831	2.16
May	1,643	1,643	627,209	2.62
June	1,550	1,550	633,321	2.45
July	1,492	1,492	653,570	2.28
August	1,702	1,702	661,346	2.57
September	1,549	1,549	653,630	2.37
October	1,618	1,618	659,534	2.45
November	1,662	1,662	656,816	2.53
December	1,540	1,540	661,416	2.33
2018				
January	1,858	1,859	642,857	2.89
February	1,599	1,599	641,687	2.49
March	1,822	1,822	653,543	2.79
April	1,847	1,847	658,593	2.80
May	1,979	1,980	668,085	2.96
June	1,817	1,817	671,786	2.70
July	1,952	1,952	693,257	2.82
August	2,063	2,063	701,105	2.94
September	1,751	1,751	692,223	2.53
October	2,015	2,015	702,024	2.87
November	1,981	1,983	696,374	2.84
December	1,898	1,898	699,161	2.71

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
2019				
January	2,148	2,148	646,554	3.32
February	1,644	1,644	564,332	2.91
March	1,848	1,848	568,374	3.25
April	22	22	14,310	1.54
May	18	18	12,675	1.42
June	19	19	12,942	1.47
July	18	18	13,315	1.35
Exclusion Criteria: SV -183 to -1, ARBs on Index Date				
2015				
January	0	0	537,085	0.00
February	0	0	532,548	0.00
March	0	0	542,118	0.00
April	0	0	547,379	0.00
May	0	0	550,119	0.00
June	0	0	554,450	0.00
July	13	13	581,354	0.02
August	72	72	582,762	0.12
September	163	163	579,716	0.28
October	249	249	586,227	0.42
November	268	268	578,350	0.46
December	275	275	585,558	0.47
2016				
January	307	307	570,489	0.54
February	326	326	569,489	0.57
March	474	474	580,417	0.82
April	483	483	580,542	0.83
May	616	616	583,120	1.06
June	676	676	589,244	1.15
July	742	742	613,749	1.21
August	776	776	620,188	1.25
September	795	795	615,629	1.29
October	758	758	618,403	1.23
November	876	876	614,649	1.43
December	885	885	620,448	1.43
2017				
January	844	844	598,747	1.41
February	838	838	598,848	1.40
March	1,055	1,055	611,455	1.73

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
April	1,029	1,029	612,803	1.68
May	1,237	1,237	620,792	1.99
June	1,140	1,140	626,373	1.82
July	1,049	1,049	646,045	1.62
August	1,213	1,213	653,466	1.86
September	1,072	1,072	645,429	1.66
October	1,157	1,157	651,061	1.78
November	1,180	1,180	648,182	1.82
December	1,102	1,102	652,575	1.69
2018				
January	1,239	1,239	634,399	1.95
February	1,120	1,120	632,978	1.77
March	1,325	1,325	644,620	2.06
April	1,354	1,354	649,313	2.09
May	1,479	1,479	658,413	2.25
June	1,284	1,284	661,714	1.94
July	1,342	1,342	682,698	1.97
August	1,456	1,456	690,155	2.11
September	1,197	1,197	681,055	1.76
October	1,400	1,400	690,785	2.03
November	1,435	1,435	685,045	2.09
December	1,334	1,334	687,623	1.94
2019				
January	1,435	1,435	636,428	2.25
February	1,188	1,188	555,167	2.14
March	1,403	1,403	559,033	2.51
April	17	17	14,190	1.20
May	13	13	12,560	1.04
June	15	15	12,822	1.17
July	13	13	13,185	0.99
SV Users				
Exclusion Criteria: None				
2015				
January	0	0	2,317,565	0.00
February	0	0	2,288,861	0.00
March	0	0	2,322,237	0.00
April	0	0	2,336,656	0.00
May	0	0	2,338,629	0.00
June	0	0	2,351,736	0.00

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
July	33	33	2,466,035	0.01
August	168	168	2,471,192	0.07
September	450	450	2,454,914	0.18
October	712	713	2,474,702	0.29
November	782	783	2,436,645	0.32
December	921	921	2,462,707	0.37
2016				
January	1,050	1,050	2,392,981	0.44
February	1,231	1,231	2,378,433	0.52
March	1,716	1,716	2,409,164	0.71
April	1,808	1,808	2,397,063	0.75
May	2,185	2,186	2,400,644	0.91
June	2,656	2,656	2,416,647	1.10
July	2,972	2,973	2,521,837	1.18
August	3,482	3,482	2,547,631	1.37
September	3,501	3,501	2,524,771	1.39
October	3,663	3,664	2,536,302	1.44
November	4,133	4,133	2,516,621	1.64
December	4,185	4,185	2,527,077	1.66
2017				
January	4,586	4,586	2,441,524	1.88
February	4,387	4,387	2,437,578	1.80
March	5,277	5,278	2,478,145	2.13
April	5,306	5,306	2,476,717	2.14
May	6,167	6,169	2,499,424	2.47
June	5,988	5,990	2,516,041	2.38
July	6,072	6,072	2,608,720	2.33
August	6,803	6,803	2,634,573	2.58
September	6,293	6,293	2,597,324	2.42
October	6,995	6,997	2,615,887	2.67
November	7,056	7,057	2,598,194	2.72
December	6,933	6,936	2,616,254	2.65
2018				
January	8,633	8,635	2,532,997	3.41
February	7,169	7,169	2,515,499	2.85
March	8,051	8,052	2,546,701	3.16
April	7,975	7,975	2,551,412	3.13
May	8,557	8,559	2,571,176	3.33
June	8,166	8,167	2,571,893	3.18

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
July	8,674	8,675	2,657,511	3.26
August	9,286	9,288	2,673,942	3.47
September	8,268	8,270	2,631,357	3.14
October	9,350	9,351	2,663,424	3.51
November	9,132	9,136	2,635,405	3.47
December	9,056	9,057	2,647,761	3.42
2019				
January	11,062	11,063	2,437,981	4.54
February	7,699	7,699	2,123,028	3.63
March	8,230	8,233	2,133,569	3.86
April	67	67	52,320	1.28
May	58	58	46,125	1.26
June	66	66	47,013	1.40
July	65	65	48,346	1.34
Exclusion Criteria: SV/ACEI/ARB -183 to -1				
2015				
January	0	0	975,571	0.00
February	0	0	959,059	0.00
March	0	0	975,241	0.00
April	0	0	979,107	0.00
May	0	0	978,607	0.00
June	0	0	983,419	0.00
July	*****	*****	*****	0.00
August	*****	*****	*****	0.02
September	76	76	1,033,733	0.07
October	105	105	1,044,508	0.10
November	106	106	1,028,051	0.10
December	120	120	1,041,741	0.12
2016				
January	146	146	1,014,128	0.14
February	157	157	1,004,802	0.16
March	227	227	1,016,790	0.22
April	238	238	1,005,948	0.24
May	299	299	1,006,229	0.30
June	368	368	1,011,896	0.36
July	412	412	1,059,554	0.39
August	473	473	1,073,046	0.44
September	432	432	1,063,676	0.41
October	475	475	1,071,377	0.44

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
November	499	499	1,063,614	0.47
December	527	527	1,063,462	0.50
2017				
January	643	643	1,032,187	0.62
February	609	609	1,026,212	0.59
March	726	726	1,044,866	0.69
April	701	701	1,039,923	0.67
May	851	851	1,049,162	0.81
June	864	864	1,054,789	0.82
July	809	809	1,101,023	0.73
August	933	933	1,114,582	0.84
September	776	776	1,098,538	0.71
October	889	889	1,109,486	0.80
November	921	921	1,100,904	0.84
December	915	915	1,110,871	0.82
2018				
January	1,113	1,113	1,078,527	1.03
February	981	981	1,064,341	0.92
March	1,158	1,158	1,077,718	1.07
April	1,117	1,117	1,074,758	1.04
May	1,159	1,159	1,080,539	1.07
June	1,095	1,095	1,077,509	1.02
July	1,054	1,054	1,118,092	0.94
August	1,213	1,213	1,126,143	1.08
September	1,079	1,079	1,105,785	0.98
October	1,138	1,138	1,122,663	1.01
November	1,085	1,085	1,110,840	0.98
December	1,222	1,222	1,119,444	1.09
2019				
January	1,462	1,462	1,034,734	1.41
February	1,149	1,149	901,903	1.27
March	1,178	1,178	908,200	1.30
April	*****	*****	*****	0.25
May	*****	*****	*****	0.28
June	*****	*****	*****	0.39
July	*****	*****	*****	0.27
Exclusion Criteria: ACEI -183 to 0, SV/ARB -183 to -1				
2015				
January	0	0	974,610	0.00

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
February	0	0	958,225	0.00
March	0	0	974,299	0.00
April	0	0	977,598	0.00
May	0	0	977,250	0.00
June	0	0	982,060	0.00
July	*****	*****	*****	0.00
August	*****	*****	*****	0.02
September	76	76	1,032,417	0.07
October	105	105	1,043,109	0.10
November	106	106	1,027,150	0.10
December	120	120	1,040,314	0.12
2016				
January	146	146	1,013,199	0.14
February	157	157	1,003,319	0.16
March	227	227	1,015,173	0.22
April	238	238	1,004,455	0.24
May	298	298	1,005,305	0.30
June	368	368	1,010,509	0.36
July	412	412	1,058,311	0.39
August	472	472	1,071,732	0.44
September	432	432	1,062,313	0.41
October	475	475	1,070,363	0.44
November	498	498	1,062,268	0.47
December	527	527	1,062,098	0.50
2017				
January	643	643	1,031,260	0.62
February	609	609	1,024,889	0.59
March	726	726	1,043,432	0.70
April	701	701	1,038,911	0.67
May	851	851	1,047,894	0.81
June	862	862	1,053,482	0.82
July	808	808	1,100,149	0.73
August	933	933	1,113,238	0.84
September	775	775	1,097,315	0.71
October	889	889	1,108,633	0.80
November	921	921	1,099,562	0.84
December	915	915	1,109,611	0.82
2018				
January	1,113	1,113	1,077,697	1.03

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
February	981	981	1,063,077	0.92
March	1,158	1,158	1,076,396	1.08
April	1,115	1,115	1,073,905	1.04
May	1,157	1,157	1,079,277	1.07
June	1,095	1,095	1,076,357	1.02
July	1,054	1,054	1,117,257	0.94
August	1,213	1,213	1,124,915	1.08
September	1,079	1,079	1,105,006	0.98
October	1,137	1,137	1,121,430	1.01
November	1,084	1,084	1,109,681	0.98
December	1,221	1,221	1,118,656	1.09
2019				
January	1,461	1,461	1,033,909	1.41
February	1,147	1,147	900,959	1.27
March	1,178	1,178	907,218	1.30
April	*****	*****	*****	0.25
May	*****	*****	*****	0.28
June	*****	*****	*****	0.39
July	*****	*****	*****	0.27
Exclusion Criteria: ARB -183 to 0, SV/ACEI -183 to -1				
2015				
January	0	0	975,244	0.00
February	0	0	958,773	0.00
March	0	0	974,898	0.00
April	0	0	978,597	0.00
May	0	0	978,106	0.00
June	0	0	982,904	0.00
July	*****	*****	*****	0.00
August	*****	*****	*****	0.02
September	76	76	1,033,248	0.07
October	104	104	1,043,935	0.10
November	106	106	1,027,721	0.10
December	120	120	1,041,092	0.12
2016				
January	146	146	1,013,743	0.14
February	157	157	1,004,197	0.16
March	227	227	1,016,136	0.22
April	238	238	1,005,398	0.24
May	298	298	1,005,855	0.30

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
June	368	368	1,011,311	0.36
July	412	412	1,059,022	0.39
August	473	473	1,072,490	0.44
September	431	431	1,063,119	0.41
October	475	475	1,070,967	0.44
November	496	496	1,063,053	0.47
December	527	527	1,062,872	0.50
2017				
January	643	643	1,031,766	0.62
February	607	607	1,025,554	0.59
March	726	726	1,044,250	0.70
April	701	701	1,039,472	0.67
May	851	851	1,048,521	0.81
June	863	863	1,054,141	0.82
July	809	809	1,100,611	0.74
August	933	933	1,113,963	0.84
September	775	775	1,097,941	0.71
October	887	887	1,109,062	0.80
November	921	921	1,100,254	0.84
December	914	914	1,110,199	0.82
2018				
January	1,113	1,113	1,078,013	1.03
February	979	979	1,063,703	0.92
March	1,157	1,157	1,077,004	1.07
April	1,115	1,115	1,074,240	1.04
May	1,159	1,159	1,079,738	1.07
June	1,094	1,094	1,076,742	1.02
July	1,053	1,053	1,117,607	0.94
August	1,210	1,210	1,125,423	1.08
September	1,078	1,078	1,105,340	0.98
October	1,137	1,137	1,121,935	1.01
November	1,084	1,084	1,110,164	0.98
December	1,222	1,222	1,119,024	1.09
2019				
January	1,462	1,462	1,034,321	1.41
February	1,147	1,147	901,408	1.27
March	1,178	1,178	907,693	1.30
April	*****	*****	*****	0.25
May	*****	*****	*****	0.28

Table 7. Summary of Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB), and Sacubitril/Valsartan (SV) Users among Patients Diagnosed with Heart Failure in the Sentinel Distributed Database (SDD) between January 1, 2015 and July 31, 2019 by Year and Month

Month	Members with Heart Failure Diagnosis and at Least One Qualifying Episode	Qualifying Episodes	Eligible Members[1] with Heart Failure Diagnosis	Members with at Least One Qualifying Episode per 1,000 Members with Heart Failure Diagnosis
June	*****	*****	*****	0.39
July	*****	*****	*****	0.27

[1]Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Appendix A. Dates of Available Data for Each Data Partner (DP) in the Sentinel Distributed Database (SDD) as of Request Distribution Date (February 27, 2020)

DP ID	Start Date[1]	End Date[1]
DP01	01/01/2000	02/28/2019
DP02	01/01/2000	01/31/2019
DP03	01/01/2004	03/31/2019
DP04	01/01/2008	03/31/2019
DP05	01/01/2006	12/31/2018
DP06	01/01/2000	12/31/2017
DP07	01/01/2010	03/31/2019
DP08	01/01/2000	07/31/2019
DP09	06/01/2007	01/31/2019
DP10	01/01/2000	04/30/2018
DP11	01/01/2005	07/31/2018
DP12	01/01/2000	04/30/2019
DP13	01/01/2000	06/30/2018
DP14	01/01/2008	12/31/2018
DP15	01/01/2000	03/31/2019
DP16	01/01/2012	06/30/2017

[1]The start and end dates are based on the minimum and maximum dates within each DP. The month with the maximum date must have at least 80% of the number of records in the previous month.

Appendix B. Generic and Brand Names of Medical Products Used to Define Exposures and Inclusion/Exclusion Criteria in this Request

Generic Name	Brand Name
Angiotensin-Converting Enzyme Inhibitors	
lisinopril	Prinivil
ramipril	Ramipril
perindopril erbumine	Perindopril Erbumine
quinapril HCl/hydrochlorothiazide	Accuretic
quinapril HCl	Accupril
trandolapril	Mavik
trandolapril/verapamil HCl	Tarka
amlodipine besylate/benazepril HCl	Lotrel
moexipril HCl	Univasc
moexipril HCl/hydrochlorothiazide	Uniretic
moexipril HCl	Moexipril
enalapril maleate	Enalapril Maleate
enalapril maleate/hydrochlorothiazide	Enalapril-Hydrochlorothiazide
benazepril HCl	Benazepril
moexipril HCl/hydrochlorothiazide	Moexipril-Hydrochlorothiazide
fosinopril sodium	Fosinopril
trandolapril	Trandolapril
amlodipine besylate/benazepril HCl	Amlodipine-Benazepril
captopril	Captopril
lisinopril/hydrochlorothiazide	Lisinopril-Hydrochlorothiazide
lisinopril	Lisinopril
benazepril HCl/hydrochlorothiazide	Benazepril-Hydrochlorothiazide
fosinopril sodium/hydrochlorothiazide	Fosinopril-Hydrochlorothiazide
enalapril maleate	Vasotec
enalapril maleate/hydrochlorothiazide	Vaseretic
lisinopril	Zestril
lisinopril/hydrochlorothiazide	Zestoretic
captopril/hydrochlorothiazide	Captopril-Hydrochlorothiazide
quinapril HCl/hydrochlorothiazide	Quinapril-Hydrochlorothiazide
benazepril HCl	Lotensin
benazepril HCl/hydrochlorothiazide	Lotensin Hct
quinapril HCl	Quinapril
ramipril	Altace
enalapril maleate	Epaned
lisinopril	Qbrelis
trandolapril/verapamil HCl	Trandolapril-Verapamil
perindopril erbumine	Aceon
perindopril arginine/amlodipine besylate	Prestalia
Angiotensin II Receptor Blockers	
losartan potassium/hydrochlorothiazide	Hyzaar
losartan potassium	Cozaar
nebivolol HCl/valsartan	Byvalson
irbesartan	Avapro
irbesartan/hydrochlorothiazide	Avalide
losartan potassium	Losartan

Appendix B. Generic and Brand Names of Medical Products Used to Define Exposures and Inclusion/Exclusion Criteria in this Request

Generic Name	Brand Name
losartan potassium/hydrochlorothiazide	Losartan-Hydrochlorothiazide
irbesartan	Irbesartan
irbesartan/hydrochlorothiazide	Irbesartan-Hydrochlorothiazide
telmisartan	Telmisartan
telmisartan/hydrochlorothiazide	Telmisartan-Hydrochlorothiazid
eprosartan mesylate/hydrochlorothiazide	Teveten Hct
eprosartan mesylate	Teveten
valsartan/hydrochlorothiazide	Diovan Hct
valsartan	Diovan
amlodipine besylate/valsartan	Exforge
amlodipine besylate/valsartan/hydrochlorothiazide	Exforge Hct
olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide	Olmesartan-Amlodipin-Hcthiazid
amlodipine besylate/olmesartan medoxomil	Amlodipine-Olmesartan
amlodipine besylate/valsartan/hydrochlorothiazide	Amlodipine-Valsartan-Hcthiazid
valsartan	Valsartan
olmesartan medoxomil	Olmesartan
olmesartan medoxomil/hydrochlorothiazide	Olmesartan-Hydrochlorothiazide
amlodipine besylate/valsartan	Amlodipine-Valsartan
candesartan cilexetil	Atacand
candesartan cilexetil/hydrochlorothiazide	Atacand Hct
telmisartan/amlodipine besylate	Telmisartan-Amlodipine
candesartan cilexetil/hydrochlorothiazide	Candesartan-Hydrochlorothiazid
valsartan/hydrochlorothiazide	Valsartan-Hydrochlorothiazide
eprosartan mesylate	Eprosartan
telmisartan	Micardis
telmisartan/hydrochlorothiazide	Micardis Hct
telmisartan/amlodipine besylate	Twynsta
candesartan cilexetil	Candesartan
olmesartan medoxomil	Benicar
olmesartan medoxomil/hydrochlorothiazide	Benicar Hct
amlodipine besylate/olmesartan medoxomil	Azor
azilsartan medoxomil	Edarbi
azilsartan medoxomil/chlorthalidone	Edarbyclor
olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide	Tribenzor
Sacubitril/Valsartan	
sacubitril/valsartan	Entresto

Appendix C. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Type	Code Category
	Heart failure		
402.01	Malignant hypertensive heart disease with heart failure	ICD-9-CM	Diagnosis
402.11	Benign hypertensive heart disease with heart failure	ICD-9-CM	Diagnosis
402.91	Hypertensive heart disease, unspecified, with heart failure	ICD-9-CM	Diagnosis
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	ICD-9-CM	Diagnosis
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure	ICD-9-CM	Diagnosis
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	ICD-9-CM	Diagnosis
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	ICD-9-CM	Diagnosis
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or	ICD-9-CM	Diagnosis
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	ICD-9-CM	Diagnosis
428	Heart failure	ICD-9-CM	Diagnosis
428.0	Congestive heart failure, unspecified	ICD-9-CM	Diagnosis
428.1	Left heart failure	ICD-9-CM	Diagnosis
428.2	Systolic heart failure	ICD-9-CM	Diagnosis
428.20	Unspecified systolic heart failure	ICD-9-CM	Diagnosis
428.21	Acute systolic heart failure	ICD-9-CM	Diagnosis
428.22	Chronic systolic heart failure	ICD-9-CM	Diagnosis
428.23	Acute on chronic systolic heart failure	ICD-9-CM	Diagnosis
428.3	Diastolic heart failure	ICD-9-CM	Diagnosis
428.30	Unspecified diastolic heart failure	ICD-9-CM	Diagnosis
428.31	Acute diastolic heart failure	ICD-9-CM	Diagnosis
428.32	Chronic diastolic heart failure	ICD-9-CM	Diagnosis
428.33	Acute on chronic diastolic heart failure	ICD-9-CM	Diagnosis
428.4	Combined systolic and diastolic heart failure	ICD-9-CM	Diagnosis
428.40	Unspecified combined systolic and diastolic heart failure	ICD-9-CM	Diagnosis
428.41	Acute combined systolic and diastolic heart failure	ICD-9-CM	Diagnosis
428.42	Chronic combined systolic and diastolic heart failure	ICD-9-CM	Diagnosis
428.43	Acute on chronic combined systolic and diastolic heart failure	ICD-9-CM	Diagnosis
428.9	Unspecified heart failure	ICD-9-CM	Diagnosis
I11.0	Hypertensive heart disease with heart failure	ICD-10-CM	Diagnosis
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	ICD-10-CM	Diagnosis
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	ICD-10-CM	Diagnosis
I50	Heart failure	ICD-10-CM	Diagnosis
I50.1	Left ventricular failure, unspecified	ICD-10-CM	Diagnosis
I50.2	Systolic (congestive) heart failure	ICD-10-CM	Diagnosis
I50.20	Unspecified systolic (congestive) heart failure	ICD-10-CM	Diagnosis

Appendix C. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Inclusion Criteria in this Request

Code	Description	Code Type	Code Category
I50.21	Acute systolic (congestive) heart failure	ICD-10-CM	Diagnosis
I50.22	Chronic systolic (congestive) heart failure	ICD-10-CM	Diagnosis
I50.23	Acute on chronic systolic (congestive) heart failure	ICD-10-CM	Diagnosis
I50.3	Diastolic (congestive) heart failure	ICD-10-CM	Diagnosis
I50.30	Unspecified diastolic (congestive) heart failure	ICD-10-CM	Diagnosis
I50.31	Acute diastolic (congestive) heart failure	ICD-10-CM	Diagnosis
I50.32	Chronic diastolic (congestive) heart failure	ICD-10-CM	Diagnosis
I50.33	Acute on chronic diastolic (congestive) heart failure	ICD-10-CM	Diagnosis
I50.4	Combined systolic (congestive) and diastolic (congestive) heart failure	ICD-10-CM	Diagnosis
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	ICD-10-CM	Diagnosis
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	ICD-10-CM	Diagnosis
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart	ICD-10-CM	Diagnosis
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	ICD-10-CM	Diagnosis
I50.810	Right heart failure, unspecified	ICD-10-CM	Diagnosis
I50.811	Acute right heart failure	ICD-10-CM	Diagnosis
I50.812	Chronic right heart failure	ICD-10-CM	Diagnosis
I50.813	Acute on chronic right heart failure	ICD-10-CM	Diagnosis
I50.814	Right heart failure due to left heart failure	ICD-10-CM	Diagnosis
I50.82	Biventricular heart failure	ICD-10-CM	Diagnosis
I50.83	High output heart failure	ICD-10-CM	Diagnosis
I50.84	End stage heart failure	ICD-10-CM	Diagnosis
I50.89	Other heart failure	ICD-10-CM	Diagnosis
I50.9	Heart failure, unspecified	ICD-10-CM	Diagnosis

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
Angiotensin-Converting Enzyme (ACE) Inhibitors	
lisinopril	Prinivil
ramipril	Ramipril
perindopril erbumine	Perindopril Erbumine
quinapril HCl/hydrochlorothiazide	Accuretic
quinapril HCl	Accupril
trandolapril	Mavik
trandolapril/verapamil HCl	Tarka
amlodipine besylate/benazepril HCl	Lotrel
moexipril HCl	Univasc
moexipril HCl/hydrochlorothiazide	Uniretic
moexipril HCl	Moexipril
enalapril maleate	Enalapril Maleate
enalapril maleate/hydrochlorothiazide	Enalapril-Hydrochlorothiazide
benazepril HCl	Benazepril
moexipril HCl/hydrochlorothiazide	Moexipril-Hydrochlorothiazide
fosinopril sodium	Fosinopril
trandolapril	Trandolapril
amlodipine besylate/benazepril HCl	Amlodipine-Benazepril
captopril	Captopril
lisinopril/hydrochlorothiazide	Lisinopril-Hydrochlorothiazide
lisinopril	Lisinopril
benazepril HCl/hydrochlorothiazide	Benazepril-Hydrochlorothiazide
fosinopril sodium/hydrochlorothiazide	Fosinopril-Hydrochlorothiazide
enalapril maleate	Vasotec
enalapril maleate/hydrochlorothiazide	Vaseretic
lisinopril	Zestril
lisinopril/hydrochlorothiazide	Zestoretic
captopril/hydrochlorothiazide	Captopril-Hydrochlorothiazide
quinapril HCl/hydrochlorothiazide	Quinapril-Hydrochlorothiazide
benazepril HCl	Lotensin
benazepril HCl/hydrochlorothiazide	Lotensin HCT
quinapril HCl	Quinapril
ramipril	Altace
enalapril maleate	Epaned
lisinopril	Qbrelis
trandolapril/verapamil HCl	Trandolapril-Verapamil
perindopril erbumine	Aceon
perindopril arginine/amlodipine besylate	Prestalia
Angiotensin II Receptor Blockers (ARBs)	
losartan potassium/hydrochlorothiazide	Hyzaar
losartan potassium	Cozaar
nebivolol HCl/valsartan	Byvalson
irbesartan	Avapro
irbesartan/hydrochlorothiazide	Avalide
losartan potassium	Losartan
losartan potassium/hydrochlorothiazide	Losartan-Hydrochlorothiazide

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
irbesartan	Irbesartan
irbesartan/hydrochlorothiazide	Irbesartan-Hydrochlorothiazide
telmisartan	Telmisartan
telmisartan/hydrochlorothiazide	Telmisartan-Hydrochlorothiazid
eprosartan mesylate/hydrochlorothiazide	Teveten HCT
eprosartan mesylate	Teveten
valsartan/hydrochlorothiazide	Diovan HCT
valsartan	Diovan
amlodipine besylate/valsartan	Exforge
amlodipine besylate/valsartan/hydrochlorothiazide	Exforge HCT
olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide	Olmesartan-Amlodipin-HCThiazid
amlodipine besylate/olmesartan medoxomil	Amlodipine-Olmesartan
amlodipine besylate/valsartan/hydrochlorothiazide	Amlodipine-Valsartan-HCThiazid
valsartan	Valsartan
olmesartan medoxomil	Olmesartan
olmesartan medoxomil/hydrochlorothiazide	Olmesartan-Hydrochlorothiazide
amlodipine besylate/valsartan	Amlodipine-Valsartan
candesartan cilexetil	Atacand
candesartan cilexetil/hydrochlorothiazide	Atacand HCT
telmisartan/amlodipine besylate	Telmisartan-Amlodipine
candesartan cilexetil/hydrochlorothiazide	Candesartan-Hydrochlorothiazid
valsartan/hydrochlorothiazide	Valsartan-Hydrochlorothiazide
eprosartan mesylate	Eprosartan
telmisartan	Micardis
telmisartan/hydrochlorothiazide	Micardis HCT
telmisartan/amlodipine besylate	Twynsta
candesartan cilexetil	Candesartan
olmesartan medoxomil	Benicar
olmesartan medoxomil/hydrochlorothiazide	Benicar HCT
amlodipine besylate/olmesartan medoxomil	Azor
azilsartan medoxomil	Edarbi
azilsartan medoxomil/chlorthalidone	Edarbyclor
olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide	Tribenzor
Sacubitril/Valsartan	
sacubitril/valsartan	Entresto
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)	
naproxen	Naprosyn
naproxen sodium	Anaprox
naproxen sodium	Anaprox Ds
naproxen	Ec-Naprosyn
oxaprozin	Daypro
diclofenac sodium/misoprostol	Arthrotec 50
diclofenac sodium/misoprostol	Arthrotec 75
celecoxib	Celebrex
ibuprofen	Children'S Motrin

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
ibuprofen	Motrin Ib
meloxicam	Meloxicam
piroxicam	Feldene
hydrocodone/ibuprofen	Vicoprofen
diclofenac potassium	Cataflam
diclofenac sodium	Voltaren-Xr
naproxen	Naproxen
ketorolac tromethamine	Ketorolac
naproxen sodium	Naproxen Sodium
flurbiprofen	Flurbiprofen
piroxicam	Piroxicam
etodolac	Etodolac
oxaprozin	Oxaprozin
diclofenac potassium	Diclofenac Potassium
nabumetone	Nabumetone
diclofenac sodium	Diclofenac Sodium
tolmetin sodium	Tolmetin
ketoprofen	Ketoprofen
indomethacin	Indomethacin
hydrocodone/ibuprofen	Hydrocodone-Ibuprofen
celecoxib	Celecoxib
ibuprofen/diphenhydramine citrate	Ibuprofen PM
ibuprofen	Infant'S Ibuprofen
ibuprofen	Ibuprofen
ibuprofen	Children'S Ibuprofen
naproxen sodium	All Day Pain Relief
ibuprofen	Ibuprofen Jr Strength
sumatriptan succinate/naproxen sodium	Treximet
ibuprofen/oxycodone HCl	Ibuprofen-Oxycodone
naproxen sodium/pseudoephedrine HCl	Aleve Cold And Sinus
naproxen sodium/pseudoephedrine HCl	Aleve Sinus And Headache
ibuprofen/pseudoephedrine HCl	Wal-Profen Cold-Sinus
ibuprofen	Wal-Profen
naproxen sodium	Wal-Proxen
naproxen sodium/pseudoephedrine HCl	All Day Pain Relief Sinus,Cold
ibuprofen/pseudoephedrine HCl	Wal-Profen D Cold And Sinus
ibuprofen/diphenhydramine HCl	Ibuprofen PM
sulindac	Sulindac
fenoprofen calcium	Fenoprofen
meclofenamate sodium	Meclofenamate
ibuprofen	Infant'S Motrin
ibuprofen/diphenhydramine citrate	Motrin PM
naproxen sodium	All Day Relief
ibuprofen/phenylephrine HCl	Congestion Relief (Ibuprof-Pe)
ibuprofen	Advil
ibuprofen/diphenhydramine citrate	Advil PM
ibuprofen/diphenhydramine HCl	Advil PM Liqui-Gels
ibuprofen	Advil Migraine

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
ibuprofen	Advil Liqui-Gel
ibuprofen	Children'S Advil
ibuprofen/pseudoephedrine HCl	Advil Cold And Sinus
chlorpheniramine maleate/pseudoephedrine HCl/ibuprofen	Advil Allergy Sinus
ibuprofen	Infant'S Advil
ibuprofen/phenylephrine HCl	Advil Congestion Relief
chlorpheniramine maleate/phenylephrine HCl/ibuprofen	Advil Allergy-Congestion Rlf
mefenamic acid	Mefenamic Acid
diclofenac sodium/misoprostol	Diclofenac-Misoprostol
meloxicam	Mobic
ibuprofen	Ibu-200
ibuprofen	Ibuprofen Ib
ibuprofen/pseudoephedrine HCl	Ibuprofen Cold-Sinus(With Pse)
naproxen sodium/pseudoephedrine HCl	Sinus And Cold-D
ibuprofen	Children'S Ibu-Drops
naproxen sodium	Midol (Naproxen)
diclofenac potassium	Zipsor
diclofenac potassium	Cambia
naproxen sodium	Naprelan Cr
ibuprofen/pseudoephedrine HCl	Cold And Sinus Pain Relief
hydrocodone/ibuprofen	Reprexain
naproxen sodium	Aleve
naproxen sodium/pseudoephedrine HCl	Aleve-D Sinus And Headache
naproxen sodium/pseudoephedrine HCl	Aleve-D Sinus And Cold
naproxen sodium/diphenhydramine HCl	Aleve PM
naproxen sodium	Flanax (Naproxen)
ibuprofen	Child Ibuprofen
ibuprofen	Infants Ibu-Drops
ibuprofen	Ibu-Drops
ibuprofen/diphenhydramine HCl	Ibuprofen-Diphenhydramine HCl
ibuprofen/pseudoephedrine HCl	Ibuprofen Cold
ibuprofen	Children'S Profen Ib
ibuprofen	Infants Profenib
fenoprofen calcium	Nalfon
indomethacin	Indocin
indomethacin, submicronized	Tivorbex
diclofenac submicronized	Zorvolex
meloxicam, submicronized	Vivlodex
ibuprofen	I-Prin
naproxen sodium	Mediproxen
ibuprofen	Addaprin
ibuprofen	Medi-Profen
ibuprofen	Infant'S Medi-Profen
ibuprofen	Children'S Medi-Profen
ibuprofen/diphenhydramine citrate	Ibuprofen-Diphenhydramine Cit
ibuprofen/pseudoephedrine HCl	Cold-Sinus Relief
hydrocodone/ibuprofen	Ibudone
hydrocodone/ibuprofen	Xylon 10

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
flurbiprofen	Ansaid
fenoprofen calcium	Fenortho
ibuprofen	Ibu
mefenamic acid	Ponstel
ibuprofen	Provil
fenoprofen calcium	Profeno
etodolac	Lodine
naproxen	Ec-Naproxen
meloxicam	Qmiiz Odt
ibuprofen/famotidine	Duexis
naproxen/esomeprazole magnesium	Vimovo
Sirolimus	
sirolimus	Rapamune
sirolimus	Sirolimus
Everolimus	
everolimus	Zortress
everolimus	Afinitor
everolimus	Afinitor Disperz
Aliskiren	
aliskiren hemifumarate	Tekturna
aliskiren hemifumarate/hydrochlorothiazide	Tekturna HCT
aliskiren hemifumarate/amlodipine besylate	Tekamlo
aliskiren hemifumarate/amlodipine/hydrochlorothiazide	Amturnide
aliskiren hemifumarate	Aliskiren
Beta Blockers	
carvedilol phosphate	Coreg CR
carvedilol	Coreg
propranolol HCl	Propranolol
carvedilol	Carvedilol
metoprolol tartrate	Metoprolol Tartrate
atenolol	Atenolol
sotalol HCl	Sotalol
nadolol	Nadolol
bisoprolol fumarate	Bisoprolol Fumarate
nadolol/bendroflumethiazide	Nadolol-Bendroflumethiazide
labetalol HCl	Labetalol
propranolol HCl	Innopran XL
bisoprolol fumarate/hydrochlorothiazide	Bisoprolol-Hydrochlorothiazide
metoprolol succinate	Toprol XL
sotalol HCl	Sorine
atenolol	Tenormin
atenolol/chlorthalidone	Tenoretic 50
atenolol/chlorthalidone	Tenoretic 100
metoprolol succinate/hydrochlorothiazide	Dutoprol
pindolol	Pindolol
timolol maleate	Timolol Maleate
propranolol HCl/hydrochlorothiazide	Propranolol-Hydrochlorothiazid

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
metoprolol tartrate/hydrochlorothiazide	Metoprolol Ta-Hydrochlorothiaz
acebutolol HCl	Acebutolol
atenolol/chlorthalidone	Atenolol-Chlorthalidone
metoprolol succinate	Metoprolol Succinate
sotalol HCl	Sotalol AF
nebivolol HCl	Bystolic
betaxolol HCl	Betaxolol
metoprolol succinate	Kapspargo Sprinkle
propranolol HCl	Inderal La
sotalol HCl	Sotylize
nadolol	Corgard
metoprolol tartrate	Lopressor
metoprolol tartrate/hydrochlorothiazide	Lopressor HCT
sotalol HCl	Betapace
sotalol HCl	Betapace AF
bisoprolol fumarate/hydrochlorothiazide	Ziac
bisoprolol fumarate	Zebeta
carvedilol phosphate	Carvedilol Phosphate
penbutolol sulfate	Levatol
nadolol/bendroflumethiazide	Corzide
propranolol HCl	Inderal XL
propranolol HCl	Hemangeol
labetalol HCl	Trandate
acebutolol HCl	Sectral
metoprolol succinate/hydrochlorothiazide	Metoprolol Su-Hydrochlorothiaz
Allergy Treatments	
triamcinolone acetonide	Kenalog
triamcinolone acetonide	Kenalog-80
montelukast sodium	Singulair
methylprednisolone sodium succinate/PF	Solu-Medrol (Pf)
hydrocortisone sodium succinate/PF	Solu-Cortef (Pf)
hydrocortisone	Cortef
methylprednisolone	Medrol
methylprednisolone	Medrol (Pak)
methylprednisolone acetate	Depo-Medrol
methylprednisolone sodium succinate	Solu-Medrol
hydrocortisone sod succinate	Solu-Cortef
alcaftadine	Lastacaft
nedocromil sodium	Alocril
epinastine HCl	Elestat
levocetirizine dihydrochloride	Xyzal
epinephrine	Auvi-Q
dupilumab	Dupixent
brompheniramine maleate/phenylephrine HCl/dextromethorphan	Dimetapp DM Cold-Cough (Pe)
brompheniramine maleate/phenylephrine HCl	Dimetapp Cold-Allergy (Pe)
chlorpheniramine maleate/dextromethorphan HBr	Dimetapp Long-Acting (Cpm-DM)

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
dextromethorphan/phenylephrine/acetaminophen/chlorpheniramin	Children'S Dimetapp Cold-Flu
phenylephrine HCl/diphenhydramine HCl	Dimetapp Cold-Congestion
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Children Dimetapp M-S Cold-Flu
chlorpheniramine maleate/dextromethorphan HBr	Robitussin Long-Acting
guaifenesin/dextromethorphan HBr	Chld Robitussin Cough-Chest DM
guaifenesin/dextromethorphan HBr/phenylephrine	Robitussin Cough And Cold CF
dextromethorphan HBr/doxylamine succinate	Robitussin Nighttime Cough DM
guaifenesin/dextromethorphan HBr	Robitussin Cough-Chest Cong DM
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Robitussin Cold-Flu Day
dextromethorphan HBr/acetaminophen/doxylamine	Robitussin Cold-Flu Night
guaifenesin/dextromethorphan HBr/phenylephrine	Robitussin M-S Cold CF Max
guaifenesin/dextromethorphan HBr/phenylephrine	Adult Robitussin M-S Cold
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Adult Robitussin Night M-S Cld
guaifenesin/dextromethorphan HBr	Adult Robitussin Peak Cold DM
guaifenesin/dextromethorphan HBr	Adt Robitussin Peak Cld DM Max
guaifenesin/dextromethorphan HBr/phenylephrine	Adult Robitussin Peak Cold M-S
azelastine HCl	Astelin
azelastine HCl	Astepro
azelastine HCl/fluticasone propionate	Dymista
dyphylline	Lufyllin
hydrocortisone acetate/pramoxine HCl	Epifoam
azelastine HCl	Optivar
flunisolide	Aerospan
clemastine fumarate	Tavist-1
phenylephrine HCl/diphenhydramine HCl	Triaminic Cold And Coughnt(Pe)
dextromethorphan HBr/phenylephrine HCl	Triaminic Cold And Cough (Pe)
dextromethorphan HBr/acetaminophen/chlorpheniramine maleate	Child'S Tylenol Pluscough,Rnos
cetirizine HCl	Zyrtec
prednisone	Prednisone
montelukast sodium	Montelukast
azelastine HCl	Azelastine
dexamethasone	Dexamethasone Intensol
dexamethasone	Dexamethasone
fluticasone propionate	Fluticasone Propionate
prednisone	Prednisone Intensol
olopatadine HCl	Patanol
olopatadine HCl	Pataday
emedastine difumarate	Emadine
olopatadine HCl	Patanase
ketotifen fumarate	Zaditor
lodoxamide tromethamine	Alomide
olopatadine HCl	Pazeo
loratadine	Loratadine
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Theraflu Nighttime Powerpod
loratadine	Allergy Relief (Loratadine)

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
chlorpheniramine maleate/phenylephrine HCl	Triaminic Cold- Allergy Pe
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Theraflu Multi-Symptom Cold
pheniramine maleate/phenylephrine HCl/acetaminophen	Theraflu Flu-Sore Throat
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Theraflu Night Severe Cold-Cgh
acetaminophen/dextromethorphan HBr	Child Triaminic Cough-Sore Thr
dextromethorphan/phenylephrine/acetaminophen/chlorpheniramin	Child Triaminic Ms Fever-Cold
brompheniramine maleate/phenylephrine HCl	Child Triaminic Cold-Allergy
guaifenesin/dextromethorphan HBr	Child Triaminic Cough-Congest
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Theraflu Expressmax Cold Day
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Theraflu Expressmax Cold Night
indacaterol maleate	Arcapta Neohaler
glycopyrrolate	Seebri Neohaler
indacaterol maleate/glycopyrrolate	Utibron Neohaler
chlorpheniramine maleate	Chlor-Trimeton
betamethasone acetate/betamethasone sodium phosphate	Celestone Soluspan
albuterol sulfate	Proventil Hfa
desloratadine	Clarinex
mometasone furoate	Nasonex
desloratadine/pseudoephedrine sulfate	Clarinex-D 24 Hour
desloratadine/pseudoephedrine sulfate	Clarinex-D 12 Hour
mometasone furoate	Asmanex Twisthaler
formoterol fumarate	Foradil Aerolizer
chlorpheniramine maleate/dextromethorphan HBr	Coricidin Hbp Cough And Cold
mometasone furoate	Asmanex Hfa
mometasone furoate/formoterol fumarate	Dulera
clemastine fumarate	Clemastine
albuterol sulfate	Albuterol Sulfate
cromolyn sodium	Cromolyn
triamcinolone acetonide	Triamcinolone Acetonide
cyproheptadine HCl	Cyproheptadine
fluticasone propionate/salmeterol xinafoate	Fluticasone Propion-Salmeterol
levalbuterol HCl	Levalbuterol HCl
epinephrine	Epinephrine
prednisolone	Prednisolone
cetirizine HCl	Cetirizine
ipratropium bromide/albuterol sulfate	Ipratropium-Albuterol
budesonide	Budesonide
olopatadine HCl	Olopatadine
levocetirizine dihydrochloride	Levocetirizine
hydrocodone polistirex/chlorpheniramine polistirex	Tussicaps
dexamethasone	Dexpak 10 Day
dexamethasone	Dexpak 13 Day
dexamethasone	Dexpak 6 Day
brompheniramine maleate/pseudoephedrine HCl	Lodrane D
loratadine/pseudoephedrine sulfate	Allergy And Congestion Relief
chlorpheniramine maleate	Allergy Relief(Chlorpheniramn)

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
diphenhydramine HCl	Sleep Time
dextromethorphan HBr/acetaminophen/doxylamine	Nighttime Cold-Flu
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Flu-Severe Cold-Cough Daytime
loratadine/pseudoephedrine sulfate	Allerclear D-24Hr
cetirizine HCl/pseudoephedrine HCl	All Day Allergy-D
cetirizine HCl	Child'S All Day Allergy(Cetir)
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Cold Head Congestion Sever Day
phenylephrine HCl/acetaminophen	Sinus Congestion And Pain
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Multi-Symptom Cold (Pe)
dextromethorphan HBr/acetaminophen/doxylamine	Nighttime Cold-Flu Relief
guaifenesin/dextromethorphan HBr	Tussin DM
guaifenesin/dextromethorphan HBr	Tussin DM Cough And Chest
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Cold Multi-Symptom
diphenhydramine HCl	Children'S Allergy (Diphenhyd)
guaifenesin/dextromethorphan HBr	Child Mucus Relief Cough
fexofenadine HCl	Aller-Ease
diphenhydramine HCl	Sleep Aid (Diphenhydramine)
triamcinolone acetonide	Nasal Allergy
diphenhydramine HCl	Allergy Relief(Diphenhydramin)
phenylephrine HCl/acetaminophen/chlorpheniramine	Allergy Multi-Symptom
guaifenesin/dextromethorphan HBr/phenylephrine	Tussin CF (Pe-DM-Guaif)
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Severe Cold And Flu (Pe)
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Daytime Cold-Flu
guaifenesin/dextromethorphan HBr	Tussin DM Max
guaifenesin/dextromethorphan HBr/phenylephrine	Child'S Mucus Relief M-S Cold
brompheniramine maleate/phenylephrine HCl	Children'S Cold-Allergy (Pe)
brompheniramine maleate/phenylephrine HCl/dextromethorphan	Children'S Cold And Cough (Pe)
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Daytime Cold-Flu Relief (Pe)
guaifenesin/pseudoephedrine HCl	Mucus D
cetirizine HCl	All Day Allergy (Cetirizine)
hydrocortisone	Hydrocortisone
terbutaline sulfate	Terbutaline
fludrocortisone acetate	Fludrocortisone
diphenhydramine HCl	Diphenhydramine HCl
guaifenesin/dextromethorphan HBr	Dextromethorphan-Guaifenesin
prednisolone sodium phosphate	Prednisolone Sodium Phosphate
codeine phosphate/guaifenesin	Codeine-Guaifenesin
theophylline anhydrous	Theophylline
hydrocodone bitartrate/homatropine methylbromide	Hydrocodone-Homatropine
fluticasone propionate	Flonase Allergy Relief
fluticasone propionate	Children'S Flonase Allergy Rlf
fluticasone furoate	Flonase Sensimist
fluticasone furoate	Children'S Flonase Sensimist

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
cortisone acetate	Cortisone
ephedrine sulfate	Ephedrine Sulfate
beclomethasone dipropionate	Beconase Aq
fluticasone propionate	Flonase
salmeterol xinafoate	Serevent Diskus
fluticasone propionate	Flovent Diskus
albuterol sulfate	Ventolin Hfa
fluticasone propionate/salmeterol xinafoate	Advair Diskus
fluticasone propionate/salmeterol xinafoate	Advair Hfa
fluticasone propionate	Flovent Hfa
fluticasone furoate	Veramyst
fluticasone furoate/vilanterol trifenatate	Breo Ellipta
umeclidinium bromide/vilanterol trifenatate	Anoro Ellipta
umeclidinium bromide	Incruse Ellipta
fluticasone furoate	Arnuity Ellipta
mepolizumab	Nucala
fluticasone furoate/umeclidinium bromide/vilanterol trifenat	Trelegy Ellipta
hydrocodone bitartrate/pseudoephedrine HCl/guaifenesin	Hycofenix
guaifenesin/hydrocodone bitartrate	Flowtuss
hydrocortisone/aloe vera	Hydrocortisone-Aloe Vera
fexofenadine HCl	Fexofenadine
ketotifen fumarate	Ketotifen Fumarate
budesonide/formoterol fumarate	Symbicort
budesonide	Pulmicort Flexhaler
budesonide	Rhinocort Aqua
budesonide	Pulmicort
guaifenesin/pseudoephedrine HCl	Congestac
ephedrine sulfate/guaifenesin	Bronkaid Dual Action
hydrocortisone/skin cleanser combination no.25	Aqua Glycolic Hc
theophylline in dextrose 5 % in water	Theophylline In Dextrose 5 %
fluticasone propionate	Clarispray
dextromethorphan HBr/phenylephrine/acetaminophen/doxylamine	Alka-Seltzer Plus Sin-Allg-Cgh
dextromethorphan/pseudoephedrine/acetaminophen/chlorpheniram	Alka-Seltzer Plus-D Sinus-Cold
naproxen sodium/pseudoephedrine HCl	Aleve Cold And Sinus
naproxen sodium/pseudoephedrine HCl	Aleve Sinus And Headache
roflumilast	Daliresp
zafirlukast	Accolate
aclidinium bromide	Tudorza Pressair
benralizumab	Fasenra
glycopyrrolate/formoterol fumarate	Bevespi Aerosphere
hydrocortisone/skin cleanser combination no.35	Dermasorb Hc Complete Kit
triamcinolone acetonide/emollient combination no.86	Dermasorb Ta Complete Kit
chlorpheniramine maleate/dextromethorphan HBr	Chld Robitussin Night Cough DM
loratadine/pseudoephedrine sulfate	Wal-Itin D 12 Hour
fluticasone propionate	24 Hour Allergy Relief

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
diphenhydramine HCl	Wal-Som (Diphenhydramine)
dextromethorphan HBr/doxylamine succinate	Daytime-Nighttime Cough
dextromethorphan HBr/acetaminophen/doxylamine	Cold-Flu Relief
fexofenadine HCl	Children'S Wal-Fex
diphenhydramine HCl	Wal-Sleep Z
ibuprofen/pseudoephedrine HCl	Wal-Profen Cold-Sinus
loratadine	Wal-Itin
cetirizine HCl	Children'S Wal-Zyr
diphenhydramine HCl	Children'S Wal-Dryl Allergy
diphenhydramine HCl	Wal-Dryl Allergy
chlorpheniramine maleate/pseudoephedrine HCl	Wal-Phed
guaifenesin/pseudoephedrine HCl	Mucus Relief D (Pseudoephed)
guaifenesin/phenylephrine HCl/acetaminophen	Mucus Rlf Severe Sinus Congest
loratadine/pseudoephedrine sulfate	Wal-Itin D
cetirizine HCl/pseudoephedrine HCl	Wal-Zyr D
triprolidine HCl/pseudoephedrine HCl	Wal-Act D Cold And Allergy
pheniramine maleate/phenylephrine HCl/acetaminophen	Wal-Flu Night Time
diphenhydramine HCl	Sleep Ii
dextromethorphan HBr/acetaminophen/doxylamine	Cough-Sore Throat Night
chlorpheniramine maleate	Wal-Finate
cetirizine HCl	Wal-Zyr (Cetirizine)
diphenhydramine HCl	Child Allergy Relief (Diphen)
guaifenesin/dextromethorphan HBr	Mucus Relief DM Max
guaifenesin/dextromethorphan HBr/phenylephrine	Mucus Relief Congestion-Cough
dextromethorphan HBr/phenylephrine/acetaminophen/doxylamine	Cold Multi-Symptom Nighttime
pseudoephedrine HCl/acetaminophen/chlorpheniramine	Allergy Sinus-D
guaifenesin/dextromethorphan HBr	Wal-Tussin DM
diphenhydramine HCl	Nighttime Sleep Aid (Diphen)
chlorpheniramine maleate/pseudoephedrine HCl	Wal-Finate-D
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Mucus Relief Severe Cold
guaifenesin/phenylephrine HCl/acetaminophen	Wal-Phed Pe Triple Relief
naproxen sodium/pseudoephedrine HCl	All Day Pain Relief Sinus,Cold
guaifenesin/dextromethorphan HBr	Cough-Chest Congestion DM
guaifenesin/dextromethorphan HBr	Children'S Cough
diphenhydramine HCl/phenylephrine HCl/dextromethorphan HBr	Child Cold-Cough Day-Night
ibuprofen/pseudoephedrine HCl	Wal-Profen D Cold And Sinus
fexofenadine HCl	Wal-Fex Allergy
fexofenadine HCl/pseudoephedrine HCl	Wal-Fex D 12 Hour
dextromethorphan HBr/acetaminophen/chlorpheniramine maleate	Flu Hbp
chlorpheniramine maleate/phenylephrine HCl	Wal-Phed Pe Sinus And Allergy
phenylephrine HCl/diphenhydramine HCl	Wal-Dryl-D Allergy And Sinus
phenylephrine HCl/acetaminophen	Wal-Phed Pe Sinus Headache

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Severe Cold Multi-Symptom
guaifenesin/dextromethorphan HBr/phenylephrine	Wal-Tussin Cough And Cold CF
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-Phed Pe Severe Cold
guaifenesin/phenylephrine HCl/acetaminophen	Sinus Congestion-Pain(Guaif)
dextromethorphan/phenylephrine/acetaminophen/chlorpheniramin	Head Congestion Day-Night
dextromethorphan/phenylephrine/acetaminophen/chlorpheniramin	Cold Multi-Symptom Day/Night
guaifenesin/dextromethorphan HBr	Mucus Relief DM
guaifenesin/phenylephrine HCl	Mucus Relief Pe
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-Dryl Severe Allergy-Sinus
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-Phed Pe Nighttime Cold
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Wal-Phed Pe Cold-Cough
phenylephrine HCl/acetaminophen/doxylamine succinate	Sinus Daytime-Nightime
fexofenadine HCl/pseudoephedrine HCl	Wal-Fex D 24 Hour
dextromethorphan HBr/phenylephrine/acetaminophen/doxylamine	Daytime-Nighttime Cold-Flu
dextromethorphan/phenylephrine/acetaminophen/chlorpheniramin	Cold Multi-Symptom (Chlorphen)
pheniramine maleate/phenylephrine HCl/acetaminophen	Wal-Flu Cold And Sore Throat
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-Flu Severe Cold And Cough
ketotifen fumarate	Wal-Zyr (Ketotifen)
guaifenesin/phenylephrine HCl/acetaminophen	Mucus Relief Sinuspressur-Pain
phenylephrine HCl/dextromethorphan	Cold And Flu Severe
dextromethorphan HBr/doxylamine succinate	Nighttime Cough
acetaminophen/dextromethorphan HBr	Daytime Cold And Cough
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Cold And Flu Relief(Diphen-Pe)
chlorpheniramine maleate/dextromethorphan HBr	Children'S Cough-Cold Relief
dextromethorphan	Severe Cold And Flu Nighttime
guaifenesin/dextromethorphan HBr	Adult Wal-Tussin DM Max
triamcinolone acetonide	24 Hour Nasal Allergy
chlorpheniramine maleate/phenylephrine bitartrate/aspirin	Cold Relief Plus
brompheniramine maleate/phenylephrine HCl	Child Wal-Tap Cold-Allergy
diphenhydramine/phenylephrin/dextromethorph/acetaminophen/GG	Wal-Phed Pe Day-Night
ketotifen fumarate	Eye Itch Relief
brompheniramine maleate/phenylephrine HCl/dextromethorphan	Wal-Tap DM
dextromethorphan HBr/phenylephrine/acetaminophen/doxylamine	Cold And Flu Relief Plus (D/N)
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Wal-Flu Severe Cold-Cough
dextromethorphan/phenylephrine/acetaminophen/diphenhydramine	Wal-Flu Day-Night Cold-Cough
doxylamine/phenylephrine/dextromethorphan/acetaminophen/GG	Severe Cold And Flu(Day/Night)

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
hydrocortisone/aloe vera	Hydrocortisone Plus
guaifenesin/phenylephrine HCl/acetaminophen	Mucus Relief Cold And Sinus
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Mucus Relief Cold-Flu-Sore Thr
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Children'S Cold-Cough-Sore
diphenhydramine/phenylephrin/dextromethorph/acetaminophen/GG	Children'S M-S Cold Day-Night
guaifenesin/phenylephrine HCl/acetaminophen	Severe Sinus
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Wal-Phed Pe Pressure+Pain+Cold
diphenhydramine HCl	Nighttime Allergy Relief
guaifenesin/dextromethorphan HBr/phenylephrine	Child Multi-Symptom Cold/Cough
chlorpheniramine maleate/dextromethorphan HBr	Scot-Tussin DM
guaifenesin/dextromethorphan HBr	Scot-Tussin Senior
desloratadine	Desloratadine
ipratropium bromide	Ipratropium Bromide
fluticasone propionate/salmeterol xinafoate	Wixela Inhub
fluticasone propionate, micronized	Fluticasone Prop, Micro (Bulk)
promethazine HCl	Promethazine (Bulk)
tranilast	Tranilast (Bulk)
budesonide, micronized	Budesonide, Micronized (Bulk)
dexamethasone sodium phosphate	Dexamethasone Sod Phos (Bulk)
prednisone micronized	Prednisone Micronized (Bulk)
hydrocortisone sod succinate	A-Hydrocort
aminophylline	Aminophylline
phenylephrine HCl/diphenhydramine HCl	Child Benadryl Plus Congestion
cetirizine HCl/pseudoephedrine HCl	Zyrtec-D
cetirizine HCl	Children'S Zyrtec Allergy
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Tylenol Cold Multi-Symptom Day
guaifenesin/phenylephrine HCl/acetaminophen	Tylenol Cold Head Congest Sevr
guaifenesin/phenylephrine HCl/acetaminophen	Tylenol Sinus Congestion Pain
dextromethorphan HBr/phenylephrine/acetaminophen/doxylamine	Tylenol Cold Max Night
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Tylenol Cold And Flu Severe
phenylephrine HCl/acetaminophen	Tylenol Sinus Congestion Pain
diphenhydramine HCl	Benadryl Allergy
dextromethorphan HBr/phenylephrine HCl	Children'S Sudafed Pe Cough
phenylephrine HCl/acetaminophen	Sudafed Pe Pressure+Pain
chlorpheniram/phenyleph/dextromethorphn/acetaminophen/guaifn	Tylenol Cold-Flu Severe Day-Nt
diphenhydramine HCl	Children'S Benadryl Allergy
guaifenesin/phenylephrine HCl/acetaminophen	Sudafed Pe Pressure+Pain+Mucus
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Sudafed Pe Pressure+Pain+Cough
budesonide	Rhinocort Allergy
diphenhydramine HCl	Simply Sleep

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
theophylline anhydrous	Theochron
hydrocodone bitartrate/homatropine methylbromide	Hydromet
promethazine HCl/codeine	Promethazine-Codeine
dexchlorpheniramine maleate/phenylephrine HCl	Rymed (Dexchlorpheniramine-Pe)
chlorpheniramine maleate	Ed-Chlortan
chlorpheniramine maleate	Ed-Chlorped
chlorpheniramine maleate/phenylephrine HCl	Ed Chlorped D
chlorpheniramine maleate	Ed Chlorped Jr
chlorpheniramine maleate/phenylephrine HCl	Ed A-Hist
chlorpheniramine maleate/phenylephrine HCl/dextromethorphan	Ed A-Hist DM
brompheniramine maleate/phenylephrine HCl	Rynex Pe
brompheniramine maleate/phenylephrine HCl/dextromethorphan	Rynex DM
brompheniramine maleate/pseudoephedrine HCl	Rynex Pse
guaifenesin/phenylephrine HCl	Ed Bron Gp
triprolidine HCl/pseudoephedrine HCl	Ed A-Hist Pse
guaifenesin/phenylephrine HCl	Mucaphed
racepinephrine HCl	Asthmanefrin Refill
racepinephrine HCl	Asthmanefrin Starter Kit
racepinephrine HCl	Racepinephrine
racepinephrine HCl	S2 Racepinephrine
hydrocortisone acetate/pramoxine HCl/emollient base	Pramosone E
hydrocortisone acetate/pramoxine HCl	Pramosone
betamethasone acetate/betamethasone sodium phosphate	Betamethasone Acet,Sod Phos
epinephrine HCl/PF	Epinephrine HCl (Pf)
carbinoxamine maleate	Palgic
chlorpheniramine maleate	Aller-Chlor
diphenhydramine HCl	Diphenhist
guaifenesin/dextromethorphan HBr	Cough Syrup DM
guaifenesin/dextromethorphan HBr	Cough Suppressant-Expectorant
ibuprofen/phenylephrine HCl	Congestion Relief (Ibuprof-Pe)
hydrocortisone/aloe vera	Hydroskin With Aloe
guaifenesin/dextromethorphan HBr	Mucus DM
guaifenesin/dextromethorphan HBr	Mucus DM Max Er
chlorpheniramine	Kidkare Cough/Cold
ibuprofen/pseudoephedrine HCl	Advil Cold And Sinus
chlorpheniramine maleate/pseudoephedrine HCl/ibuprofen	Advil Allergy Sinus
ibuprofen/phenylephrine HCl	Advil Congestion Relief
chlorpheniramine maleate/phenylephrine HCl/ibuprofen	Advil Allergy-Congestion Rlf
phenylephrine HCl/acetaminophen/chlorpheniramine	Dristan Cold
loratadine	Alavert
loratadine/pseudoephedrine sulfate	Alavert D-12 Allergy-Sinus
guaifenesin/ephedrine HCl	Primatene Asthma
hydrocodone bitart/chlorpheniramine maleate/pseudoephedrine	Hydrocodone-Cpm-Pseudoephed

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
brompheniramine maleate/pseudoephedrine HCl/dextromethorphan	Brompheniramine-Pseudoeph-DM
methylprednisolone	Methylprednisolone
promethazine HCl	Phenadoz
levalbuterol tartrate	Levalbuterol Tartrate
promethazine HCl	Promethazine
ipratropium bromide/albuterol sulfate	Combivent Respimat
tiotropium bromide	Spiriva With Handihaler
ipratropium bromide	Atrovent Hfa
tiotropium bromide	Spiriva Respimat
tiotropium bromide/olodaterol HCl	Stiolto Respimat
olodaterol HCl	Striverdi Respimat
diphenhydramine HCl	Q-Dryl
pyrilamine maleate/phenylephrine HCl/dextromethorphan HBr	Codituss DM
brompheniramine maleate/pseudoephedrine HCl	Q-Tapp
brompheniramine maleate/pseudoephedrine HCl/dextromethorphan	Q-Tapp DM
guaifenesin/dextromethorphan HBr	Q-Tussin DM
diphenhydramine HCl	Quenalin
codeine phosphate/guaifenesin	Cheratussin Ac
pseudoephedrine HCl/codeine phosphate/guaifenesin	Cheratussin Dac
codeine phosphate/guaifenesin	Iophen C-Nr
guaifenesin/dextromethorphan HBr	Iophen DM-Nr
pseudoephedrine HCl/codeine/chlorpheniramine	Phenylhistine Dh
promethazine HCl/dextromethorphan HBr	Promethazine-DM
phenylephrine HCl/promethazine HCl	Promethazine Vc
promethazine/phenylephrine HCl/codeine	Promethazine Vc-Codeine
dexamethasone sodium phosphate	Dexamethasone Sodium Phosphate
promethazine HCl	Phenergan
codeine phosphate/guaifenesin	Mar-Cof Cg
brompheniramine maleate/pseudoephedrine HCl/codeine phosphat	Mar-Cof Bp
methylprednisolone acetate	Methylprednisolone Acetate
promethazine HCl	Promethegan
triamcinolone hexacetonide	Aristospan Intralesional
triamcinolone hexacetonide	Aristospan Intra-Articular
epinephrine	Symjepi
mometasone furoate	Mometasone
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Rompe Pecho Max Multi Symptoms
chlorpheniramine maleate	Allergy (Chlorpheniramine)
guaifenesin/dextromethorphan HBr	Robafen DM
guaifenesin/dextromethorphan HBr	Robafen DM Cough-Chest Congest
triprolidine HCl/pseudoephedrine HCl	Aprodine
diphenhydramine HCl	Banophen Allergy
diphenhydramine HCl	Banophen

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
diphenhydramine HCl	Sleep-Tabs
chlorpheniramine maleate/pseudoephedrine/dextromethorphan	Pedia Relief Cough-Cold
chlorpheniramine maleate/pseudoephedrine HCl	Sudogest Cold And Allergy
chlorpheniramine maleate/pseudoephedrine HCl	Sudogest Sinus And Allergy
loratadine	Non-Drowsy Allergy
dextromethorphan HBr/acetaminophen/doxylamine	Nite Time Cold-Flu Relief
dextromethorphan HBr/acetaminophen/doxylamine	All-Nite Cold-Flu
brompheniramine maleate/phenylephrine HCl	Dimaphen (Pe)
brompheniramine maleate/phenylephrine HCl/dextromethorphan	Dimaphen DM
phenylephrine HCl/acetaminophen	Mapap Sinus Max Strength (Pe)
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Mapap Cold Formula
guaifenesin/phenylephrine HCl	Mucus Relief Sinus
chlorpheniramine maleate/dextromethorphan HBr	Cough And Cold (Chlorphen-DM)
loratadine/pseudoephedrine sulfate	Loratadine-D
guaifenesin/dextromethorphan HBr	Robafen DM Cough
guaifenesin/dextromethorphan HBr/phenylephrine	Robafen CF (Phenylephrine)
codeine phosphate/guaifenesin	Robafen Ac
zafirlukast	Zafirlukast
phenylephrine HCl/acetaminophen	Acetaminophen Congestion-Pain
cetirizine HCl	Children'S Cetirizine
guaifenesin/dextromethorphan HBr	Mucus Relief DM Cough
hydrocortisone/colloidal oatmeal/aloe/vitamin E	Aveeno Anti-Itch (Hydrocortsn)
ketotifen fumarate	Children'S Alaway
zileuton	Zyflo
zileuton	Zyflo Cr
chlorpheniramine maleate	Chlorpheniramine Maleate
halobetasol propionate/ammonium lactate	Ultravate Pac
halobetasol propionate/lactic acid	Ultravate X
guaifenesin/dextromethorphan HBr	Chest Congestion Relief DM
epinephrine	Bronchial Mist Refill
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Decongestant Cough
dextromethorphan/pseudoephrine HCl/acetaminophen/doxylamine	Night Time Cold Medicine
dextromethorphan/pseudoephrine HCl/acetaminophen/doxylamine	Night Time Cold-Flu Relief
triprolidine HCl/pseudoephedrine HCl	Nasal Decongestant-Antihist
triprolidine HCl/pseudoephedrine HCl	Cold And Allergy(Triprolidine)
chlorpheniramine maleate	Allergy 4-Hour
chlorpheniramine maleate/dextromethorphan HBr	Cough And Runny Nose
diphenhydramine HCl	Valu-Dryl
diphenhydramine HCl	Valu-Dryl Allergy
pseudoephedrine HCl/acetaminophen/diphenhydramine	Non-Aspirin Allergy Sinus Pm
pseudoephedrine HCl/acetaminophen/diphenhydramine	Non-Aspirin Flu
guaifenesin/phenylephrine HCl	Chest Congestion Relief Pe

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
dextromethorphan HBr/pseudoephedrine HCl/acetaminophen	Non-Aspirin Flu
diphenhydramine HCl	Sleepgels
brompheniramine maleate/phenylephrine HCl	Cold And Allergy (Bromphen-Pe)
brompheniramine maleate/phenylephrine HCl/dextromethorphan	Cold And Cough DM
diphenhydramine HCl	Antihistamine
phenylephrine HCl/acetaminophen	Sinus Maximum Strength
guaifenesin/acetaminophen	Chest Congestion
guaifenesin/dextromethorphan HBr	Mucus Relief Cough
diphenhydramine HCl	Antihist
dextromethorphan HBr/phenylephrine HCl	Cold And Cough (Pe-DM)
dextromethorphan HBr/pseudoephedrine HCl/acetaminophen	Daytime Cold And Flu Relief
dextromethorphan/pseudoephrine HCl/acetaminophen/doxylamine	Nite Time
dexbrompheniramine maleate/pseudoephedrine sulfate	12 Hour Relief
loratadine/pseudoephedrine sulfate	Lorata-Dine D
dextromethorphan/phenylephrine/acetaminophen/chlorpheniramin	Childrens Plus Multi-Symp Cold
chlorpheniramine maleate/pseudoephedrine/dextromethorphan	Pedia Relief
guaifenesin/pseudoephedrine HCl	Tussin Pe
diphenhydramine HCl	Valu-Dryl Child'S Allergy
pseudoephedrine HCl/acetaminophen/diphenhydramine	Valu-Dryl Allergy-Sinus-Head
dextromethorphan HBr/pseudoephedrine HCl/acetaminophen	Infants' Non-Aspirin Cold
pseudoephedrine/dextromethorphan/guaifenesin/acetaminophen	Daytime Cold And Flu Relief
dextromethorphan/pseudoephrine HCl/acetaminophen/doxylamine	Night Time Cold-Flu
triprolidine HCl/pseudoephedrine HCl	Nasal Decongest-Antihistamine
clemastine fumarate	Allergy Relief (Clemastine)
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Flu Relief Therapy Nighttime
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Tussin CF
ibuprofen/pseudoephedrine HCl	Ibuprofen Cold-Sinus(With Pse)
dextromethorphan HBr/pseudoephedrine HCl	Expectorant Max Strength
dextromethorphan/pseudoephedrine/acetaminophen/chlorpheniram	Flu Severe Cold-Congestion
dextromethorphan HBr/doxylamine succinate	Nite Time Cough
ibuprofen/pseudoephedrine HCl	Cold-Sinus Relief
chlorpheniramine maleate/phenylephrine HCl	Sinus-Allergy (Phenylephrine)
dextromethorphan HBr/pseudoephedrine HCl	Pedia Relief Infant
pseudoephedrine HCl/acetaminophen	Non-Aspirin Sinus Non-Drowsy
pseudoephedrine HCl/acetaminophen/chlorpheniramine	Non-Aspirin Allergy Sinus
pseudoephedrine/dextromethorphan/guaifenesin/acetaminophen	Cough And Cold

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
pseudoephedrine HCl/acetaminophen	Sinus Maximum Strength
pseudoephedrine HCl/acetaminophen	Max Str Non-Drowsy Sinus
dextromethorphan HBr/acetaminophen/doxylamine	Nite Time Cold-Flu
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Day Time Pe
naproxen sodium/pseudoephedrine HCl	Sinus And Cold-D
diphenhydramine HCl	Z-Sleep
dextromethorphan/pseudoephedrine/acetaminophen/chlorpheniram	Non-Aspirin Cold
clemastine fumarate	Dailyhist-1
epinephrine	Bronchial Mist
fluticasone propionate	Allergy Relief (Fluticasone)
pseudoephedrine/dextromethorphan/guaifenesin/acetaminophen	Day Time Liquid Cold
guaifenesin/dextromethorphan HBr	Tussin DM Clear
chlorpheniramine maleate/pseudoephedrine HCl	Sinus And Allergy(Pseudoephed)
cromolyn sodium	Nasal Allergy Symptom Control
pseudoephedrine HCl/acetaminophen/chlorpheniramine	Pain Reliever Allergy Sinus
pseudoephedrine HCl/acetaminophen	Sinus Headache
pseudoephedrine HCl/acetaminophen	Pain Reliever Sinus
loratadine	Children'S Allergy Relief(Lor)
chlorpheniramine maleate/pseudoephedrine HCl	Triacting Orange
dextromethorphan HBr/pseudoephedrine HCl/acetaminophen	Suphedrine Severe Cold Max Str
chlorpheniramine maleate/pseudoephedrine/dextromethorphan	Triacting M-Sym Cold/Cough
pseudoephedrine HCl/acetaminophen/chlorpheniramine	Non-Aspirin Child'S Cold
guaifenesin/pseudoephedrine HCl	Triacting Expectorant
brompheniramine maleate/pseudoephedrine HCl	Valu-Tapp
brompheniramine maleate/pseudoephedrine HCl/dextromethorphan	Valu-Tapp DM
chlorpheniramine maleate/phenylephrine HCl	Cold And Allergy Pe
chlorpheniramine maleate/phenylephrine HCl	Sinus And Allergy Pe
diphenhydramine HCl/hydrocortisone	Hc Derma-Pax
guaifenesin/dextromethorphan HBr	Refenesen DM
guaifenesin/dextromethorphan HBr	Double-Tussin DM
guaifenesin/phenylephrine HCl	Refenesen Pe
guaifenesin/dextromethorphan HBr	Broncotron-S
dexchlorpheniramine maleate/pseudoephedrine/chlophedianol	Panatuss Ped
guaifenesin/dextromethorphan HBr/phenylephrine	Broncotron Ped
dexchlorpheniramine maleate/pseudoephedrine/chlophedianol	Panatuss Ped Drops
diphenhydramine HCl	Sleeping
guaifenesin/dextromethorphan HBr	Expectorant DM
guaifenesin/pseudoephedrine HCl	Congest-Eze
guaifenesin/dextromethorphan HBr	Ultra DM Free And Clear
phenylephrine HCl/acetaminophen/chlorpheniramine	Sinutrol Pe

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
guaifenesin/dextromethorphan HBr	G-Fenesin DM
guaifenesin/phenylephrine HCl	Congest-Eze Pe
loratadine/pseudoephedrine sulfate	Allergy Relief,Nasal Decongest
diphenhydramine HCl	Ormir
loratadine	Children'S Claritin
loratadine/pseudoephedrine sulfate	Claritin-D 24 Hour
loratadine	Claritin Reditabs
guaifenesin/dextromethorphan HBr	Coricidin Hbp
loratadine	Claritin
loratadine/pseudoephedrine sulfate	Claritin-D 12 Hour
loratadine	Claritin Liqui-Gel
dextromethorphan HBr/acetaminophen/doxylamine	Coricidin Hbp Cold-Multi Sympt
guaifenesin/phenylephrine HCl	Despec
guaifenesin/dextromethorphan HBr/phenylephrine	Despec-DM (Phenyleph-DM-Guaif)
guaifenesin/dextromethorphan HBr/phenylephrine	Despec DM-G
guaifenesin/pseudoephedrine HCl	Despec-Tab
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Despec-DM (Pseudoeph-DM-Guaif)
guaifenesin/dextromethorphan HBr/phenylephrine	Despec Eda Cough-Cold Drops
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Fast Mucus Relief Severe Cold
fexofenadine HCl/pseudoephedrine HCl	Allergy-Congest Relief-D(Fexo)
dextromethorphan HBr/phenylephrine/acetaminophen/doxylamine	Cold-Flu Relief, Day/Night
guaifenesin/dextromethorphan HBr	Mucus And Cough Relief
loratadine/pseudoephedrine sulfate	Allergy-Congestion Relief-D
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Cold-Flu Relief
dextromethorphan/phenylephrine/acetaminophen/chlorpheniramin	Cold Relief M/S Day/Night
guaifenesin/dextromethorphan HBr	Tussin DM Cough
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Cold Head Congestion Daytime
cetirizine HCl	All Day Allergy Relief(Cetir)
cetirizine HCl	Allergy Relief (Cetirizine)
guaifenesin/dextromethorphan HBr/phenylephrine	Cough And Cold
cetirizine HCl/pseudoephedrine HCl	Allergy-Congest Relief-D (Cet)
fexofenadine HCl	Allergy Relief (Fexofenadine)
dextromethorphan	Daytime-Nighttime
cetirizine HCl	Child Allergy Relf(Cetirizine)
diphenhydramine/phenylephrin/dextromethorph/acetaminophen/GG	Daytime-Cold Nighttime-Cld-Flu
guaifenesin/dextromethorphan HBr/phenylephrine	Fast Mucus Rlf Congest-Cough
guaifenesin/dextromethorphan HBr	Adult Cough Formula DM Max
dextromethorphan/phenylephrine/acetaminophen/chlorpheniramin	Multi-Symptom Cold (Pe-Cpm)
hydrocortisone/aloe vera/vitamin E acetate/vitamins A and D	Anti-Itch (Hc) With Aloe-Vit E
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Flu-Severe Cold-Cough Night
diphenhydramine HCl	Allergy Medicine
diphenhydramine HCl	Allergy Medication

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
chlorpheniramine maleate/phenylephrine HCl	Acta-Tabs Pe
phenylephrine HCl/acetaminophen	Suphedrine Pe Sinus Headache
chlorpheniramine maleate/phenylephrine HCl	Suphedrine Pe Cold And Allergy
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Multi-Symptom Cold Daytime
dextromethorphan HBr/acetaminophen/chlorpheniramine maleate	Maximum Strength Flu
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Mucus Relief Plus
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Mucus Relief Sev Congest-Cold
doxylamine/phenylephrine/dextromethorphan/acetaminophen/GG	Day-Cold Night-Cold-Flu(Doxyl)
dextromethorphan HBr/doxylamine succinate	Tussin Nighttime Cough DM
diphenhydramine HCl/phenylephrine/acetaminophen/guaifenesin	Sinus Relief Max Str Day-Night
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Allergy M-S Nighttime
phenylephrine HCl/acetaminophen/chlorpheniramine	Sinus Congest-Pain Day-Night
diphenhydramine HCl	Diphedryl Allergy
diphenhydramine HCl	Sleep Tablet (Diphenhydramine)
guaifenesin/dextromethorphan HBr	Tussin Cough-Chest Congestion
guaifenesin/dextromethorphan HBr	Antitussive DM
loratadine/pseudoephedrine sulfate	Lorata-D
diphenhydramine HCl	Diphedryl
dextromethorphan/phenylephrine/acetaminophen/diphenhydramine	Flu Formula Daytime-Nighttime
phenylephrine HCl/diphenhydramine HCl	Allergy And Sinus Relief
diphenhydramine/phenylephrin/dextromethorph/acetaminophen/GG	Suphedrine Pe Day-Night
dextromethorphan/phenylephrine/acetaminophen/chlorpheniramin	Head Congestion Cold Relief
diphenhydramine HCl	Complete Allergy
diphenhydramine HCl	Complete Allergy Medicine
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Head Congestion Cold Relief
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Severe Cold Pe
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Cold-Cough Sinus Relief Pe
diphenhydramine HCl	Allergy (Diphenhydramine)
cetirizine HCl/pseudoephedrine HCl	Cetiri-D
diphenhydramine HCl	Nightime Sleep
dextromethorphan/phenylephrine/acetaminophen/chlorpheniramin	Children'S Flu Relief
dextromethorphan HBr/acetaminophen/chlorpheniramine maleate	Child Plus Cough And Runnynose
dextromethorphan/phenylephrine/acetaminophen/chlorpheniramin	Multi-Symptom Cold Night Time
guaifenesin/dextromethorphan HBr/phenylephrine	Cough And Cold Mucus Relief CF

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
fexofenadine HCl/pseudoephedrine HCl	Allergy Relief-D(Fexofenadine)
phenylephrine HCl/acetaminophen	Sinus Formula Daytime
guaifenesin/dextromethorphan HBr	Cough Formula DM
guaifenesin/dextromethorphan HBr	Wal-Tussin DM Clear
brompheniramine maleate/phenylephrine HCl	Wal-Tap
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Wal-Flu Night Severe Cold
dextromethorphan/pseudoephrine HCl/acetaminophen/doxylamine	Nite Time-D Cold-Flu Relief
guaifenesin/ephedrine HCl	Bronchial Asthma Relief
dextromethorphan/phenylephrine/acetaminophen/chlorpheniramin	Children'S Plus Flu
phenylephrine HCl/acetaminophen/chlorpheniramine	Childrens Plus Cold
guaifenesin/dextromethorphan HBr	Neo-Tuss
chlorpheniramine maleate/phenylephrine HCl/dextromethorphan	Neotuss Plus
guaifenesin/dextromethorphan HBr/phenylephrine	Neotuss-D (Improved Formula)
diphenhydramine HCl	Benadryl
codeine phosphate/guaifenesin	M-Clear Wc
brompheniramine maleate/pseudoephedrine HCl/codeine	M-End Wc
dexbrompheniramine maleate/pseudoephedrine HCl/codeine phos	M-End Max D
brompheniramine maleate/phenylephrine HCl/codeine phosphate	M-End Pe
dexbrompheniramine maleate/pseudoephedrine HCl/chlophedianol	Chlo Tuss
chlophedianol HCl/guaifenesin	Chlo Tuss Ex
chlorpheniramine maleate/pseudoephedrine/dextromethorphan	M-End DM
dexbromphen-pseudoephedrine-dextromethorphan	M-End DMx
dexbrompheniramine maleate/chlophedianol HCl	Chlo Hist
carbinoxamine maleate	Karbinal Er
loratadine/pseudoephedrine sulfate	Allergy Relief D-24Hr
loratadine/pseudoephedrine sulfate	Allergy Relief-D (Loratadine)
guaifenesin/phenylephrine HCl	Tl-DMx
chlorpheniramine maleate/phenylephrine	Trigofen DM
lidocaine HCl/hydrocortisone acetate	Lidocaine HCl-Hydrocortison Ac
dextromethorphan HBr/phenylephrine HCl	Pediacare Multi-Symptom Cold
cromolyn sodium	Nasalcrom
hydrocortisone acetate/aloe vera	Nucort
dexamethasone	Hidex
phenylephrine HCl/pyrilamine maleate	Vazotab (Pyrilamine)
chlorpheniramine maleate/dextromethorphan HBr	Cough And Cold Bp
dextromethorphan HBr/acetaminophen/chlorpheniramine maleate	Flu Bp
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Allergy And Cold Pe
guaifenesin/dextromethorphan HBr	Cough Control DM Max
guaifenesin/dextromethorphan HBr	Cough Control DM

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
guaifenesin/dextromethorphan HBr	Tab Tussin DM
chlorpheniramine maleate/phenylephrine HCl	Allerfed Cold And Allergy
diphenhydramine HCl	Sleep
guaifenesin/dextromethorphan HBr/phenylephrine	Cough Control CF (Pe)
dexbrompheniramine maleate	Pediavent
carbinoxamine maleate	Ryvent
brompheniramine maleate/pseudoephedrine HCl/chlophedianol	Atuss Da
dexchlorpheniramine maleate	Ryclora
levocetirizine dihydrochloride	Levocetirizine (Bulk)
chlorpheniramine maleate	Pharbechlor
diphenhydramine HCl	Pharbedryl
pseudoephedrine HCl/chlophedianol HCl	Rondec-D
chlorpheniramine maleate/phenylephrine HCl	Dallergy (Chlorpheniramine-Pe)
chlorcyclizine HCl/phenylephrine HCl	Dallergy (Chlorcyclizine-Pe)
dexbrompheniramine maleate/phenylephrine HCl	Dallergy (Dexbrompheniramn-Pe)
phenylephrine HCl/chlophedianol HCl/guaifenesin	Donatussin Pediatric
chlorpheniramine maleate/phenylephrine HCl/dextromethorphan	Donatussin
guaifenesin/pseudoephedrine HCl	Respaire-30
prednisolone	Millipred
prednisolone	Millipred Dp
prednisolone sodium phosphate	Millipred
brompheniramine maleate/pseudoephedrine HCl/dextromethorphan	Neo DM
chlorpheniramine maleate/phenylephrine bitartrate/aspirin	Alka-Seltzer Plus Cold (Pe)
chlorpheniramine mal/phenylephrine/d-methorphan Hb/aspirin	Alka-Seltzer Plus C/C(Pe,DM)
doxylamine succinate/phenylephrine/dextromethorphan HBr/ASA	Alka-Seltzer Plus Night (Asa)
doxylamine succinate/phenylephrine/dextromethorphan HBr/ASA	Alka-Seltzer Plus Day-Night
dextromethorphan HBr/phenylephrine/acetaminophen/doxylamine	Alka-Seltzer Plus Night
guaifenesin/dextromethorphan HBr	Alka-Seltzer Plus Mucus-Conges
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Alka-Seltzer Plus Day
dextromethorphan/phenylephrine/acetaminophen/chlorpheniramin	Alka-Seltzer Plus Cold/Coughfm
dextromethorphan/phenylephrine/acetaminophen/chlorpheniramin	Alka-Seltzer Plus Flu
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Alka-Seltzer Plus Sinus-Cough
diphenhydramine HCl	Alka-Seltzer Plus Allergy
dextromethorphan HBr/phenylephrine/acetaminophen/doxylamine	Alka-Seltzer Plus D-N (Acetam)
dextromethorphan/pseudoephrine HCl/acetaminophen/doxylamine	Alka-Seltzer Plus Cold+Flu
pseudoephedrine HCl/codeine phosphate/guaifenesin	Guaifenesin Dac

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
codeine phosphate/guaifenesin	Guaifenesin Ac
epinephrine	Primatene Mist
levalbuterol HCl	Xopenex Concentrate
levalbuterol HCl	Xopenex
hydrocodone polistirex/chlorpheniramine polistirex	Hydrocodone-Chlorpheniramine
theophylline anhydrous	Elixophyllin
cetirizine HCl	24Hour Allergy
ibuprofen/pseudoephedrine HCl	Cold And Sinus Pain Relief
cetirizine HCl/pseudoephedrine HCl	Allergy Relief-D (Cetirizine)
chlorpheniramine maleate/phenylephrine HCl	Centergy
chlorpheniramine maleate/phenylephrine	Centergy DM
brompheniramine maleate/pseudoephedrine HCl/codeine phosphat	Rydex
triprolidine HCl/pseudoephedrine HCl/chlophedianol HCl	Trymine Cd
triprolidine HCl/pseudoephedrine HCl	Trymine D
codeine phosphate/guaifenesin	Trymine Cg
pyrilamine maleate/chlophedianol HCl	Ninjacof
pyrilamine maleate/chlophedianol HCl/acetaminophen	Ninjacof-A
pyrilamine maleate/pseudoephedrine HCl/chlophedianol HCl	Ninjacof-D
codeine phosphate/guaifenesin	Ninjacof-Xg
guaifenesin/dextromethorphan HBr	Cheracol D
guaifenesin/dextromethorphan HBr	Creo-Terpin (DM-Guaifenesin)
phenylephrine HCl/acetaminophen	Pyrroxate Cold And Congestion
prednisolone sodium phosphate	Veripred 20
dextromethorphan HBr/acetaminophen/doxylamine	Vicks Nyquil Cold/Flu Liquicap
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Vicks Nature Fusion
diphenhydramine HCl	Zzzquil
guaifenesin/dextromethorphan HBr	Vicks Nature Fusion Cough-Cong
dextromethorphan HBr/acetaminophen/doxylamine	Vicks Nature Fusion Cold-Flu
dextromethorphan HBr/acetaminophen/doxylamine	Vicks Nyquil Nighttime Relief
dextromethorphan HBr/doxylamine succinate	Vicks Nyquil Cough
chlorpheniramine maleate/dextromethorphan HBr	Vicks Children'S Nyquil Cold-C
dextromethorphan HBr/acetaminophen/chlorpheniramine maleate	Vicks Nyquil Cold/Flu (Cpm)
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Vicks Dayquil Cold-Flu Relief
guaifenesin/dextromethorphan HBr	Vicks Dayquil Mucus Control DM
phenylephrine HCl/acetaminophen	Vicks Dayquil Sinex
phenylephrine HCl/acetaminophen/doxylamine succinate	Vicks Nyquil Sinex
dextromethorphan HBr/phenylephrine/acetaminophen/doxylamine	Vicks Dayquil-Nyquil
phenylephrine HCl/acetaminophen/doxylamine succinate	Vicks Dayquil-Nyquil Sinex
dextromethorphan HBr/phenylephrine/acetaminophen/doxylamine	Vicks Dayquil-Nyquil Cold-Flu
doxylamine/phenylephrine/dextromethorphan/acetaminophen/GG	Vicks Dayquil-Nyquil Severe
phenylephrine HCl/acetaminophen	Vicks Qlearquil Daytime Sinus
phenylephrine HCl/acetaminophen/doxylamine succinate	Vicks Qlearquil Nightime Sinus

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
phenylephrine HCl/acetaminophen	Vicks Sinex Daytime
phenylephrine HCl/acetaminophen/doxylamine succinate	Vicks Sinex Nighttime
dextromethorphan/pseudoephrine HCl/acetaminophen/doxylamine	Nyquil D
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Vicks Dayquil Severe Cold-Flu
dextromethorphan HBr/phenylephrine/acetaminophen/doxylamine	Vicks Nyquil Severe Cold-Flu
loratadine	Vicks Qlearquil Allergy
diphenhydramine HCl	Vicks Qlearquil Nighttime Rlf
flunisolide	Flunisolide
ketotifen fumarate	Alaway
bepotastine besilate	Bepreve
hydrocortisone/emollient combination no.45	Pediaderm Hc
triamcinolone acetonide/emollient combination no.45	Pediaderm Ta
epinephrine	Episnap
epinephrine	Epinephrinesnap-V
guaifenesin/dextromethorphan HBr	Chest Congestion-Cough Relief
dextromethorphan HBr/acetaminophen/doxylamine	Night Time (Doxy-DM-Acetam)
phenylephrine HCl/diphenhydramine HCl	Childs Triacting Cold-Cough
phenylephrine HCl/acetaminophen/chlorpheniramine	Pain Relief Allergy Sinus
clemastine fumarate	Dayhist Allergy
dextromethorphan/phenylephrine/acetaminophen/chlorphe	Cold Head Congestion Nighttime
brompheniramine maleate/phenylephrine	Cold And Cough Elixir
guaifenesin/phenylephrine HCl	Chest-Sinus Congestion Relief
dextromethorphan/phenylephrine/acetaminophen/chlorphe niramin	Cold Head Congestion Day/Nite
brompheniramine maleate/phenylephrine HCl/dextromethorphan	Brompheniramin-Phenylephrin-DM
guaifenesin/dyphylline	Difil-G 400
methylprednisolone sodium succinate	Methylprednisolone Sodium Succ
naproxen sodium/pseudoephedrine HCl	Aleve-D Sinus And Headache
naproxen sodium/pseudoephedrine HCl	Aleve-D Sinus And Cold
triprolidine HCl/phenylephrine HCl/codeine phosphate	Histex-Ac
brompheniramine maleate/phenylephrine HCl	Brohist D
guaifenesin/dextromethorphan HBr/phenylephrine	Endacon
brompheniramine maleate/phenylephrine	Ap-Hist DM
triprolidine HCl	Histex Pd
triprolidine HCl	Histex (Triprolidine)
phenylephrine HCl/triprolidine HCl	Histex Pe
triprolidine HCl/phenylephrine HCl/dextromethorphan HBr	Histex DM
triprolidine HCl	Histex Pdx
brompheniramine maleate/phenylephrine HCl	Ru-Hist D
guaifenesin/phenylephrine HCl	Duravent Pe
guaifenesin/dextromethorphan HBr/phenylephrine	Duravent DM
pyrilamine maleate/dextromethorphan HBr	Capron DM

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
pyrilamine maleate/dextromethorphan HBr	Capron DMt
chlorpheniramine maleate/phenylephrine HCl/codeine phosphate	Capcof
guaifenesin/dextromethorphan HBr/phenylephrine	Aquanaz
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Capmist DM
guaifenesin/phenylephrine HCl/acetaminophen	Sinus Relief Pressure And Pain
phenylephrine HCl/diphenhydramine HCl	Children Night Time Cold-Cough
doxylamine/phenylephrine/dextromethorphan/acetaminophen/GG	Day-Nite Severe Cold-Flu
diphenhydramine HCl	Ez Nite Sleep
guaifenesin/phenylephrine HCl/acetaminophen	Flu Relief Therapy Cold-Chest
diphenhydramine HCl	Sleep Aid Max Str (Diphenhydr)
dextromethorphan HBr/phenylephrine/acetaminophen/doxylamine	Severe Sinus Congest Alrgy-Cgh
fluticasone propionate	Childrens 24 Hr Allergy Relief
diphenhydramine HCl	Allergy
phenylephrine HCl/acetaminophen/chlorpheniramine	Allergy Relief(Chlorphen-Acet)
guaifenesin/dextromethorphan HBr	Mucus Relief Er DM-Max
ketotifen fumarate	Itchy Eye Drops
dextromethorphan HBr/acetaminophen/doxylamine	Nite-Time Cold-Flu
guaifenesin/phenylephrine HCl/acetaminophen	Sinus Relief Severe Congestion
hydrocodone polistirex/chlorpheniramine polistirex	Tussionex Pennkinetic Er
guaifenesin/pseudoephedrine HCl	Mucinex D
diphenhydramine HCl	Rest Simply Nighttime Sleep
dextromethorphan HBr/acetaminophen/doxylamine	Night Time Cold
dextromethorphan HBr/acetaminophen/doxylamine	Night Time
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Allergy Sinus Headache (Pe)
phenylephrine HCl/acetaminophen	Sinus Pain Relief
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Daytime
cetirizine HCl	Children'S Allergy(Cetirizine)
hydrocortisone/aloe vera	Anti-Itch(Hydrocortisone)-Aloe
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Cough And Severe Cold
codeine phosphate/guaifenesin	Relcof C
brompheniramine maleate/phenylephrine	Relcof DM
guaifenesin/dextromethorphan HBr/phenylephrine	Relhist DMx
guaifenesin/phenylephrine HCl	Relcof Ir
brompheniramine maleate/phenylephrine HCl	Relhist Bp
pheniramine maleate/phenylephrine HCl/acetaminophen	Flu And Sore Throat
guaifenesin/dextromethorphan HBr/phenylephrine	Tussin CF Max
guaifenesin/dextromethorphan HBr/phenylephrine	Tussin CF Cough-Cold
acetaminophen/dextromethorphan HBr	Pain Relief Cold And Cough
phenylephrine HCl/acetaminophen/chlorpheniramine	Sinus Congestion-Pain(Chlorph)
diphenhydramine HCl	Restfully Sleep
clemastine fumarate	Allerhist-1
dextromethorphan HBr/pseudoephedrine HCl/acetaminophen	Day-Time
phenylephrine HCl/acetaminophen	Pain Relief Sinus Pe

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
guaifenesin/dextromethorphan HBr	Intense Cough Reliever
ketotifen fumarate	Allergy Eye (Ketotifen)
cetirizine HCl/pseudoephedrine HCl	Allergy D-12
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Pain Relief Cold
brompheniramine maleate/phenylephrine HCl/dextromethorphan	Children'S Cold And Cough DM
aminophylline	Aminophylline (Bulk)
betamethasone acetate, micronized	Betamethasone Acet,Micro(Bulk)
fluticasone propionate	Fluticasone Propionate (Bulk)
formoterol fumarate	Formoterol Fumarate (Bulk)
loratadine	Loratadine (Bulk)
prednisolone	Prelone
triamcinolone acetonide	Triamcinolone Acetonide (Bulk)
prednisolone, micronized	Prednisolone, Micro (Bulk)
prednisolone acetate, micronized	Prednisolone Ac, Micro (Bulk)
dexamethasone, micronized	Dexamethasone,Micronized(Bulk)
cyproheptadine HCl	Cyproheptadine (Bulk)
dexamethasone acetate, micronized	Dexamethasone Ac, Micro (Bulk)
mometasone furoate	Mometasone Furoate (Bulk)
loratadine, micronized	Loratadine, Micronized (Bulk)
guaifenesin/dextromethorphan HBr	Tussin Cough DM
brompheniramine maleate/pseudoephedrine HCl	Childrens Cold-Alrgy (P-Ephed)
pseudoephedrine/dextromethorphan/guaifenesin/acetamin	Cold And Cough (Pe-DM-Gg-Acet)
guaifenesin/pseudoephedrine HCl	Non-Drying Sinus
dextromethorphan/pseudoephrine HCl/acetaminophen/doxylamine	Night Time
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Tussin Cold-Congestion
guaifenesin/pseudoephedrine HCl	Tussin Cold Severe Congestion
phenylephrine HCl/acetaminophen	Non-Aspirin Sinus
pseudoephedrine HCl/acetaminophen	Daytime Sinus Relief
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Intense Cold And Flu
phenylephrine HCl/acetaminophen/dexbrompheniramine maleate	Complete Sinus Relief
chlorpheniramine maleate/phenylephrine HCl	Cold And Allergy
phenylephrine HCl/triprolidine HCl	Sinus Nighttime
dextromethorphan HBr/acetaminophen/doxylamine	Night Time Cold-Flu Relief
dextromethorphan HBr/acetaminophen/doxylamine	Night Time Cold-Flu
guaifenesin/phenylephrine HCl	Mucus Relief D (Phenylephrine)
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Non-Aspirin Severe Congest M-S
phenylephrine HCl/acetaminophen	Daytime Sinus
phenylephrine HCl/acetaminophen/doxylamine succinate	Nighttime Sinus
guaifenesin/phenylephrine HCl	Tussin Pe
dextromethorphan HBr/acetaminophen/doxylamine	Night Time Cough-Sore Throat
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Flu Relief Therapy Daytime
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Childs Plus Cold And Allergy

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
guaifenesin/pseudoephedrine HCl	Chest Congestion Relief D
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Allergy-Sinus
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Allergy Relief-Sinus Headache
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Severe Cold (Diphen-Pe-Acetam)
diphenhydramine HCl	Children'S Complete Allergy
phenylephrine HCl/acetaminophen	Pressure And Pain
dextromethorphan HBr/acetaminophen/doxylamine	Night Time Cold And Flu Relief
phenylephrine HCl/diphenhydramine HCl	Nighttime Cough-Cold
guaifenesin/dextromethorphan HBr/phenylephrine	Severe Congestion And Coughmax
guaifenesin/dextromethorphan HBr	DM Max
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Flu And Sore Throat Relief
diphenhydramine HCl	Nyt-Time Sleep
phenylephrine HCl/acetaminophen	Daytime Sinus-Congestion
phenylephrine HCl/acetaminophen/doxylamine succinate	Nighttime Sinus-Congestion
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Pressure-Pain-Cold
guaifenesin/phenylephrine HCl/acetaminophen	Cold Head Congest(Gg-Pe-Acetm)
dextromethorphan HBr/phenylephrine/acetaminophen/doxylamine	Nite Time Cold-Flu Relief (Pe)
diphenhydramine HCl	Children'S Allergy Medicine
dextromethorphan HBr/acetaminophen/chlorpheniramine maleate	Coricidin Hbp
chlorpheniramine/dextromethorphan/acetaminophen/guaifenesin	Coricidin Hbp Day-Night
dextromethorphan/phenylephrine/acetaminophen/chlorpheniramin	Night Time Cold
ibuprofen/pseudoephedrine HCl	Ibuprofen Cold
pseudoephedrine/dextromethorphan/guaifenesin/acetaminophen	Day-Time
dextromethorphan/phenylephrine/acetaminophen/chlorpheniramin	Daytime And Nighttime Cold
dextromethorphan HBr/pseudoephedrine HCl/acetaminophen	Pain Reliever Flu
chlorpheniramine maleate/dextromethorphan HBr	Cough-Cold Relief Hbp
phenylephrine HCl/acetaminophen	Sinus Headache Pe
guaifenesin/phenylephrine HCl/acetaminophen	Pressure-Pain Pe Plus Mucus
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Pressure-Pain Pe Plus Cold
diphenhydramine HCl	Unisom Sleepgels
diphenhydramine HCl	Unisom Sleepmelts
hydrocortisone/aloe vera	Cortizone-10 With Aloe
diphenhydramine HCl	Unisom (Diphenhydramine)
fexofenadine HCl	Allegra Allergy
fexofenadine HCl	Children'S Allegra Allergy
fexofenadine HCl/pseudoephedrine HCl	Allegra-D 12 Hour
fexofenadine HCl/pseudoephedrine HCl	Allegra-D 24 Hour
triamcinolone acetonide	Nasacort

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
triamcinolone acetonide	Children'S Nasacort
dextromethorphan HBr/doxylamine succinate	Nitetime Cough
phenylephrine HCl/acetaminophen/chlorpheniramine	Allergy Sinus Pe
dextromethorphan HBr/acetaminophen/doxylamine	Nitetime Multi-Symptom
brompheniramine maleate/phenylephrine HCl/dextromethorphan	Children'S Dibromm DM Cold-Cou
brompheniramine maleate/phenylephrine HCl	Children'S Dibromm Cold-Allerg
phenylephrine HCl/acetaminophen	Sinus Relief (Non-Drowsy)
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Severe Cold
epinephrine	Adrenalin
diphenhydramine HCl	Nytol
phenylephrine HCl/pyrilamine maleate	Pyrilamine-Phenylephrine
triprolidine HCl/pseudoephedrine HCl	Entre-Hist Pse
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Entre-Cough
dexamethasone	Taperdex
dexamethasone	Zodex
guaifenesin/dextromethorphan HBr	Ultra Tuss Safe
epinastine HCl	Epinastine
deflazacort	Emflaza
DIPHENHYDRAMINE HCl	Dicopanol
guaifenesin/dextromethorphan HBr	Mucosa DM
chlorpheniramine maleate	Chlorhist
diphenhydramine HCl	Aler-Tab
diphenhydramine HCl	Aler-Cap
chlorpheniramine maleate/codeine phosphate	Zodryl Ac 25
chlorpheniramine maleate/codeine phosphate	Zodryl Ac 30
chlorpheniramine maleate/codeine phosphate	Zodryl Ac 35
chlorpheniramine maleate/codeine phosphate	Zodryl Ac 40
chlorpheniramine maleate/codeine phosphate	Zodryl Ac 50
chlorpheniramine maleate/codeine phosphate	Zodryl Ac 60
chlorpheniramine maleate/codeine phosphate	Zodryl Ac 80
chlorpheniramine maleate/pseudoephedrine HCl/codeine	Zodryl Dac 25
chlorpheniramine maleate/pseudoephedrine HCl/codeine	Zodryl Dac 30
chlorpheniramine maleate/pseudoephedrine HCl/codeine	Zodryl Dac 35
chlorpheniramine maleate/pseudoephedrine HCl/codeine	Zodryl Dac 40
chlorpheniramine maleate/pseudoephedrine HCl/codeine	Zodryl Dac 50
chlorpheniramine maleate/pseudoephedrine HCl/codeine	Zodryl Dac 60
chlorpheniramine maleate/pseudoephedrine HCl/codeine	Zodryl Dac 80
pseudoephedrine HCl/codeine phosphate/guaifenesin	Zodryl Dec 25
pseudoephedrine HCl/codeine phosphate/guaifenesin	Zodryl Dec 30
pseudoephedrine HCl/codeine phosphate/guaifenesin	Zodryl Dec 35
pseudoephedrine HCl/codeine phosphate/guaifenesin	Zodryl Dec 40
pseudoephedrine HCl/codeine phosphate/guaifenesin	Zodryl Dec 50
pseudoephedrine HCl/codeine phosphate/guaifenesin	Zodryl Dec 60
pseudoephedrine HCl/codeine phosphate/guaifenesin	Zodryl Dec 80
fluocinolone acetonide/emollient combination no.65	Synalar Cream Kit

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
fluocinolone acetonide/emollient combination no.65	Synalar Ointment Kit
fluocinolone acetonide/skin cleanser comb no.28	Synalar Ts
clobetasol propionate/skin cleanser combination no.28	Clodan Kit
fluticasone propionate/emollient combination no.65	Beser Kit
phenylephrine HCl/pyrilamine maleate	Pyril D
carbinoxamine maleate	Carbinoxamine Maleate
brompheniramine maleate/pseudoephedrine	Bio-Dtuss DMx
guaifenesin/dextromethorphan HBr/phenylephrine	Biogil
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Bionel
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Bionel Pediatric
guaifenesin/dextromethorphan HBr/phenylephrine	Biocotron-D
guaifenesin/dextromethorphan HBr	Biocotron
dextromethorphan HBr/phenylephrine	Bionatuss Dxp
guaifenesin/dextromethorphan HBr	Biospec DMx
guaifenesin/dextromethorphan HBr/phenylephrine	Biobron Sf
chlorpheniramine maleate/phenylephrine	Bio-B Kids
guaifenesin/dextromethorphan HBr/phenylephrine	Biodesp DM
guaifenesin/dextromethorphan HBr/phenylephrine	Bio T Pres
brompheniramine maleate/phenylephrine	Bio T Pres-B
guaifenesin/dextromethorphan HBr/phenylephrine	Bio T Pres Pediatric
guaifenesin/dextromethorphan HBr/phenylephrine	Bio-S-Pres Dx
guaifenesin/dextromethorphan HBr/phenylephrine	Biogtuss Nf
guaifenesin/dextromethorphan HBr/phenylephrine	Biobron Dx
chlorpheniramine maleate/phenylephrine	Bio-Rytuss
hydrocortisone acetate/pramoxine HCl	Hydrocortisone-Pramoxine
guaifenesin/pseudoephedrine HCl	Pseudoephedrine-Guaifenesin
cetirizine HCl/pseudoephedrine HCl	Cetirizine-Pseudoephedrine
dexamethasone sodium phosphate/PF	Active Injection Kit D (Pf)
phenylephrine HCl/acetaminophen/chlorpheniramine	Contac Cold-Flu Max Strength
phenylephrine HCl/acetaminophen	Contac Cold-Flu Day
phenylephrine HCl/acetaminophen/chlorpheniramine	Contac Cold-Flu Day And Night
dextromethorphan HBr/acetaminophen/doxylamine	Contac Cold-Flu Night
guaifenesin/dextromethorphan HBr	Daytime Mucus Relief DM
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Allergy Plus Severe Sinus Ha
phenylephrine HCl/acetaminophen/chlorpheniramine	Effervescent Cold Relief Plus
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Cold Severe Congestion
fexofenadine HCl/pseudoephedrine HCl	Fexofenadine-Pseudoephedrine
aldosterone	Aldosterone (Bulk)
hydrocortisone/mineral oil/petrolatum,white	Hydrocortisone-Min Oil-Wht Pet
guaifenesin/phenylephrine HCl/acetaminophen	Ccp Caffeine Free
phenylephrine HCl/acetaminophen/chlorpheniramine	Medicidin-D
diphenhydramine HCl	Diphen
loratadine	Loradamed
guaifenesin/dextromethorphan HBr	Guaicon DMs
guaifenesin/phenylephrine HCl/acetaminophen	Coldonyl

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Decorel Forte Plus
phenylephrine HCl/acetaminophen	Sinus Pain-Pressure (Pe)
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Non-Pseudo Cold Relief
pseudoephedrine HCl/acetaminophen	Nexafed Sinus Pressure-Pain
chlorpheniramine maleate	Chlortabs
chlorpheniramine maleate/phenylephrine HCl	Suphedrine Pe Sinus Andallergy
phenylephrine HCl/acetaminophen/doxylamine succinate	Daytime And Nitetime Sinus
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Severe Allergy-Sinus Headache
phenylephrine HCl/acetaminophen/chlorpheniramine	Allergy Relief Multi-Symptom
hydrocortisone/aloe vera/vitamin E acetate/vitamins A and D	Anti-Itch Plus
chlorpheniramine maleate/phenylephrine bitartrate/aspirin	Cold Relief
racepinephrine HCl	Racepinephrine (Bulk)
triamcinolone hexacetonide	Triamcinolone Hexaceton (Bulk)
diphenhydramine HCl	Aller-G-Time
chlorpheniramine maleate	Allergy-Time
epinephrine	Epipen
epinephrine	Epipen 2-Pak
epinephrine	Epipen Jr
epinephrine	Epipen Jr 2-Pak
formoterol fumarate	Perforomist
ipratropium bromide/albuterol sulfate	Duoneb
revefenacin	Yupelri
guaifenesin/dextromethorphan HBr	Medi-Tussin DM
guaifenesin/dextromethorphan HBr	Intense Cough
guaifenesin/dextromethorphan HBr	Medi-Tussin DM Diabetic
diphenhydramine HCl	Medi-Phedryl
triamcinolone/norflurane and pentafluoropropane (HFC 245fa)	P-Care K40G
triamcinolone acetonide	P-Care K40
triamcinolone acetonide	P-Care K80
triamcinolone/norflurane and pentafluoropropane (HFC 245fa)	P-Care K80G
methylprednisolone acetate	P-Care D40
methylprednisolone acetate/norflurane/HFC 245fa	P-Care D40G
methylprednisolone acetate	P-Care D80
methylprednisolone acetate/norflurane/HFC 245fa	P-Care D80G
betamethasone acetate/betamethasone sodium phosphate	Pod-Care 100C
betamethasone acetate and sodium phosph/norflurane/HFC 245fa	Pod-Care 100Cg
triamcinolone acetonide	Pod-Care 100K
triamcinolone/norflurane and pentafluoropropane (HFC 245fa)	Pod-Care 100Kg
metaproterenol sulfate	Metaproterenol
chlorpheniramine maleate/phenylephrine HCl/dextromethorphan	Bronkids

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
guaifenesin/dextromethorphan HBr/phenylephrine	Brontuss Sf
pseudoephedrine HCl/codeine phosphate/guaifenesin	Phenylhistine
chlorpheniramine maleate/pseudoephedrine HCl	Chlorpheniramine-Pseudoephed
albuterol sulfate	Proair Hfa
levalbuterol tartrate	Xopenex Hfa
guaifenesin/dextromethorphan HBr	Mucinex DM
guaifenesin/dextromethorphan HBr	Diabetic Siltussin-DM
beclomethasone dipropionate	Qvar
beclomethasone dipropionate	Qvar Redihaler
omalizumab	Xolair
guaifenesin/dextromethorphan HBr	Guaifenesin-DM
codeine phosphate/guaifenesin	Guaiatussin Ac
phenylephrine HCl/promethazine HCl	Promethazine-Phenylephrine
promethazine/phenylephrine HCl/codeine	Promethazine-Phenyleph-Codeine
hydrocortisone/aloe vera	Cortisone With Aloe
loratadine/pseudoephedrine sulfate	Allergy Relief D12
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Sinus Pe Pressure-Pain-Cold
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Cold-Flu-Sore Throat
guaifenesin/dextromethorphan HBr/phenylephrine	Severe Cough-Congestion
guaifenesin/dextromethorphan HBr	Child Chest Congestion-Cough
acetaminophen/dextromethorphan HBr	Child Cough And Sore Throat
fexofenadine HCl	Children'S Allergy Relief(Fex)
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Child Multi-Symptom Cold-Fever
guaifenesin/phenylephrine HCl/acetaminophen	Cold And Sinus Multi-Symptom
guaifenesin/phenylephrine HCl	Children'S Stuffy Nose-Cold
dextromethorphan HBr/phenylephrine HCl	Children'S Cold-Cough Daytime
dextromethorphan/phenylephrine/acetaminophen/diphenhydramine	Multi-Symptom Severe Cold-Nt
guaifenesin/phenylephrine HCl/acetaminophen	Severe Congestion Relief
guaifenesin/dextromethorphan HBr	Child Cough-Chest Congest DM
doxylamine succinate/dextromethorphan HBr/guaifenesin	Tussin DM Day-Night
levocetirizine dihydrochloride	Allergy Relief (Levocetirizin)
phenylephrine HCl/diphenhydramine HCl	Allergy-D
guaifenesin/phenylephrine HCl	Non-Drying Sinus
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Flu Severe Cold-Night(Diph-Pe)
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Flu And Severe Cold-Daytime
dextromethorphan HBr/acetaminophen/chlorpheniramine maleate	Children'S Cough And Runnynose
pseudoephedrine HCl/acetaminophen	Sinus Headache Degongestant
ketotifen fumarate	Antihistamine Eye Drops
fexofenadine HCl/pseudoephedrine HCl	Allergy Relief D
phenylephrine HCl/diphenhydramine HCl	Cold And Cough (Diphenhydr-Pe)
codeine phosphate/guaifenesin	Virtussin Ac
theophylline anhydrous	Theo-24

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
dextromethorphan HBr/phenylephrine/acetaminophen/doxylamine	Tylenol Cold Multi-Sympt Night
guaifenesin/phenylephrine HCl/acetaminophen	Tylenol Sinus Severe
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Tylenol Cold Max Day
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Sudafed Pe Pressure+Pain+Cold
phenylephrine HCl/diphenhydramine HCl	Child'S Benadryl-D Allergy-Sin
chlorcyclizine HCl/pseudoephedrine HCl/codeine phosphate	Poly-Tussin D
chlorcyclizine HCl/codeine phosphate	Poly-Tussin
phenylephrine HCl/pyrilamine maleate	Poly Hist Forte (Pyrilamine)
guaifenesin/pseudoephedrine HCl	Poly-Vent Ir
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Poly-Vent DM
doxylamine succinate/phenylephrine HCl	Poly Hist Forte (Doxylamine)
thonzylamine HCl/phenylephrine HCl/dextromethorphan HBr	Poly-Hist DM (Thonzylamine)
thonzylamine HCl/chlophedianol HCl	Poly Hist Pd
dexchlorpheniramine maleate/phenylephrine/dextromethorphan	Polytussin DM
pseudoephedrine/dextromethorphan/guaifenesin/acetaminophen	Duraflu
pseudoephedrine HCl/codeine phosphate/guaifenesin	Lortuss Ex
doxylamine succinate/pseudoephedrine HCl	Lortuss Lq
doxylamine succ/pseudoephedrine HCl/dextromethorphan Hbr	Lortuss DM
doxylamine succinate/phenylephrine HCl	Poly Hist Forte
brompheniramine maleate/phenylephrine HCl/codeine phosphate	Poly-Tussin Ac
guaifenesin/phenylephrine HCl	Deconex Ir
guaifenesin/dextromethorphan HBr/phenylephrine	Deconex DMx
dexbrompheniramine maleate/phenylephrine HCl	Ala-Hist Pe
dexbrompheniramine maleate	Ala-Hist Ir
dextromethorphan HBr/phenylephrine HCl/dexbrompheniramine	Alahist CF
brompheniramine maleate/phenylephrine HCl/dextromethorphan	Ala-Hist DM
dextromethorphan HBr/phenylephrine HCl/dexbrompheniramine	Alahist DM
tripelennamine HCl	Tripelennamine (Bulk)
methylprednisolone, micronized	Methylprednisolone, Mic (Bulk)
loratadine	Children'S Loratadine
prednisolone acetate	Flo-Pred
hydrocortisone acetate/urea	U-Cort
pyrilamine maleate	Pyrilamine Maleate (Bulk)
dyphylline	Dyphylline (Bulk)
desoxycorticosterone acetate	Desoxycorticosterone Ac (Bulk)
brompheniramine maleate	Brompheniramine Maleate (Bulk)
triprolidine HCl	Triprolidine HCl (Bulk)
trimeprazine tartrate	Trimeprazine Tartrate (Bulk)

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
clemizole HCl	Clemizole HCl (Bulk)
fexofenadine HCl	Fexofenadine (Bulk)
montelukast sodium	Montelukast (Bulk)
formoterol fumarate dihydrate, micronized	Formoterol Fum Dihyd,Mic(Bulk)
epinephrine	Adrenaclick
guaifenesin/dextromethorphan HBr/phenylephrine	Supress Dx
guaifenesin/phenylephrine HCl	Supress-Pe
dextromethorphan HBr/phenylephrine	Supress A
guaifenesin/dextromethorphan HBr	Supress DM
guaifenesin/dextromethorphan HBr/phenylephrine	Tussi-Pres
guaifenesin/dextromethorphan HBr/phenylephrine	Tussi-Pres Pediatric
brompheniramine maleate/phenylephrine	Tussi Pres-B
guaifenesin/dextromethorphan HBr/phenylephrine	Tusicof
guaifenesin/dextromethorphan HBr	Zyncof
guaifenesin/dextromethorphan HBr	G-Zyncof
guaifenesin/dextromethorphan HBr	G-Tron
dextromethorphan HBr/phenylephrine HCl/dexbrompheniramine	G-P-Tuss Dxp
guaifenesin/dextromethorphan HBr	Pecgen DMx
guaifenesin/dextromethorphan HBr/phenylephrine	Tusslin
dexchlorpheniramine maleate/pseudoephed/dextromethorphan HBr	Abatuss DMx
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Pecgen Pse
guaifenesin/dextromethorphan HBr/phenylephrine	Pres Gen
brompheniramine maleate/phenylephrine HCl/dextromethorphan	Presgen B
guaifenesin/dextromethorphan HBr/phenylephrine	G-Tusicof
guaifenesin/dextromethorphan HBr/phenylephrine	Desgen
guaifenesin/dextromethorphan HBr/phenylephrine	Desgen DM
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Desgen DM (Pseudoephedrine)
chlorpheniramine maleate/phenylephrine HCl/dextromethorphan	Gencontuss
guaifenesin/dextromethorphan HBr/phenylephrine	Pres Gen Pediatric
guaifenesin/dextromethorphan HBr/phenylephrine	G-Supress Dx
guaifenesin/dextromethorphan HBr	Sorbugen Nr
dexchlorpheniramine maleate/pseudoephedrine/chlophedianol	Abanatuss Ped
guaifenesin/dextromethorphan HBr/phenylephrine	G-Tron Ped
pseudoephedrine HCl/acrivastine	Semprex-D
cetirizine HCl	Children'S Allergy Complete
cetirizine HCl/pseudoephedrine HCl	Allergy Complete-D
guaifenesin/dextromethorphan HBr/phenylephrine	Adult Tussin Multi-Symp Cold
guaifenesin/dextromethorphan HBr	Adult Tussin DM
guaifenesin/dextromethorphan HBr	Adult Tussin Cough Congest DM
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Severe Cold Cough-Flu
phenylephrine HCl/acetaminophen/chlorpheniramine	Norel Ad
hydrocodone bitartrate/homatropine methylbromide	Hydrocodone Compound

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Robafen CF
guaifenesin/dextromethorphan HBr	Safe Tussin DM
dextromethorphan HBr/doxylamine succinate	Safetussin Pm
brompheniramine maleate/phenylephrine HCl/dextromethorphan	Altipres-B
guaifenesin/dextromethorphan HBr/phenylephrine	Altipres Pediatric
guaifenesin/dextromethorphan HBr/phenylephrine	Altipres
triamcinolone acetonide	Readysharp Triamcinolone
methylprednisolone acetate	Readysharp Methylprednisolone
dexamethasone sodium phosphate	Readysharp Dexamethasone
betamethasone acetate/betamethasone sodium phosphate	Readysharp Betamethasone
guaifenesin/dextromethorphan HBr	Ri-Tussin DM
triprolidine HCl/pseudoephedrine HCl	Ritifed
guaifenesin/dextromethorphan HBr/phenylephrine	Dometuss-DMx
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Dometuss G
chlorpheniramine maleate/phenylephrine HCl	Child Dometuss-Da
triamcinolone acetonide	Nasacort Aq
hydrocortisone acetate/pramoxine HCl	Analpram-Hc
chlorpheniramine maleate/pseudoephedrine/dextromethorphan	Pediatric Cough And Cold
brompheniramine maleate/pseudoephedrine HCl	Brotapp
guaifenesin/dextromethorphan HBr	Siltussin DM Das
diphenhydramine HCl	Siladryl Sa
brompheniramine maleate/pseudoephedrine HCl/dextromethorphan	Brotapp DM
guaifenesin/dextromethorphan HBr	Diabetic Siltussin-DM Max Str
diphenhydramine HCl	Silphen Cough
guaifenesin/dextromethorphan HBr	Siltussin-DM
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Tusnel New Formula
guaifenesin/dextromethorphan HBr	Tusnel Diabetic
guaifenesin/dextromethorphan HBr/phenylephrine	Tusnel DM
pseudoephedrine HCl/codeine phosphate/guaifenesin	Tusnel C
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Tusnel Pediatric
guaifenesin/pseudoephedrine HCl	Tusnel Pediatric
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Tusnel DM Pediatric(Pseudoeph)
guaifenesin/dextromethorphan HBr/phenylephrine	Tusnel DM Pediatric(Phenyleph)
dexbrompheniramine maleate/pseudoephedrine HCl	Conex
ciclesonide	Alvesco
ciclesonide	Omnaris
guaifenesin/dextromethorphan HBr	Children'S Mucinex Cough
guaifenesin/phenylephrine HCl	Entex Lq
brompheniramine maleate/pseudoephedrine HCl/dextromethorphan	Bromfed DM
chlorpheniramine maleate/phenylephrine HCl/dextromethorphan	Rycontuss
guaifenesin/dextromethorphan HBr	Geri-Tussin DM

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
diphenhydramine HCl	Geri-Dryl
guaifenesin/dextromethorphan HBr	Guaiasorb DM
codeine phosphate/guaifenesin	G Tussin Ac
dexchlorpheniramine maleate/pseudoephed/dextromethorphan HBr	Deltuss DMx (Dexchlorphen)
dexchlorpheniramine maleate/pseudoephedrine HCl	Deltuss Dp
guaifenesin/dextromethorphan HBr	Trispec DMx
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Trispec Pse
diphenhydramine HCl	Naramin
chlorcyclizine HCl	Ahist (Chlorcyclizine)
dexchlorpheniramine maleate/phenylephrine HCl	Stahist (Dexchlorpheniramine)
chlorcyclizine HCl/pseudoephedrine HCl	Stahist Ad
chlorpheniramine maleate/codeine phosphate	Z-Tuss Ac
dexamethasone	Decadron
guaifenesin/dextromethorphan HBr/phenylephrine	Giltuss Pediatric
guaifenesin/dextromethorphan HBr/phenylephrine	Giltuss
guaifenesin/dextromethorphan HBr/phenylephrine	Exactuss
chlorpheniramine maleate/phenylephrine HCl/chlophedianol	Carbaphen Ch
chlorpheniramine maleate/phenylephrine HCl/chlophedianol HCl	Carbaphen Ped Ch
guaifenesin/dextromethorphan HBr/phenylephrine	Giltuss Cough-Cold
guaifenesin/phenylephrine HCl	Gilphex Tr
guaifenesin/dextromethorphan HBr/phenylephrine	Giltuss Tr
chlorpheniramine maleate/phenylephrine HCl	Phenabid
chlorpheniramine maleate/phenylephrine HCl/dextromethorphan	Phenabid DM
chlorpheniramine maleate/phenylephrine HCl	Phenagil
chlorpheniramine maleate/phenylephrine HCl/chlophedianol HCl	Phenagil Ch
guaifenesin/dextromethorphan HBr/phenylephrine	Exactuss Tr
guaifenesin/phenylephrine HCl	Exaphex Tr
chlorpheniramine maleate/phenylephrine HCl/chlophedianol HCl	Exaphen Ch
chlorpheniramine maleate/phenylephrine HCl	Exaphen
guaifenesin/pseudoephedrine HCl	Maxifed
chlorpheniramine maleate/phenylephrine HCl/dextromethorphan	Maxichlor Peh DM
brompheniramine maleate/phenylephrine HCl	Brovex Peb
brompheniramine maleate/phenylephrine HCl/dextromethorphan	Brovex Peb DM
chlorpheniramine maleate/phenylephrine HCl/codeine phosphate	Maxi-Tuss Cd
chlorpheniramine maleate/dextromethorphan HBr	Maxi-Tuss DM(Chlorpheniramine)
guaifenesin/dextromethorphan HBr	Allfen DM
guaifenesin/phenylephrine HCl	Maxiphen
guaifenesin/dextromethorphan HBr/phenylephrine	Maxiphen DM

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
pseudoephedrine HCl/codeine phosphate/acetaminophen/guaifen	Maxiflu Cd
pseudoephedrine HCl/codeine	Maxiflu Cdx
phenylephrine HCl/codeine phosphate/acetaminophen/guaifen	Phenflu Cd
phenylephrine HCl/codeine phosphate/acetaminophen/guaifen	Phenflu Cdx
Chlorpheniramine Maleate/Codeine Phosphate/Acetaminophen	Cotabflu
brompheniramine maleate/phenylephrine HCl/dextromethorphan	M-Hist DM
triprolidine HCl	M-Hist Pd
guaifenesin/dextromethorphan HBr/phenylephrine	Vanatab DM
pyrilamine maleate/chlophedianol HCl	Dayclear Allergy Relief
thonzylamine HCl/phenylephrine HCl/chlophedianol HCl	Vanacof Ape
pyrilamine maleate/chlophedianol HCl	Vanacof Ac
pyrilamine maleate/chlophedianol HCl	Vanatab Ac
pyrilamine maleate/chlophedianol HCl	Vanacof-8
chlorpheniramine maleate	Chlorphen Sr
pseudoephedrine HCl/chlophedianol HCl/guaifenesin	Vanatab Dx
triprolidine HCl	Vanaclear Pd
triprolidine HCl	Vanahist Pd
guaifenesin/dextromethorphan HBr/phenylephrine	Vanacof DM
chlophedianol HCl/guaifenesin	Vanacof G
chlorcyclizine HCl/pseudoephedrine HCl	Nasopen
phenylephrine HCl/chlophedianol HCl/guaifenesin	Vanacof Gpe
diphenhydramine HCl	Vanamine Pd
thonzylamine HCl/phenylephrine HCl	Nasopen Pe
pseudoephedrine HCl/chlophedianol HCl/guaifenesin	Vanacof Dx
dexchlorpheniramine maleate/pseudoephedrine/chlophedianol	Vanacof
triamcinolone acetonide/dimethicone/silicone, adhesive	Dermacinrx Silapak
triamcinolone acetonide/lidocaine/prilocaine	Dermacinrx Cinlone-I Cpi
fluticasone propionate/sodium chloride/sodium bicarbonate	Ticanase
triamcinolone acetonide/dimethicone	Ellzia Pak
prednisolone sodium phosphate	Orapred Odt
beclomethasone dipropionate	Qnasl
albuterol sulfate	Proair Respiclick
reslizumab	Cinqair
fluticasone propionate	Armonair Respiclick
fluticasone propionate/salmeterol xinafoate	Airduo Respiclick
prednisolone sodium phosphate	Orapred
hydrocortisone acetate/aloe vera	Hydrocortisone Acet-Aloe Vera
guaifenesin/dextromethorphan HBr	Diabetic Tussin DM
dextromethorphan HBr/acetaminophen/diphenhydramine HCl	Diabetic Tussin Night Time
pseudoephedrine HCl/chlorpheniramine maleate/bellad alk	Respa-Ar

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
chlorpheniramine maleate/codeine phosphate	Codar Ar
chlorpheniramine maleate/pseudoephedrine HCl/codeine	Tricode Ar
pseudoephedrine HCl/codeine phosphate/guaifenesin	Tricode Gf
pseudoephedrine HCl/codeine phosphate	Codar D
codeine phosphate/guaifenesin	Codar Gf
triamcinolone acetonide	Arze-Ject-A
dexamethasone sodium phosphate in 0.9 % sodium chloride	Dexamethasone In 0.9 % Sod Chl
hydrocodone bitartrate/homatropine methylbromide	Tussigon
guaifenesin/dextromethorphan HBr	Diabetic Tussin Max St
guaifenesin/phenylephrine HCl	Fenesin Pe Ir
guaifenesin/dextromethorphan HBr	Fenesin DM Ir
levalbuterol HCl	Levalbuterol HCl (Bulk)
triamcinolone hexacetonide, micronized	Triamcin Hexacet, Micro (Bulk)
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Actinel
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Actinel Pediatric
dexbrompheniramine maleate/pseudoephedrine HCl	Acticon (Dexbromph-Pse)
guaifenesin/dextromethorphan HBr/phenylephrine	Actidom DMx
chlorpheniramine maleate/phenylephrine HCl/dextromethorphan	Balamine DM (Chlor-Pe)
dexamethasone sodium phosphate/PF	Dexamethasone Sodium Phos (Pf)
glycopyrrolate/nebulizer and accessories	Lonhala Magnair Starter
glycopyrrolate/nebulizer accessories	Lonhala Magnair Refill
ciclesonide	Zetonna
arformoterol tartrate	Brovana
loratadine/pseudoephedrine sulfate	Loratadine-Pseudoephedrine
chlorpheniramine maleate/phenylephrine HCl/dextromethorphan	Nasohist DM
chlorpheniramine maleate/phenylephrine HCl	Nasohist
chlorcyclizine hydrochloride/chlophedianol hydrochloride	Biclora
chlorcyclizine HCl/pseudoephedrine HCl/chlophedianol HCl	Biclora-D
carbinoxamine maleate	Arbinoxa
pseudoephedrine HCl/hydrocodone bitartrate	Rezira
hydrocodone bitart/chlorpheniramine maleate/pseudoephedrine	Zutripro
hydrocodone bitartrate/chlorpheniramine maleate	Vituz
guaifenesin/dextromethorphan HBr/phenylephrine	Children'S Mucinex Multi-Symp
guaifenesin/dextromethorphan HBr/phenylephrine	Mucinex Fast-Max Congest-Cough
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Mucinex Cold,Flu,Sore Throat
guaifenesin/phenylephrine HCl/acetaminophen	Mucinex Cold And Sinus
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Children'S Mucinex Cold-Fever
guaifenesin/dextromethorphan HBr	Mucinex Fast-Max DM Max
phenylephrine HCl/dextromethorphan	Mucinex Fast-Max Severe Cold
guaifenesin/pseudoephedrine HCl	Mucinex D Maximum Strength
guaifenesin/phenylephrine HCl/acetaminophen	Mucinex Fast-Max Cold-Sinus

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Mucinex Fast-Max Cold-Flu-Thrt
guaifenesin/phenylephrine HCl/acetaminophen	Mucinex Sinus-Max Pressur-Pain
guaifenesin/phenylephrine HCl/acetaminophen	Mucinex Sinus-Max Sev Congestn
diphenhydramine HCl/phenylephrine/acetaminophen/guaifenesin	Mucinex Sinus-Max D-N (Diphen)
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Delsym Cough-Cold Nighttime
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Child Delsym Cough+Cold
guaifenesin/dextromethorphan HBr	Delsym Cough-Chest Congest DM
guaifenesin/dextromethorphan HBr	Child Delsym Cough+Chest DM
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Delsym Cough-Cold Daytime
diphenhydramine/phenylephrin/dextromethorph/acetaminophen/GG	Mucinex Fast-Max Day-Nite Cold
guaifenesin/dextromethorphan HBr	Mucinex Cough Mini-Melts
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Mucinex Sinus-Max Nite Congest
guaifenesin/phenylephrine HCl	Child Mucinex Stuffy Nose-Cold
guaifenesin/dextromethorphan HBr/phenylephrine	Child Mucinex Congestion-Cough
diphenhydramine/phenylephrin/dextromethorph/acetaminophen/GG	Child Mucinex M-S Cold Day-Nte
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Mucinex Fast-Max Nite Cold-Flu
diphenhydramine/phenylephrin/dextromethorph/acetaminophen/GG	Mucinex Fst-Mx Dy-Nt Cold(Dph)
diphenhydramine/phenylephrin/dextromethorph/acetaminophen/GG	Mucinex Fast-Max Day-Nite Cong
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Mucinex Fast-Max Congest-Head
dextromethorphan HBr/phenylephrine/acetaminophen/doxylamine	Mucinex Fast-Max Nite (Doxyl)
doxylamine/phenylephrine/dextromethorphan/acetaminoph	Mucinex Fast-Max Day-Nt(Doxyl)
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Mucinex Fast-Maxsev Cold-Sinus
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Children'S Mucinex Night Time
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Mucinex Sinus-Max Pressure-Cgh
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Mucinex Sinus-Max Sev Cong(DM)
doxylamine/phenylephrine/dextromethorphan/acetaminoph	Mucinex Sinus-Max Dy-Nt (Dxyl)
fexofenadine HCl	Mucinex Allergy
guaifenesin/phenylephrine HCl	Child Mucinex Stuffy Nose-Chst
fluticasone propionate	Aller-Flo
loratadine/pseudoephedrine sulfate	Allerclear D-12Hr
cetirizine HCl/pseudoephedrine HCl	Aller-Tec D
cetirizine HCl	Aller-Tec
fexofenadine HCl	Aller-Fex
loratadine	Allerclear
chlorpheniram/phenyleph/dextromethorphn/acetaminophen/guaifn	Cold-Flu M-Symptom Day-Night
cetirizine HCl	Children'S Aller-Tec

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
guaifenesin/phenylephrine HCl	Rescon-Gg
dexchlorpheniramine maleate/pseudoephedrine HCl	Rescon
chlorpheniramine maleate/pseudoephedrine/dextromethorphan	Rescon-DM
pseudoephedrine HCl/chlophedianol HCl/guaifenesin	Certuss-D
guaifenesin/phenylephrine HCl	Liquibid Pd-R
guaifenesin/phenylephrine HCl	Liquibid D-R
brompheniramine maleate/phenylephrine HCl/chlophedianol HCl	Trexbrom
guaifenesin/phenylephrine HCl	J-Max
brompheniramine maleate	J-Tan Pd
brompheniramine maleate/pseudoephedrine HCl	J-Tan D Pd
zileuton	Zileuton
triprolidine HCl/pseudoephedrine HCl	Pediatex Td
phenylephrine HCl/diphenhydramine HCl	Aldex-Ct
phenylephrine HCl/pyrilamine maleate	Aldex D
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Z-Cof 12 DM
diphenhydramine HCl	Total Allergy Medicine
codeine phosphate/guaifenesin	Pro-Clear Caps
pyrilamine maleate/phenylephrine HCl/chlophedianol HCl	Pro-Chlo
codeine phosphate/pyrilamine maleate	Pro-Clear Ac
dexchlorpheniramine maleate/phenylephrine HCl/codeine	Pro-Red Ac (W/ Dexchlorphenir)
diphenhydramine HCl in 0.9 % sodium chloride	Diphenhydramine In 0.9 % Nacl
guaifenesin/dextromethorphan HBr/phenylephrine	Phenylephrine-DM-Guaifenesin
dexchlorpheniramine maleate/pseudoephedrine/chlophedianol	Dexchlorphen-Pse-Chlophedianol
chlophedianol HCl/guaifenesin	Chlophedianol-Guaifenesin
phenylephrine HCl/chlophedianol HCl/guaifenesin	Phenylephrine-Chlophedianol-Gg
phenylephrine HCl/diphenhydramine HCl	Diphenhydramine-Phenylephrine
chlorpheniramine maleate/phenylephrine HCl/dextromethorphan	Chlorpheniramine-Phenyleph-DM
guaifenesin/pseudoephedrine HCl	Ambi 60Pse-400Gfn
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Ambi 40Pse-400Gfn-20DM
chlorpheniramine maleate/pseudoephedrine HCl	Ambi 60Pse-4Cpm
chlorpheniramine maleate/pseudoephedrine/dextromethorphan	Ambi 60Pse-4Cpm-20DM
chlorpheniramine maleate/phenylephrine HCl	Ambi 10Peh-4Cpm
chlorpheniramine maleate/phenylephrine	Ambi 10Peh-4Cpm-20DM
chlorpheniramine maleate/dextromethorphan HBr	Ambi 20DM-4Cpm
codeine phosphate/guaifenesin	Ambitussin Ac
guaifenesin/pseudoephedrine HCl	Entex T
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Entex Pac
brompheniramine maleate/phenylephrine HCl	Vazobid-Pd
hydrocortisone acetate/pramoxine HCl/aloe polysaccharide	Novacort (With Aloe)
chlorpheniramine maleate/pseudoephedrine HCl	Lohist - D
brompheniramine maleate/phenylephrine HCl/dextromethorphan	Lohist-DM

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
brompheniramine maleate/phenylephrine	Endacof - DM
chlorpheniramine maleate/codeine phosphate	Endacof-C
guaifenesin/dextromethorphan HBr/pseudoephedrine HCl	Exefen DMx
guaifenesin/pseudoephedrine HCl	Exefen-Ir
chlorpheniramine maleate/phenylephrine HCl	Nohist-Lq
chlorpheniramine maleate/phenylephrine HCl/dextromethorphan	Nohist-DM
brompheniramine maleate/phenylephrine HCl	Lohist-Peb
brompheniramine maleate/phenylephrine HCl/dextromethorphan	Lohist Peb DM
diphenhydramine HCl	Children'S Diphenhydramine
guaifenesin/dextromethorphan HBr/potassium citrate	Sorbutuss
mometasone furoate/ammonium lactate	Momexin
halobetasol propionate/ammonium lactate	Halonate
halobetasol propionate/ammonium lactate	Halonate Pac
albuterol sulfate	Vospire Er
prednisolone sodium phosphate	Pediapred
dexchlorpheniramine maleate	Dexchlorpheniramine Maleate
guaifenesin/hydrocodone bitartrate	Hydrocodone-Guaifenesin
guaifenesin/hydrocodone bitartrate	Obredon
triamcinolone acetonide	Pro-C-Dure 5
triamcinolone acetonide	Pro-C-Dure 6
betamethasone acetate/betamethasone sodium phosphate	Beta-1
triamcinolone acetonide/dimethicone/silicone, adhesive	Dermasilkrx Sds
triamcinolone acetonide/dimethicone/silicone, adhesive	Dermawerx Sds
triprolidine HCl	Triprolidine HCl
dexbrompheniramine maleate/phenylephrine HCl	Dexbrompheniramine-Phenyleph
doxylamine succinate/phenylephrine HCl	Doxylamine-Phenylephrine
codeine polistirex/chlorpheniramine polistirex	Tuzistra Xr
pseudoephedrine HCl/codeine phosphate/guaifenesin	Virtussin Dac
fluticasone propionate/sodium chloride/sodium bicarbonate	Ticaspray
triamcinolone acetonide/dimethicone/silicone, adhesive	Tri-Sila
azelastine/fluticasone/sodium chloride/sodium bicarbonate	Ticalast
hydrocortisone acetate/pramoxine HCl	Novacort
prednisone	Deltasone
dexamethasone sodium phosphate/PF	Mas Care-Pak (Pf)
triamcinolone acetonide/dimethicone/silicone, adhesive	Whytederm Tdpak
triamcinolone acetonide/dimethicone/silicone, adhesive	Whytederm Trilasil Pak
triamcinolone acetonide/dimethicone/silicone, adhesive	Sure Result Tac Pak
phenylephrine HCl/diphenhydramine HCl	Child Allergy Plus Congestion
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Day Multi-Symp Flu-Severe Cold
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Daytime Cold
clemastine fumarate	Allerhist (Clemastine)
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Tussin CF Max Severe M-S Cold
levocetirizine dihydrochloride	24Hr Allergy Relief
clemastine fumarate	Dayhist

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
promethazine HCl in 0.9 % sodium chloride	Promethazine In 0.9 % Nacl
phenylephrine HCl/dextromethorphan HBr/acetaminophen/guaifen	Herbiomed Severe Cold-Flu M-S
dextromethorphan/phenylephrine/acetaminophen/diphenhydramine	Herbiomed Deep Cold-Flu Night
dextromethorphan HBr/phenylephrine HCl/acetaminophen	Herbiomed Body Aches-Sinus M-S
diphenhydramine HCl/phenylephrine HCl/acetaminophen	Herbiomed Allergy Cold-Sinus
brompheniramine maleate/phenylephrine HCl	Glenmax Peb
brompheniramine maleate/phenylephrine HCl/dextromethorphan	Glenmax Peb DM Forte
phenylephrine HCl/pyrilamine maleate	Glen Pe
brompheniramine maleate/phenylephrine HCl/dextromethorphan	Glenmax Peb DM
doxylamine succ/pseudoephedrine HCl/dextromethorphan Hbr	Glentuss
codeine phosphate/guaifenesin	Coditussin Ac
pseudoephedrine HCl/codeine phosphate/guaifenesin	Coditussin Dac
fluocinolone acetonide/urea/silicone, adhesive	Noxipak
fluocinolone acetonide/skin cleanser no.10/silicone, tape	Xilapak
dexamethasone	Dxevo
triamcinolone acetonide	Zilretta
triamcinolone acetonide/dimethicone/silicone, adhesive	Nutriarx
dexamethasone	Zonacort
fluticasone propionate	Xhance
betamethasone sodium phosph in sterile water for injection	Betamethasone Sod Phosph-Water
chlorpheniramine maleate/codeine phosphate	Tuxarin Er
methylprednisolone acetate in sterile water for injection	Methylprednisolone Acet-Water
betamethasone acetate and sodium phos in sterile water/PF	Betameth Ac,Sod Phos(Pf)-Water
betamethasone acetate/betamethasone sodium phosphate/water	Betamethasone Ace,Sod Phos-Wtr
dexamethasone acetate and sodium phosphate in sterile water	Dexamethasone Ac, Sod Ph-Water
methylprednisolone acetate/bupivacaine HCl in sterile water	Methylprednisol Ac-Bupivac-Wat
methylprednisolone acetate in sodium chloride,iso-osmotic/PF	Methylpred Ac(Pf)-Nacl,Iso-Osm
triamcinolone diacetate in 0.9 % sodium chloride	Triamcinolone Diacet-0.9% Nacl
triamcinolone diacetate in 0.9 % sodium chloride/PF	Triamcinolone Dia(Pf)-0.9%Nacl
dexamethasone acetate in sodium chloride, iso-osmotic	Dexamethasone Ace-Nacl,Iso-Osm
triamcinolone acetonide/bupivacaine/in 0.9% sodium chloride	Triamcinol Ace-Bupiv-0.9% Nacl
triamcinolone acetonide in 0.9 % sodium chloride	Triamcinolone Aceton-0.9% Nacl
triamcinolone acetonide/0.9% sodium chloride/PF	Triamcinol Ac (Pf) In 0.9%Nacl
dexamethasone	Locort
triamcinolone acetonide/lidocaine HCl	Lidocilone I
dexamethasone sodium phosphate/lidocaine HCl	Lidocidex-I
dexamethasone sodium phosphate	Dexonto
hydrocortisone acetate/pramoxine HCl	Mezparox-Hc

Appendix D. Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
epinephrine	Epinephrinesnap-Ems
methylprednisolone	Methylpred Dp
diphenhydramine HCl	Compoz
guaifenesin/dextromethorphan HBr/phenylephrine	Nivanex DMx
brompheniramine maleate/phenylephrine HCl/dextromethorphan	Niva-Hist DM
triamcinolone acetonide/dimethicone/silicone, adhesive	Sanadermrx
prednisone	Rayos
triamcinolone/norflurane and pentafluoropropane (HFC 245fa)	Triloan Suik
triamcinolone/norflurane and pentafluoropropane (HFC 245fa)	Triloan Ii Suik
betamethasone acetate and sodium phosph/norflurane/HFC 245fa	Betaloan Suik
methylprednisolone acetate/norflurane/HFC 245fa	Medroloan Suik
methylprednisolone acetate/norflurane/HFC 245fa	Medroloan Ii Suik
dexamethasone/PF/norflurane/pentafluoropropane (HFC 245fa)	DMt Suik
methylprednisolone acetate/bupivacaine HCl	Physicians Ez Use M-Pred
triamcinolone acetonide/lidocaine HCl	Ez Use Joint-Tunnel-Trigger
epinephrine	Epy
epinephrine	Adyphren
epinephrine	Adyphren Ii
epinephrine	Adyphren Amp
epinephrine	Adyphren Amp Ii
dexamethasone sodium phosphate/PF	Doubledex (Pf)
chlorpheniramine maleate/phenylephrine HCl	Virdec
chlorpheniramine maleate/phenylephrine HCl/dextromethorphan	Virdec DM

Appendix E. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Type	Code Category
	Angioedema		
995.1	Angioedema	ICD-9-CM	Diagnosis
T783XXA	Angioedema	ICD-10-CM	Diagnosis
	Diabetes		
250	Diabetes mellitus	ICD-9-CM	Diagnosis
250.0	Diabetes mellitus without mention of complication	ICD-9-CM	Diagnosis
250.00	Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled	ICD-9-CM	Diagnosis
250.01	Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled	ICD-9-CM	Diagnosis
250.02	Diabetes mellitus without mention of complication, type II or unspecified type, uncontrolled	ICD-9-CM	Diagnosis
250.03	Diabetes mellitus without mention of complication, type I [juvenile type], uncontrolled	ICD-9-CM	Diagnosis
250.1	Diabetes with ketoacidosis	ICD-9-CM	Diagnosis
250.10	Diabetes with ketoacidosis, type II or unspecified type, not stated as uncontrolled	ICD-9-CM	Diagnosis
250.11	Diabetes with ketoacidosis, type I [juvenile type], not stated as uncontrolled	ICD-9-CM	Diagnosis
250.12	Diabetes with ketoacidosis, type II or unspecified type, uncontrolled	ICD-9-CM	Diagnosis
250.13	Diabetes with ketoacidosis, type I [juvenile type], uncontrolled	ICD-9-CM	Diagnosis
250.2	Diabetes with hyperosmolarity	ICD-9-CM	Diagnosis
250.20	Diabetes with hyperosmolarity, type II or unspecified type, not stated as uncontrolled	ICD-9-CM	Diagnosis
250.21	Diabetes with hyperosmolarity, type I [juvenile type], not stated as	ICD-9-CM	Diagnosis
250.22	Diabetes with hyperosmolarity, type II or unspecified type, uncontrolled	ICD-9-CM	Diagnosis
250.23	Diabetes with hyperosmolarity, type I [juvenile type], uncontrolled	ICD-9-CM	Diagnosis
250.3	Diabetes with other coma	ICD-9-CM	Diagnosis
250.30	Diabetes with other coma, type II or unspecified type, not stated as uncontrolled	ICD-9-CM	Diagnosis
250.31	Diabetes with other coma, type I [juvenile type], not stated as uncontrolled	ICD-9-CM	Diagnosis
250.32	Diabetes with other coma, type II or unspecified type, uncontrolled	ICD-9-CM	Diagnosis
250.33	Diabetes with other coma, type I [juvenile type], uncontrolled	ICD-9-CM	Diagnosis
250.4	Diabetes with renal manifestations	ICD-9-CM	Diagnosis
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	ICD-9-CM	Diagnosis
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	ICD-9-CM	Diagnosis
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	ICD-9-CM	Diagnosis
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	ICD-9-CM	Diagnosis
250.5	Diabetes with ophthalmic manifestations	ICD-9-CM	Diagnosis
250.50	Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled	ICD-9-CM	Diagnosis
250.51	Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled	ICD-9-CM	Diagnosis

Appendix E. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Type	Code Category
250.52	Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled	ICD-9-CM	Diagnosis
250.53	Diabetes with ophthalmic manifestations, type I [juvenile type], uncontrolled	ICD-9-CM	Diagnosis
250.6	Diabetes with neurological manifestations	ICD-9-CM	Diagnosis
250.60	Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled	ICD-9-CM	Diagnosis
250.61	Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled	ICD-9-CM	Diagnosis
250.62	Diabetes with neurological manifestations, type II or unspecified type, uncontrolled	ICD-9-CM	Diagnosis
250.63	Diabetes with neurological manifestations, type I [juvenile type], uncontrolled	ICD-9-CM	Diagnosis
250.7	Diabetes with peripheral circulatory disorders	ICD-9-CM	Diagnosis
250.70	Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled	ICD-9-CM	Diagnosis
250.71	Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled	ICD-9-CM	Diagnosis
250.72	Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled	ICD-9-CM	Diagnosis
250.73	Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolled	ICD-9-CM	Diagnosis
250.8	Diabetes with other specified manifestations	ICD-9-CM	Diagnosis
250.80	Diabetes with other specified manifestations, type II or unspecified type, not stated as uncontrolled	ICD-9-CM	Diagnosis
250.81	Diabetes with other specified manifestations, type I [juvenile type], not stated as uncontrolled	ICD-9-CM	Diagnosis
250.82	Diabetes with other specified manifestations, type II or unspecified type, uncontrolled	ICD-9-CM	Diagnosis
250.83	Diabetes with other specified manifestations, type I [juvenile type], uncontrolled	ICD-9-CM	Diagnosis
250.9	Diabetes with unspecified complication	ICD-9-CM	Diagnosis
250.90	Diabetes with unspecified complication, type II or unspecified type, not stated as uncontrolled	ICD-9-CM	Diagnosis
250.91	Diabetes with unspecified complication, type I [juvenile type], not stated as uncontrolled	ICD-9-CM	Diagnosis
250.92	Diabetes with unspecified complication, type II or unspecified type, uncontrolled	ICD-9-CM	Diagnosis
250.93	Diabetes with unspecified complication, type I [juvenile type], uncontrolled	ICD-9-CM	Diagnosis
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	ICD-10-CM	Diagnosis
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	ICD-10-CM	Diagnosis
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	ICD-10-CM	Diagnosis
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	ICD-10-CM	Diagnosis
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	ICD-10-CM	Diagnosis

Code	Description	Code Type	Code Category
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	ICD-10-CM	Diagnosis
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	ICD-10-CM	Diagnosis
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	ICD-10-CM	Diagnosis
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	ICD-10-CM	Diagnosis
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	ICD-10-CM	Diagnosis
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	ICD-10-CM	Diagnosis
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	ICD-10-CM	Diagnosis
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	ICD-10-CM	Diagnosis
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	ICD-10-CM	Diagnosis
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	ICD-10-CM	Diagnosis
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	ICD-10-CM	Diagnosis
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	ICD-10-CM	Diagnosis
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	ICD-10-CM	Diagnosis
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	ICD-10-CM	Diagnosis
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	ICD-10-CM	Diagnosis
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	ICD-10-CM	Diagnosis
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	ICD-10-CM	Diagnosis
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	ICD-10-CM	Diagnosis
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	ICD-10-CM	Diagnosis
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	ICD-10-CM	Diagnosis
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	ICD-10-CM	Diagnosis
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	ICD-10-CM	Diagnosis

Code	Description	Code Type	Code Category
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	ICD-10-CM	Diagnosis
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	ICD-10-CM	Diagnosis
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	ICD-10-CM	Diagnosis
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	ICD-10-CM	Diagnosis
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	ICD-10-CM	Diagnosis
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	ICD-10-CM	Diagnosis
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	ICD-10-CM	Diagnosis
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	ICD-10-CM	Diagnosis
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	ICD-10-CM	Diagnosis
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	ICD-10-CM	Diagnosis
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	ICD-10-CM	Diagnosis
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	ICD-10-CM	Diagnosis
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	ICD-10-CM	Diagnosis
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	ICD-10-CM	Diagnosis
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	ICD-10-CM	Diagnosis
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	ICD-10-CM	Diagnosis
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	ICD-10-CM	Diagnosis
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	ICD-10-CM	Diagnosis
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	ICD-10-CM	Diagnosis
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	ICD-10-CM	Diagnosis

Code	Description	Code Type	Code Category
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	ICD-10-CM	Diagnosis
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	ICD-10-CM	Diagnosis
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	ICD-10-CM	Diagnosis
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	ICD-10-CM	Diagnosis
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	ICD-10-CM	Diagnosis
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	ICD-10-CM	Diagnosis
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	ICD-10-CM	Diagnosis
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	ICD-10-CM	Diagnosis
E10.36	Type 1 diabetes mellitus with diabetic cataract	ICD-10-CM	Diagnosis
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	ICD-10-CM	Diagnosis
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	ICD-10-CM	Diagnosis
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	ICD-10-CM	Diagnosis
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	ICD-10-CM	Diagnosis
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	ICD-10-CM	Diagnosis
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	ICD-10-CM	Diagnosis
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	ICD-10-CM	Diagnosis
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	ICD-10-CM	Diagnosis
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	ICD-10-CM	Diagnosis
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	ICD-10-CM	Diagnosis
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	ICD-10-CM	Diagnosis
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without	ICD-10-CM	Diagnosis
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	ICD-10-CM	Diagnosis
E10.59	Type 1 diabetes mellitus with other circulatory complications	ICD-10-CM	Diagnosis
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	ICD-10-CM	Diagnosis
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	ICD-10-CM	Diagnosis
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	ICD-10-CM	Diagnosis
E10.621	Type 1 diabetes mellitus with foot ulcer	ICD-10-CM	Diagnosis
E10.622	Type 1 diabetes mellitus with other skin ulcer	ICD-10-CM	Diagnosis
E10.628	Type 1 diabetes mellitus with other skin complications	ICD-10-CM	Diagnosis
E10.630	Type 1 diabetes mellitus with periodontal disease	ICD-10-CM	Diagnosis
E10.638	Type 1 diabetes mellitus with other oral complications	ICD-10-CM	Diagnosis
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	ICD-10-CM	Diagnosis

Code	Description	Code Type	Code Category
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	ICD-10-CM	Diagnosis
E10.65	Type 1 diabetes mellitus with hyperglycemia	ICD-10-CM	Diagnosis
E10.69	Type 1 diabetes mellitus with other specified complication	ICD-10-CM	Diagnosis
E10.8	Type 1 diabetes mellitus with unspecified complications	ICD-10-CM	Diagnosis
E10.9	Type 1 diabetes mellitus without complications	ICD-10-CM	Diagnosis
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	ICD-10-CM	Diagnosis
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	ICD-10-CM	Diagnosis
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	ICD-10-CM	Diagnosis
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	ICD-10-CM	Diagnosis
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	ICD-10-CM	Diagnosis
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	ICD-10-CM	Diagnosis
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	ICD-10-CM	Diagnosis
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	ICD-10-CM	Diagnosis
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	ICD-10-CM	Diagnosis
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	ICD-10-CM	Diagnosis
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	ICD-10-CM	Diagnosis
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	ICD-10-CM	Diagnosis
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	ICD-10-CM	Diagnosis
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	ICD-10-CM	Diagnosis
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	ICD-10-CM	Diagnosis
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	ICD-10-CM	Diagnosis
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	ICD-10-CM	Diagnosis
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	ICD-10-CM	Diagnosis
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	ICD-10-CM	Diagnosis
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	ICD-10-CM	Diagnosis
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	ICD-10-CM	Diagnosis

Code	Description	Code Type	Code Category
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	ICD-10-CM	Diagnosis
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	ICD-10-CM	Diagnosis
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	ICD-10-CM	Diagnosis
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	ICD-10-CM	Diagnosis
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	ICD-10-CM	Diagnosis
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	ICD-10-CM	Diagnosis
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	ICD-10-CM	Diagnosis
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	ICD-10-CM	Diagnosis
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	ICD-10-CM	Diagnosis
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	ICD-10-CM	Diagnosis
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	ICD-10-CM	Diagnosis
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	ICD-10-CM	Diagnosis
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	ICD-10-CM	Diagnosis
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	ICD-10-CM	Diagnosis
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	ICD-10-CM	Diagnosis
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	ICD-10-CM	Diagnosis
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	ICD-10-CM	Diagnosis
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	ICD-10-CM	Diagnosis
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	ICD-10-CM	Diagnosis
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	ICD-10-CM	Diagnosis
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	ICD-10-CM	Diagnosis
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	ICD-10-CM	Diagnosis

Code	Description	Code Type	Code Category
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal	ICD-10-CM	Diagnosis
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal	ICD-10-CM	Diagnosis
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal	ICD-10-CM	Diagnosis
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	ICD-10-CM	Diagnosis
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right	ICD-10-CM	Diagnosis
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	ICD-10-CM	Diagnosis
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy,	ICD-10-CM	Diagnosis
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	ICD-10-CM	Diagnosis
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	ICD-10-CM	Diagnosis
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	ICD-10-CM	Diagnosis
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	ICD-10-CM	Diagnosis
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	ICD-10-CM	Diagnosis
E11.36	Type 2 diabetes mellitus with diabetic cataract	ICD-10-CM	Diagnosis
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	ICD-10-CM	Diagnosis
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	ICD-10-CM	Diagnosis
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	ICD-10-CM	Diagnosis
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	ICD-10-CM	Diagnosis
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	ICD-10-CM	Diagnosis
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	ICD-10-CM	Diagnosis
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	ICD-10-CM	Diagnosis
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	ICD-10-CM	Diagnosis
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	ICD-10-CM	Diagnosis
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	ICD-10-CM	Diagnosis
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	ICD-10-CM	Diagnosis
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without	ICD-10-CM	Diagnosis
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	ICD-10-CM	Diagnosis
E11.59	Type 2 diabetes mellitus with other circulatory complications	ICD-10-CM	Diagnosis
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	ICD-10-CM	Diagnosis

Code	Description	Code Type	Code Category
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	ICD-10-CM	Diagnosis
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	ICD-10-CM	Diagnosis
E11.621	Type 2 diabetes mellitus with foot ulcer	ICD-10-CM	Diagnosis
E11.622	Type 2 diabetes mellitus with other skin ulcer	ICD-10-CM	Diagnosis
E11.628	Type 2 diabetes mellitus with other skin complications	ICD-10-CM	Diagnosis
E11.630	Type 2 diabetes mellitus with periodontal disease	ICD-10-CM	Diagnosis
E11.638	Type 2 diabetes mellitus with other oral complications	ICD-10-CM	Diagnosis
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	ICD-10-CM	Diagnosis
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	ICD-10-CM	Diagnosis
E11.65	Type 2 diabetes mellitus with hyperglycemia	ICD-10-CM	Diagnosis
E11.69	Type 2 diabetes mellitus with other specified complication	ICD-10-CM	Diagnosis
E11.8	Type 2 diabetes mellitus with unspecified complications	ICD-10-CM	Diagnosis
E11.9	Type 2 diabetes mellitus without complications	ICD-10-CM	Diagnosis
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	ICD-10-CM	Diagnosis
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	ICD-10-CM	Diagnosis
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	ICD-10-CM	Diagnosis
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	ICD-10-CM	Diagnosis
E13.21	Other specified diabetes mellitus with diabetic nephropathy	ICD-10-CM	Diagnosis
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	ICD-10-CM	Diagnosis
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	ICD-10-CM	Diagnosis
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	ICD-10-CM	Diagnosis
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	ICD-10-CM	Diagnosis
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	ICD-10-CM	Diagnosis
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	ICD-10-CM	Diagnosis
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	ICD-10-CM	Diagnosis
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	ICD-10-CM	Diagnosis
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	ICD-10-CM	Diagnosis
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	ICD-10-CM	Diagnosis
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	ICD-10-CM	Diagnosis
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	ICD-10-CM	Diagnosis
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	ICD-10-CM	Diagnosis

Code	Description	Code Type	Code Category
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	ICD-10-CM	Diagnosis
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	ICD-10-CM	Diagnosis
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	ICD-10-CM	Diagnosis
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	ICD-10-CM	Diagnosis
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	ICD-10-CM	Diagnosis
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	ICD-10-CM	Diagnosis
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	ICD-10-CM	Diagnosis
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	ICD-10-CM	Diagnosis
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	ICD-10-CM	Diagnosis
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	ICD-10-CM	Diagnosis
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	ICD-10-CM	Diagnosis
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	ICD-10-CM	Diagnosis
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	ICD-10-CM	Diagnosis
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	ICD-10-CM	Diagnosis
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	ICD-10-CM	Diagnosis
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	ICD-10-CM	Diagnosis
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	ICD-10-CM	Diagnosis
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	ICD-10-CM	Diagnosis
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	ICD-10-CM	Diagnosis
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	ICD-10-CM	Diagnosis
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	ICD-10-CM	Diagnosis
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	ICD-10-CM	Diagnosis

Code	Description	Code Type	Code Category
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	ICD-10-CM	Diagnosis
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	ICD-10-CM	Diagnosis
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	ICD-10-CM	Diagnosis
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	ICD-10-CM	Diagnosis
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	ICD-10-CM	Diagnosis
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	ICD-10-CM	Diagnosis
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	ICD-10-CM	Diagnosis
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	ICD-10-CM	Diagnosis
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	ICD-10-CM	Diagnosis
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	ICD-10-CM	Diagnosis
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	ICD-10-CM	Diagnosis
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	ICD-10-CM	Diagnosis
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	ICD-10-CM	Diagnosis
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	ICD-10-CM	Diagnosis
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	ICD-10-CM	Diagnosis
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	ICD-10-CM	Diagnosis
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	ICD-10-CM	Diagnosis
E13.36	Other specified diabetes mellitus with diabetic cataract	ICD-10-CM	Diagnosis
E13.37X1	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	ICD-10-CM	Diagnosis
E13.37X2	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	ICD-10-CM	Diagnosis

Code	Description	Code Type	Code Category
E13.37X3	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	ICD-10-CM	Diagnosis
E13.37X9	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	ICD-10-CM	Diagnosis
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	ICD-10-CM	Diagnosis
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	ICD-10-CM	Diagnosis
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	ICD-10-CM	Diagnosis
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	ICD-10-CM	Diagnosis
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	ICD-10-CM	Diagnosis
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	ICD-10-CM	Diagnosis
E13.49	Other specified diabetes mellitus with other diabetic neurological	ICD-10-CM	Diagnosis
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	ICD-10-CM	Diagnosis
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	ICD-10-CM	Diagnosis
E13.59	Other specified diabetes mellitus with other circulatory complications	ICD-10-CM	Diagnosis
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	ICD-10-CM	Diagnosis
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	ICD-10-CM	Diagnosis
E13.620	Other specified diabetes mellitus with diabetic dermatitis	ICD-10-CM	Diagnosis
E13.621	Other specified diabetes mellitus with foot ulcer	ICD-10-CM	Diagnosis
E13.622	Other specified diabetes mellitus with other skin ulcer	ICD-10-CM	Diagnosis
E13.628	Other specified diabetes mellitus with other skin complications	ICD-10-CM	Diagnosis
E13.630	Other specified diabetes mellitus with periodontal disease	ICD-10-CM	Diagnosis
E13.638	Other specified diabetes mellitus with other oral complications	ICD-10-CM	Diagnosis
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	ICD-10-CM	Diagnosis
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	ICD-10-CM	Diagnosis
E13.65	Other specified diabetes mellitus with hyperglycemia	ICD-10-CM	Diagnosis
E13.69	Other specified diabetes mellitus with other specified complication	ICD-10-CM	Diagnosis
E13.8	Other specified diabetes mellitus with unspecified complications	ICD-10-CM	Diagnosis
E13.9	Other specified diabetes mellitus without complications	ICD-10-CM	Diagnosis
A5500	For diabetics only, fitting (including follow-up), custom preparation and supply of off-the-shelf depth-inlay shoe manufactured to accommodate multidensity insert(s), per shoe	HCPCS	Procedure
A5501	For diabetics only, fitting (including follow-up), custom preparation and supply of shoe molded from cast(s) of patient's foot (custom molded shoe), per shoe	HCPCS	Procedure
A5503	For diabetics only, modification (including fitting) of off-the-shelf depth-inlay shoe or custom molded shoe with roller or rigid rocker bottom, per shoe	HCPCS	Procedure
A5504	For diabetics only, modification (including fitting) of off-the-shelf depth-inlay shoe or custom molded shoe with wedge(s), per shoe	HCPCS	Procedure
A5505	For diabetics only, modification (including fitting) of off-the-shelf depth-inlay shoe or custom molded shoe with metatarsal bar, per shoe	HCPCS	Procedure

Appendix E. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Type	Code Category
A5506	For diabetics only, modification (including fitting) of off-the-shelf depth-inlay shoe or custom molded shoe with off-set heel(s), per shoe	HCPCS	Procedure
A5507	For diabetics only, not otherwise specified modification (including fitting) of off-the-shelf depth-inlay shoe or custom molded shoe, per shoe	HCPCS	Procedure
A5508	For diabetics only, deluxe feature of off-the-shelf depth-inlay shoe or custom molded shoe, per shoe	HCPCS	Procedure
A5510	For diabetics only, direct formed, compression molded to patient's foot without external heat source, multiple-density insert(s) prefabricated, per shoe	HCPCS	Procedure
A5512	For diabetics only, multiple density insert, direct formed, molded to foot after external heat source of 230 degrees Fahrenheit or higher, total contact with patient's foot, including arch, base layer minimum of 1/4 inch material of shore a 35 durometer or 3/16 inch material of shore a 40 durometer (or higher), prefabricated, each	HCPCS	Procedure
A5513	For diabetics only, multiple density insert, custom molded from model of patient's foot, total contact with patient's foot, including arch, base layer minimum of 3/16 inch material of shore a 35 durometer or higher), includes arch filler and other shaping material, custom fabricated, each	HCPCS	Procedure
G0108	Diabetes outpatient self-management training services, individual, per 30 minutes	HCPCS	Procedure
G0109	Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes	HCPCS	Procedure
G0245	Initial physician evaluation and management of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (LOPS) which must include: (1) the diagnosis of LOPS, (2) a patient history, (3) a physical examination that consists of at least the following elements: (a) visual inspection of the forefoot, hindfoot, and toe web spaces, (b) evaluation of a protective sensation, (c) evaluation of foot structure and biomechanics, (d) evaluation of vascular status and skin integrity, and (e) evaluation and recommendation of footwear, and (4) patient education	HCPCS	Procedure
G0246	Follow-up physician evaluation and management of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (LOPS) to include at least the following: (1) a patient history, (2) a physical examination that includes: (a) visual inspection of the forefoot, hindfoot, and toe web spaces, (b) evaluation of protective sensation, (c) evaluation of foot structure and biomechanics, (d) evaluation of vascular status and skin integrity, and (e) evaluation and recommendation of footwear, and (3) patient education	HCPCS	Procedure
G0247	Routine foot care by a physician of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (LOPS) to include the local care of superficial wounds (i.e., superficial to muscle and fascia) and at least the following, if present: (1) local care of superficial wounds, (2) debridement of corns and calluses, and (3) trimming and debridement of nails	HCPCS	Procedure

Code	Description	Code Type	Code Category
G8015	Diabetic patient with most recent hemoglobin A1c level (within the last 6 months) documented as greater than 9%	HCPCS	Procedure
G8016	Diabetic patient with most recent hemoglobin A1c level (within the last 6 months) documented as less than or equal to 9%	HCPCS	Procedure
G8017	Clinician documented that diabetic patient was not eligible candidate for hemoglobin A1c measure	HCPCS	Procedure
G8018	Clinician has not provided care for the diabetic patient for the required time for hemoglobin A1c measure (6 months)	HCPCS	Procedure
G8019	Diabetic patient with most recent low-density lipoprotein (within the last 12 months) documented as greater than or equal to 100 mg/dl	HCPCS	Procedure
G8020	Diabetic patient with most recent low-density lipoprotein (within the last 12 months) documented as less than 100 mg/dl	HCPCS	Procedure
G8021	Clinician documented that diabetic patient was not eligible candidate for low-density lipoprotein measure	HCPCS	Procedure
G8022	Clinician has not provided care for the diabetic patient for the required time for low-density lipoprotein measure (12 months)	HCPCS	Procedure
G8023	Diabetic patient with most recent blood pressure (within the last 6 months) documented as equal to or greater than 140 systolic or equal to or greater than 80 mm Hg diastolic	HCPCS	Procedure
G8024	Diabetic patient with most recent blood pressure (within the last 6 months) documented as less than 140 systolic and less than 80 diastolic	HCPCS	Procedure
G8025	Clinician documented that the diabetic patient was not eligible candidate for blood pressure measure	HCPCS	Procedure
G8026	Clinician has not provided care for the diabetic patient for the required time for blood pressure measure (within the last 6 months)	HCPCS	Procedure
G8332	Clinician has not provided care for the diabetic retinopathy patient for the required time for macular edema and retinopathy measurement	HCPCS	Procedure
G8333	Patient documented to have had findings of macular or fundus exam communicated to the physician managing the diabetes care	HCPCS	Procedure
G8334	Documentation of findings of macular or fundus exam not communicated to the physician managing the patient's ongoing diabetes care	HCPCS	Procedure
G8335	Clinician documentation that patient was not an eligible candidate for the findings of their macular or fundus exam being communicated to the physician managing their diabetes care during the reporting year	HCPCS	Procedure
G8336	Clinician has not provided care for the diabetic retinopathy patient for the required time for physician communication measurement	HCPCS	Procedure
G8385	Diabetic patients with no documentation of hemoglobin A1c level (within the last 12 months)	HCPCS	Procedure
G8386	Diabetic patients with no documentation of low-density lipoprotein (within the last 12 months)	HCPCS	Procedure
G8390	Diabetic patients with no documentation of blood pressure measurement (within the last 12 months)	HCPCS	Procedure
	Allergy (Serious or Ambulatory)		
472.0	Chronic rhinitis	ICD-9-CM	Diagnosis

Code	Description	Code Type	Code Category
477.0	Allergic rhinitis due to pollen	ICD-9-CM	Diagnosis
477.1	Allergic rhinitis, due to food	ICD-9-CM	Diagnosis
477.2	Allergic rhinitis due to animal (cat) (dog) hair and dander	ICD-9-CM	Diagnosis
477.8	Allergic rhinitis due to other allergen	ICD-9-CM	Diagnosis
477.9	Allergic rhinitis, cause unspecified	ICD-9-CM	Diagnosis
478.8	Upper respiratory tract hypersensitivity reaction, site unspecified	ICD-9-CM	Diagnosis
558.3	Gastroenteritis and colitis, allergic	ICD-9-CM	Diagnosis
691.0	Diaper or napkin rash	ICD-9-CM	Diagnosis
691.8	Other atopic dermatitis and related conditions	ICD-9-CM	Diagnosis
692.0	Contact dermatitis and other eczema due to detergents	ICD-9-CM	Diagnosis
692.1	Contact dermatitis and other eczema due to oils and greases	ICD-9-CM	Diagnosis
692.2	Contact dermatitis and other eczema due to solvents	ICD-9-CM	Diagnosis
692.3	Contact dermatitis and other eczema due to drugs and medicines in contact with skin	ICD-9-CM	Diagnosis
692.4	Contact dermatitis and other eczema due to other chemical products	ICD-9-CM	Diagnosis
692.5	Contact dermatitis and other eczema due to food in contact with skin	ICD-9-CM	Diagnosis
692.6	Contact dermatitis and other eczema due to plants (except food)	ICD-9-CM	Diagnosis
692.70	Unspecified dermatitis due to sun	ICD-9-CM	Diagnosis
692.71	Contact dermatitis and other eczema due to sunburn	ICD-9-CM	Diagnosis
692.72	Acute dermatitis due to solar radiation	ICD-9-CM	Diagnosis
692.73	Actinic reticuloid and actinic granuloma	ICD-9-CM	Diagnosis
692.74	Other chronic dermatitis due to solar radiation	ICD-9-CM	Diagnosis
692.75	Disseminated superficial actinic porokeratosis (DSAP)	ICD-9-CM	Diagnosis
692.76	Sunburn of second degree	ICD-9-CM	Diagnosis
692.77	Sunburn of third degree	ICD-9-CM	Diagnosis
692.79	Other dermatitis due to solar radiation	ICD-9-CM	Diagnosis
692.81	Dermatitis due to cosmetics	ICD-9-CM	Diagnosis
692.82	Dermatitis due to other radiation	ICD-9-CM	Diagnosis
692.83	Dermatitis due to metals	ICD-9-CM	Diagnosis
692.84	Contact dermatitis and other eczema due to animal (cat) (dog) dander	ICD-9-CM	Diagnosis
692.89	Contact dermatitis and other eczema due to other specified agent	ICD-9-CM	Diagnosis
692.9	Contact dermatitis and other eczema, due to unspecified cause	ICD-9-CM	Diagnosis
693.0	Dermatitis due to drugs and medicines taken internally	ICD-9-CM	Diagnosis
693.1	Dermatitis due to food taken internally	ICD-9-CM	Diagnosis
693.8	Dermatitis due to other specified substances taken internally	ICD-9-CM	Diagnosis
693.9	Dermatitis due to unspecified substance taken internally	ICD-9-CM	Diagnosis
708.0	Allergic urticaria	ICD-9-CM	Diagnosis
708.1	Idiopathic urticaria	ICD-9-CM	Diagnosis
708.2	Urticaria due to cold and heat	ICD-9-CM	Diagnosis
708.3	Dermatographic urticaria	ICD-9-CM	Diagnosis
708.4	Vibratory urticaria	ICD-9-CM	Diagnosis
708.5	Cholinergic urticaria	ICD-9-CM	Diagnosis
708.8	Other specified urticaria	ICD-9-CM	Diagnosis
708.9	Unspecified urticaria	ICD-9-CM	Diagnosis

Appendix E. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Type	Code Category
995.0	Other anaphylactic reaction	ICD-9-CM	Diagnosis
995.27	Other drug allergy	ICD-9-CM	Diagnosis
995.3	Allergy, unspecified not elsewhere classified	ICD-9-CM	Diagnosis
995.7	Other adverse food reactions, not elsewhere classified	ICD-9-CM	Diagnosis
J30.0	Vasomotor rhinitis	ICD-10-CM	Diagnosis
J30.1	Allergic rhinitis due to pollen	ICD-10-CM	Diagnosis
J30.2	Other seasonal allergic rhinitis	ICD-10-CM	Diagnosis
J30.5	Allergic rhinitis due to food	ICD-10-CM	Diagnosis
J30.81	Allergic rhinitis due to animal (cat) (dog) hair and dander	ICD-10-CM	Diagnosis
J30.89	Other allergic rhinitis	ICD-10-CM	Diagnosis
J30.9	Allergic rhinitis, unspecified	ICD-10-CM	Diagnosis
J31.0	Chronic rhinitis	ICD-10-CM	Diagnosis
J39.3	Upper respiratory tract hypersensitivity reaction, site unspecified	ICD-10-CM	Diagnosis
K52.21	Food protein-induced enterocolitis syndrome	ICD-10-CM	Diagnosis
K52.22	Food protein-induced enteropathy	ICD-10-CM	Diagnosis
K52.29	Other allergic and dietetic gastroenteritis and colitis	ICD-10-CM	Diagnosis
L20.0	Besnier's prurigo	ICD-10-CM	Diagnosis
L20.81	Atopic neurodermatitis	ICD-10-CM	Diagnosis
L20.82	Flexural eczema	ICD-10-CM	Diagnosis
L20.84	Intrinsic (allergic) eczema	ICD-10-CM	Diagnosis
L20.89	Other atopic dermatitis	ICD-10-CM	Diagnosis
L20.9	Atopic dermatitis, unspecified	ICD-10-CM	Diagnosis
L22	Diaper dermatitis	ICD-10-CM	Diagnosis
L23.0	Allergic contact dermatitis due to metals	ICD-10-CM	Diagnosis
L23.1	Allergic contact dermatitis due to adhesives	ICD-10-CM	Diagnosis
L23.2	Allergic contact dermatitis due to cosmetics	ICD-10-CM	Diagnosis
L23.3	Allergic contact dermatitis due to drugs in contact with skin	ICD-10-CM	Diagnosis
L23.4	Allergic contact dermatitis due to dyes	ICD-10-CM	Diagnosis
L23.5	Allergic contact dermatitis due to other chemical products	ICD-10-CM	Diagnosis
L23.6	Allergic contact dermatitis due to food in contact with the skin	ICD-10-CM	Diagnosis
L23.7	Allergic contact dermatitis due to plants, except food	ICD-10-CM	Diagnosis
L23.81	Allergic contact dermatitis due to animal (cat) (dog) dander	ICD-10-CM	Diagnosis
L23.89	Allergic contact dermatitis due to other agents	ICD-10-CM	Diagnosis
L23.9	Allergic contact dermatitis, unspecified cause	ICD-10-CM	Diagnosis
L24.0	Irritant contact dermatitis due to detergents	ICD-10-CM	Diagnosis
L24.1	Irritant contact dermatitis due to oils and greases	ICD-10-CM	Diagnosis
L24.2	Irritant contact dermatitis due to solvents	ICD-10-CM	Diagnosis
L24.3	Irritant contact dermatitis due to cosmetics	ICD-10-CM	Diagnosis
L24.4	Irritant contact dermatitis due to drugs in contact with skin	ICD-10-CM	Diagnosis
L24.5	Irritant contact dermatitis due to other chemical products	ICD-10-CM	Diagnosis
L24.6	Irritant contact dermatitis due to food in contact with skin	ICD-10-CM	Diagnosis
L24.7	Irritant contact dermatitis due to plants, except food	ICD-10-CM	Diagnosis
L24.81	Irritant contact dermatitis due to metals	ICD-10-CM	Diagnosis
L24.89	Irritant contact dermatitis due to other agents	ICD-10-CM	Diagnosis

Code	Description	Code Type	Code Category
L24.9	Irritant contact dermatitis, unspecified cause	ICD-10-CM	Diagnosis
L25.0	Unspecified contact dermatitis due to cosmetics	ICD-10-CM	Diagnosis
L25.1	Unspecified contact dermatitis due to drugs in contact with skin	ICD-10-CM	Diagnosis
L25.2	Unspecified contact dermatitis due to dyes	ICD-10-CM	Diagnosis
L25.3	Unspecified contact dermatitis due to other chemical products	ICD-10-CM	Diagnosis
L25.4	Unspecified contact dermatitis due to food in contact with skin	ICD-10-CM	Diagnosis
L25.5	Unspecified contact dermatitis due to plants, except food	ICD-10-CM	Diagnosis
L25.8	Unspecified contact dermatitis due to other agents	ICD-10-CM	Diagnosis
L25.9	Unspecified contact dermatitis, unspecified cause	ICD-10-CM	Diagnosis
L27.0	Generalized skin eruption due to drugs and medicaments taken internally	ICD-10-CM	Diagnosis
L27.1	Localized skin eruption due to drugs and medicaments taken internally	ICD-10-CM	Diagnosis
L27.2	Dermatitis due to ingested food	ICD-10-CM	Diagnosis
L27.8	Dermatitis due to other substances taken internally	ICD-10-CM	Diagnosis
L27.9	Dermatitis due to unspecified substance taken internally	ICD-10-CM	Diagnosis
L50.0	Allergic urticaria	ICD-10-CM	Diagnosis
L50.1	Idiopathic urticaria	ICD-10-CM	Diagnosis
L50.2	Urticaria due to cold and heat	ICD-10-CM	Diagnosis
L50.3	Dermatographic urticaria	ICD-10-CM	Diagnosis
L50.4	Vibratory urticaria	ICD-10-CM	Diagnosis
L50.5	Cholinergic urticaria	ICD-10-CM	Diagnosis
L50.6	Contact urticaria	ICD-10-CM	Diagnosis
L50.8	Other urticaria	ICD-10-CM	Diagnosis
L50.9	Urticaria, unspecified	ICD-10-CM	Diagnosis
L55.0	Sunburn of first degree	ICD-10-CM	Diagnosis
L55.1	Sunburn of second degree	ICD-10-CM	Diagnosis
L55.2	Sunburn of third degree	ICD-10-CM	Diagnosis
L55.9	Sunburn, unspecified	ICD-10-CM	Diagnosis
L56.0	Drug phototoxic response	ICD-10-CM	Diagnosis
L56.1	Drug photoallergic response	ICD-10-CM	Diagnosis
L56.2	Photocontact dermatitis [berloque dermatitis]	ICD-10-CM	Diagnosis
L56.3	Solar urticaria	ICD-10-CM	Diagnosis
L56.4	Polymorphous light eruption	ICD-10-CM	Diagnosis
L56.5	Disseminated superficial actinic porokeratosis (DSAP)	ICD-10-CM	Diagnosis
L56.8	Other specified acute skin changes due to ultraviolet radiation	ICD-10-CM	Diagnosis
L56.9	Acute skin change due to ultraviolet radiation, unspecified	ICD-10-CM	Diagnosis
L57.1	Actinic reticuloid	ICD-10-CM	Diagnosis
L57.5	Actinic granuloma	ICD-10-CM	Diagnosis
L57.8	Other skin changes due to chronic exposure to nonionizing radiation	ICD-10-CM	Diagnosis
L57.9	Skin changes due to chronic exposure to nonionizing radiation, unspecified	ICD-10-CM	Diagnosis
L58.0	Acute radiodermatitis	ICD-10-CM	Diagnosis
L58.1	Chronic radiodermatitis	ICD-10-CM	Diagnosis
L58.9	Radiodermatitis, unspecified	ICD-10-CM	Diagnosis
T78.0	Anaphylactic reaction due to food	ICD-10-CM	Diagnosis
T78.00	Anaphylactic reaction due to unspecified food	ICD-10-CM	Diagnosis

Appendix E. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Type	Code Category
T78.00XA	Anaphylactic reaction due to unspecified food, initial encounter	ICD-10-CM	Diagnosis
T78.00XD	Anaphylactic reaction due to unspecified food, subsequent encounter	ICD-10-CM	Diagnosis
T78.00XS	Anaphylactic reaction due to unspecified food, sequela	ICD-10-CM	Diagnosis
T78.01	Anaphylactic reaction due to peanuts	ICD-10-CM	Diagnosis
T78.01XA	Anaphylactic reaction due to peanuts, initial encounter	ICD-10-CM	Diagnosis
T78.01XD	Anaphylactic reaction due to peanuts, subsequent encounter	ICD-10-CM	Diagnosis
T78.01XS	Anaphylactic reaction due to peanuts, sequela	ICD-10-CM	Diagnosis
T78.02	Anaphylactic reaction due to shellfish (crustaceans)	ICD-10-CM	Diagnosis
T78.02XA	Anaphylactic reaction due to shellfish (crustaceans), initial encounter	ICD-10-CM	Diagnosis
T78.02XD	Anaphylactic reaction due to shellfish (crustaceans), subsequent encounter	ICD-10-CM	Diagnosis
T78.02XS	Anaphylactic reaction due to shellfish (crustaceans), sequela	ICD-10-CM	Diagnosis
T78.03	Anaphylactic reaction due to other fish	ICD-10-CM	Diagnosis
T78.03XA	Anaphylactic reaction due to other fish, initial encounter	ICD-10-CM	Diagnosis
T78.03XD	Anaphylactic reaction due to other fish, subsequent encounter	ICD-10-CM	Diagnosis
T78.03XS	Anaphylactic reaction due to other fish, sequela	ICD-10-CM	Diagnosis
T78.04	Anaphylactic reaction due to fruits and vegetables	ICD-10-CM	Diagnosis
T78.04XA	Anaphylactic reaction due to fruits and vegetables, initial encounter	ICD-10-CM	Diagnosis
T78.04XD	Anaphylactic reaction due to fruits and vegetables, subsequent encounter	ICD-10-CM	Diagnosis
T78.04XS	Anaphylactic reaction due to fruits and vegetables, sequela	ICD-10-CM	Diagnosis
T78.05	Anaphylactic reaction due to tree nuts and seeds	ICD-10-CM	Diagnosis
T78.05XA	Anaphylactic reaction due to tree nuts and seeds, initial encounter	ICD-10-CM	Diagnosis
T78.05XD	Anaphylactic reaction due to tree nuts and seeds, subsequent encounter	ICD-10-CM	Diagnosis
T78.05XS	Anaphylactic reaction due to tree nuts and seeds, sequela	ICD-10-CM	Diagnosis
T78.06	Anaphylactic reaction due to food additives	ICD-10-CM	Diagnosis
T78.06XA	Anaphylactic reaction due to food additives, initial encounter	ICD-10-CM	Diagnosis
T78.06XD	Anaphylactic reaction due to food additives, subsequent encounter	ICD-10-CM	Diagnosis
T78.06XS	Anaphylactic reaction due to food additives, sequela	ICD-10-CM	Diagnosis
T78.07	Anaphylactic reaction due to milk and dairy products	ICD-10-CM	Diagnosis
T78.07XA	Anaphylactic reaction due to milk and dairy products, initial encounter	ICD-10-CM	Diagnosis
T78.07XD	Anaphylactic reaction due to milk and dairy products, subsequent encounter	ICD-10-CM	Diagnosis
T78.07XS	Anaphylactic reaction due to milk and dairy products, sequela	ICD-10-CM	Diagnosis
T78.08	Anaphylactic reaction due to eggs	ICD-10-CM	Diagnosis
T78.08XA	Anaphylactic reaction due to eggs, initial encounter	ICD-10-CM	Diagnosis
T78.08XD	Anaphylactic reaction due to eggs, subsequent encounter	ICD-10-CM	Diagnosis
T78.08XS	Anaphylactic reaction due to eggs, sequela	ICD-10-CM	Diagnosis
T78.09	Anaphylactic reaction due to other food products	ICD-10-CM	Diagnosis
T78.09XA	Anaphylactic reaction due to other food products, initial encounter	ICD-10-CM	Diagnosis
T78.09XD	Anaphylactic reaction due to other food products, subsequent encounter	ICD-10-CM	Diagnosis
T78.09XS	Anaphylactic reaction due to other food products, sequela	ICD-10-CM	Diagnosis
T78.2	Anaphylactic shock, unspecified	ICD-10-CM	Diagnosis
T78.2XXA	Anaphylactic shock, unspecified, initial encounter	ICD-10-CM	Diagnosis
T78.2XXD	Anaphylactic shock, unspecified, subsequent encounter	ICD-10-CM	Diagnosis
T78.2XXS	Anaphylactic shock, unspecified, sequela	ICD-10-CM	Diagnosis
T78.40	Allergy, unspecified	ICD-10-CM	Diagnosis

Appendix E. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Type	Code Category
T78.40XA	Allergy, unspecified, initial encounter	ICD-10-CM	Diagnosis
T78.40XD	Allergy, unspecified, subsequent encounter	ICD-10-CM	Diagnosis
T78.40XS	Allergy, unspecified, sequela	ICD-10-CM	Diagnosis
T78.49XA	Other allergy, initial encounter	ICD-10-CM	Diagnosis
T80.5	Anaphylactic reaction due to serum	ICD-10-CM	Diagnosis
T80.51	Anaphylactic reaction due to administration of blood and blood products	ICD-10-CM	Diagnosis
T80.51XA	Anaphylactic reaction due to administration of blood and blood products, initial encounter	ICD-10-CM	Diagnosis
T80.51XD	Anaphylactic reaction due to administration of blood and blood products, subsequent encounter	ICD-10-CM	Diagnosis
T80.51XS	Anaphylactic reaction due to administration of blood and blood products, sequela	ICD-10-CM	Diagnosis
T80.52	Anaphylactic reaction due to vaccination	ICD-10-CM	Diagnosis
T80.52XA	Anaphylactic reaction due to vaccination, initial encounter	ICD-10-CM	Diagnosis
T80.52XD	Anaphylactic reaction due to vaccination, subsequent encounter	ICD-10-CM	Diagnosis
T80.52XS	Anaphylactic reaction due to vaccination, sequela	ICD-10-CM	Diagnosis
T80.59	Anaphylactic reaction due to other serum	ICD-10-CM	Diagnosis
T80.59XA	Anaphylactic reaction due to other serum, initial encounter	ICD-10-CM	Diagnosis
T80.59XD	Anaphylactic reaction due to other serum, subsequent encounter	ICD-10-CM	Diagnosis
T80.59XS	Anaphylactic reaction due to other serum, sequela	ICD-10-CM	Diagnosis
T88.6	Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered	ICD-10-CM	Diagnosis
T88.6XXA	Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, initial encounter	ICD-10-CM	Diagnosis
T88.6XXD	Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, subsequent encounter	ICD-10-CM	Diagnosis
T88.6XXS	Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequela	ICD-10-CM	Diagnosis
V07.1	Need for desensitization to allergens	ICD-9-CM	Diagnosis
V13.81	Personal history of anaphylaxis	ICD-9-CM	Diagnosis
V14.0	Personal history of allergy to penicillin	ICD-9-CM	Diagnosis
V14.1	Personal history of allergy to other antibiotic agent	ICD-9-CM	Diagnosis
V14.2	Personal history of allergy to sulfonamides	ICD-9-CM	Diagnosis
V14.3	Personal history of allergy to other anti-infective agent	ICD-9-CM	Diagnosis
V14.4	Personal history of allergy to anesthetic agent	ICD-9-CM	Diagnosis
V14.5	Personal history of allergy to narcotic agent	ICD-9-CM	Diagnosis
V14.6	Personal history of allergy to analgesic agent	ICD-9-CM	Diagnosis
V14.7	Personal history of allergy to serum or vaccine	ICD-9-CM	Diagnosis
V14.8	Personal history of allergy to other specified medicinal agents	ICD-9-CM	Diagnosis
V14.9	Personal history of allergy to unspecified medicinal agent	ICD-9-CM	Diagnosis
V15.09	Personal history of other allergy, other than to medicinal agents	ICD-9-CM	Diagnosis
V72.7	Diagnostic skin and sensitization tests	ICD-9-CM	Diagnosis
Z51.6	Encounter for desensitization to allergens	ICD-10-CM	Diagnosis
Z87.892	Personal history of anaphylaxis	ICD-10-CM	Diagnosis

Code	Description	Code Type	Code Category
Z88.0	Allergy status to penicillin	ICD-10-CM	Diagnosis
Z88.1	Allergy status to other antibiotic agents status	ICD-10-CM	Diagnosis
Z88.2	Allergy status to sulfonamides status	ICD-10-CM	Diagnosis
Z88.3	Allergy status to other anti-infective agents status	ICD-10-CM	Diagnosis
Z88.4	Allergy status to anesthetic agent status	ICD-10-CM	Diagnosis
Z88.5	Allergy status to narcotic agent status	ICD-10-CM	Diagnosis
Z88.6	Allergy status to analgesic agent status	ICD-10-CM	Diagnosis
Z88.7	Allergy status to serum and vaccine status	ICD-10-CM	Diagnosis
Z88.8	Allergy status to other drugs, medicaments and biological substances status	ICD-10-CM	Diagnosis
Z88.9	Allergy status to unspecified drugs, medicaments and biological substances status	ICD-10-CM	Diagnosis
Z91.0	Allergy status, other than to drugs and biological substances	ICD-10-CM	Diagnosis
Z91.01	Food allergy status	ICD-10-CM	Diagnosis
Z91.010	Allergy to peanuts	ICD-10-CM	Diagnosis
Z91.011	Allergy to milk products	ICD-10-CM	Diagnosis
Z91.012	Allergy to eggs	ICD-10-CM	Diagnosis
Z91.013	Allergy to seafood	ICD-10-CM	Diagnosis
Z91.018	Allergy to other foods	ICD-10-CM	Diagnosis
Z91.02	Food additives allergy status	ICD-10-CM	Diagnosis
Z91.03	Insect allergy status	ICD-10-CM	Diagnosis
Z91.030	Bee allergy status	ICD-10-CM	Diagnosis
Z91.038	Other insect allergy status	ICD-10-CM	Diagnosis
Z91.04	Nonmedicinal substance allergy status	ICD-10-CM	Diagnosis
Z91.040	Latex allergy status	ICD-10-CM	Diagnosis
Z91.041	Radiographic dye allergy status	ICD-10-CM	Diagnosis
Z91.048	Other nonmedicinal substance allergy status	ICD-10-CM	Diagnosis
Z91.09	Other allergy status, other than to drugs and biological substances	ICD-10-CM	Diagnosis
	Ischemic Heart Disease		
411	Other acute and subacute forms of ischemic heart disease	ICD-9-CM	Diagnosis
411.0	Postmyocardial infarction syndrome	ICD-9-CM	Diagnosis
411.1	Intermediate coronary syndrome	ICD-9-CM	Diagnosis
411.8	Other acute and subacute forms of ischemic heart disease	ICD-9-CM	Diagnosis
411.81	Acute coronary occlusion without myocardial infarction	ICD-9-CM	Diagnosis
411.89	Other acute and subacute form of ischemic heart disease	ICD-9-CM	Diagnosis
413	Angina pectoris	ICD-9-CM	Diagnosis
413.0	Angina decubitus	ICD-9-CM	Diagnosis
413.1	Prinzmetal angina	ICD-9-CM	Diagnosis
413.9	Other and unspecified angina pectoris	ICD-9-CM	Diagnosis
414	Other forms of chronic ischemic heart disease	ICD-9-CM	Diagnosis
414.0	Coronary atherosclerosis	ICD-9-CM	Diagnosis
414.00	Coronary atherosclerosis of unspecified type of vessel, native or graft	ICD-9-CM	Diagnosis
414.01	Coronary atherosclerosis of native coronary artery	ICD-9-CM	Diagnosis
414.02	Coronary atherosclerosis of autologous vein bypass graft	ICD-9-CM	Diagnosis
414.03	Coronary atherosclerosis of nonautologous biological bypass graft	ICD-9-CM	Diagnosis

Appendix E. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Type	Code Category
414.04	Coronary atherosclerosis of artery bypass graft	ICD-9-CM	Diagnosis
414.05	Coronary atherosclerosis of unspecified type of bypass graft	ICD-9-CM	Diagnosis
414.06	Coronary atherosclerosis, of native coronary artery of transplanted heart	ICD-9-CM	Diagnosis
414.07	Coronary atherosclerosis, of bypass graft (artery) (vein) of transplanted heart	ICD-9-CM	Diagnosis
414.1	Aneurysm and dissection of heart	ICD-9-CM	Diagnosis
414.10	Aneurysm of heart	ICD-9-CM	Diagnosis
414.11	Aneurysm of coronary vessels	ICD-9-CM	Diagnosis
414.12	Dissection of coronary artery	ICD-9-CM	Diagnosis
414.19	Other aneurysm of heart	ICD-9-CM	Diagnosis
414.2	Chronic total occlusion of coronary artery	ICD-9-CM	Diagnosis
414.3	Coronary atherosclerosis due to lipid rich plaque	ICD-9-CM	Diagnosis
414.4	Coronary atherosclerosis due to calcified coronary lesion	ICD-9-CM	Diagnosis
414.8	Other specified forms of chronic ischemic heart disease	ICD-9-CM	Diagnosis
414.9	Unspecified chronic ischemic heart disease	ICD-9-CM	Diagnosis
429.2	Unspecified cardiovascular disease	ICD-9-CM	Diagnosis
429.5	Rupture of chordae tendineae	ICD-9-CM	Diagnosis
429.6	Rupture of papillary muscle	ICD-9-CM	Diagnosis
429.7	Certain sequelae of myocardial infarction, not elsewhere classified	ICD-9-CM	Diagnosis
429.71	Acquired cardiac septal defect	ICD-9-CM	Diagnosis
429.79	Other certain sequelae of myocardial infarction, not elsewhere classified	ICD-9-CM	Diagnosis
429.9	Unspecified heart disease	ICD-9-CM	Diagnosis
I20.0	Unstable angina	ICD-10-CM	Diagnosis
I20.1	Angina pectoris with documented spasm	ICD-10-CM	Diagnosis
I20.8	Other forms of angina pectoris	ICD-10-CM	Diagnosis
I20.9	Angina pectoris, unspecified	ICD-10-CM	Diagnosis
I23.0	Hemopericardium as current complication following acute myocardial	ICD-10-CM	Diagnosis
I23.1	Atrial septal defect as current complication following acute myocardial infarction	ICD-10-CM	Diagnosis
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	ICD-10-CM	Diagnosis
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	ICD-10-CM	Diagnosis
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	ICD-10-CM	Diagnosis
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	ICD-10-CM	Diagnosis
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	ICD-10-CM	Diagnosis
I23.7	Postinfarction angina	ICD-10-CM	Diagnosis
I23.8	Other current complications following acute myocardial infarction	ICD-10-CM	Diagnosis
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	ICD-10-CM	Diagnosis
I24.1	Dressler's syndrome	ICD-10-CM	Diagnosis
I24.8	Other forms of acute ischemic heart disease	ICD-10-CM	Diagnosis
I24.9	Acute ischemic heart disease, unspecified	ICD-10-CM	Diagnosis

Code	Description	Code Type	Code Category
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	ICD-10-CM	Diagnosis
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	ICD-10-CM	Diagnosis
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	ICD-10-CM	Diagnosis
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	ICD-10-CM	Diagnosis
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	ICD-10-CM	Diagnosis
I25.3	Aneurysm of heart	ICD-10-CM	Diagnosis
I25.41	Coronary artery aneurysm	ICD-10-CM	Diagnosis
I25.42	Coronary artery dissection	ICD-10-CM	Diagnosis
I25.5	Ischemic cardiomyopathy	ICD-10-CM	Diagnosis
I25.6	Silent myocardial ischemia	ICD-10-CM	Diagnosis
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	ICD-10-CM	Diagnosis
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	ICD-10-CM	Diagnosis
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	ICD-10-CM	Diagnosis
I25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	ICD-10-CM	Diagnosis
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	ICD-10-CM	Diagnosis
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	ICD-10-CM	Diagnosis
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	ICD-10-CM	Diagnosis
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	ICD-10-CM	Diagnosis
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	ICD-10-CM	Diagnosis
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	ICD-10-CM	Diagnosis
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	ICD-10-CM	Diagnosis
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	ICD-10-CM	Diagnosis
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	ICD-10-CM	Diagnosis
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	ICD-10-CM	Diagnosis

Code	Description	Code Type	Code Category
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	ICD-10-CM	Diagnosis
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	ICD-10-CM	Diagnosis
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	ICD-10-CM	Diagnosis
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	ICD-10-CM	Diagnosis
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	ICD-10-CM	Diagnosis
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	ICD-10-CM	Diagnosis
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	ICD-10-CM	Diagnosis
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	ICD-10-CM	Diagnosis
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	ICD-10-CM	Diagnosis
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	ICD-10-CM	Diagnosis
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	ICD-10-CM	Diagnosis
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	ICD-10-CM	Diagnosis
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	ICD-10-CM	Diagnosis
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	ICD-10-CM	Diagnosis
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	ICD-10-CM	Diagnosis
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	ICD-10-CM	Diagnosis
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	ICD-10-CM	Diagnosis
I25.82	Chronic total occlusion of coronary artery	ICD-10-CM	Diagnosis
I25.83	Coronary atherosclerosis due to lipid rich plaque	ICD-10-CM	Diagnosis
I25.84	Coronary atherosclerosis due to calcified coronary lesion	ICD-10-CM	Diagnosis
I25.89	Other forms of chronic ischemic heart disease	ICD-10-CM	Diagnosis
I25.9	Chronic ischemic heart disease, unspecified	ICD-10-CM	Diagnosis
I51.0	Cardiac septal defect, acquired	ICD-10-CM	Diagnosis
I51.1	Rupture of chordae tendineae, not elsewhere classified	ICD-10-CM	Diagnosis
I51.2	Rupture of papillary muscle, not elsewhere classified	ICD-10-CM	Diagnosis
I51.9	Heart disease, unspecified	ICD-10-CM	Diagnosis
I52	Other heart disorders in diseases classified elsewhere	ICD-10-CM	Diagnosis

Code	Description	Code Type	Code Category
G8033	Prior myocardial infarction, coronary artery disease patient documented to be on beta-blocker therapy	HCPCS	Procedure
G8034	Prior myocardial infarction, coronary artery disease patient not documented to be on beta-blocker therapy	HCPCS	Procedure
G8035	Clinician documented that prior myocardial infarction, coronary artery disease patient was not eligible candidate for beta-blocker therapy measure	HCPCS	Procedure
G8036	Coronary artery disease patient documented to be on antiplatelet therapy	HCPCS	Procedure
G8037	Coronary artery disease patient not documented to be on antiplatelet therapy	HCPCS	Procedure
G8038	Clinician documented that coronary artery disease patient was not eligible candidate for antiplatelet therapy measure	HCPCS	Procedure
G8039	Coronary artery disease patient with low-density lipoprotein documented to be greater than 100 mg/dl	HCPCS	Procedure
G8040	Coronary artery disease patient with low-density lipoprotein documented to be less than or equal to 100 mg/dl	HCPCS	Procedure
G8041	Clinician documented that coronary artery disease patient was not eligible candidate for low-density lipoprotein measure	HCPCS	Procedure
	Renal Disorders		
584	Acute kidney failure	ICD-9-CM	Diagnosis
584.5	Acute kidney failure with lesion of tubular necrosis	ICD-9-CM	Diagnosis
584.6	Acute kidney failure with lesion of renal cortical necrosis	ICD-9-CM	Diagnosis
584.7	Acute kidney failure with lesion of medullary [papillary] necrosis	ICD-9-CM	Diagnosis
584.8	Acute kidney failure with other specified pathological lesion in kidney	ICD-9-CM	Diagnosis
584.9	Acute kidney failure, unspecified	ICD-9-CM	Diagnosis
585	Chronic kidney disease (CKD)	ICD-9-CM	Diagnosis
585.1	Chronic kidney disease, Stage I	ICD-9-CM	Diagnosis
585.2	Chronic kidney disease, Stage II (mild)	ICD-9-CM	Diagnosis
585.3	Chronic kidney disease, Stage III (moderate)	ICD-9-CM	Diagnosis
585.4	Chronic kidney disease, Stage IV (severe)	ICD-9-CM	Diagnosis
585.5	Chronic kidney disease, Stage V	ICD-9-CM	Diagnosis
585.6	End stage renal disease	ICD-9-CM	Diagnosis
585.9	Chronic kidney disease, unspecified	ICD-9-CM	Diagnosis
586	Unspecified renal failure	ICD-9-CM	Diagnosis
587	Unspecified renal sclerosis	ICD-9-CM	Diagnosis
N17.0	Acute kidney failure with tubular necrosis	ICD-10-CM	Diagnosis
N17.1	Acute kidney failure with acute cortical necrosis	ICD-10-CM	Diagnosis
N17.2	Acute kidney failure with medullary necrosis	ICD-10-CM	Diagnosis
N17.8	Other acute kidney failure	ICD-10-CM	Diagnosis
N17.9	Acute kidney failure, unspecified	ICD-10-CM	Diagnosis
N18.1	Chronic kidney disease, stage 1	ICD-10-CM	Diagnosis
N18.2	Chronic kidney disease, stage 2 (mild)	ICD-10-CM	Diagnosis
N18.3	Chronic kidney disease, stage 3 (moderate)	ICD-10-CM	Diagnosis
N18.4	Chronic kidney disease, stage 4 (severe)	ICD-10-CM	Diagnosis
N18.5	Chronic kidney disease, stage 5	ICD-10-CM	Diagnosis

Appendix E. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes, and Healthcare Common Procedure Coding System (HCPCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Type	Code Category
N18.6	End stage renal disease	ICD-10-CM	Diagnosis
N18.9	Chronic kidney disease, unspecified	ICD-10-CM	Diagnosis
N19	Unspecified kidney failure	ICD-10-CM	Diagnosis
N26.1	Atrophy of kidney (terminal)	ICD-10-CM	Diagnosis
N26.9	Renal sclerosis, unspecified	ICD-10-CM	Diagnosis

Appendix F. Specifications Defining Parameters for this Request

This request executed the Cohort Identification and Descriptive Analysis tool, version 9.2.1, to assess utilization of sacubitril/valsartan (SV), angiotensin II receptor blockers (ARB), and angiotensin-converting enzyme inhibitors (ACEI).

Index start date[1]: January 1, 2015
Index end date: Earliest of follow-up end date or data completeness date
Follow-up End Date: September 30, 2019
Coverage requirement: Medical & Drug
Pre-index enrollment requirement: 183 days
Enrollment gap: 45 days
Age groups: 18-44, 45-54, 55-64, 65+ years
Stratifications: Age group, race, sex, year, year-month
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Data Partners: Same data version as cder_mpl1p_wp036

		Episode Parameters					Exclusion			Exclusion			Inclusion	
	Multiple Events Episode	Index Exposure	Cohort Definition	Washout Period	Episode Gap	Defined Episode Length	Criteria	Evidence Required	Evaluation Period	Criteria	Evidence Required	Evaluation Period	Criteria	Evaluation Period
1	**Primary**	ACEI	Retain all valid episodes	0 days	14 days	N/A	Sacubitril/ valsartan	Dispensing date or days supply	-183 to 0	ACEI, ARB	Dispensing date or days supply	-183 to -1	Heart failure	-183 to 0
2	**Primary**	ARB	Retain all valid episodes	0 days	14 days	N/A	Sacubitril/ valsartan	Dispensing date or days supply	-183 to 0	ACEI, ARB	Dispensing date or days supply	-183 to -1	Heart failure	-183 to 0
3	**Primary**	ACEI	Retain all valid episodes	0 days	14 days	N/A	--	--	--	ACEI, ARB	Dispensing date or days supply	-183 to -1	Heart failure	-183 to 0
4	**Primary**	ARB	Retain all valid episodes	0 days	14 days	N/A	--	--	--	ACEI, ARB	Dispensing date or days supply	-183 to -1	Heart failure	-183 to 0
5	**Primary**	ACEI	Retain all valid episodes	0 days	14 days	N/A	--	--	--	--	--	--	Heart failure	-183 to 0

Appendix F. Specifications Defining Parameters for this Request

This request executed the Cohort Identification and Descriptive Analysis tool, version 9.2.1, to assess utilization of sacubitril/valsartan (SV), angiotensin II receptor blockers (ARB), and angiotensin-converting enzyme inhibitors (ACEI).

		Episode Parameters					Exclusion			Exclusion			Inclusion	
	Multiple Events Episode	Index Exposure	Cohort Definition	Washout Period	Episode Gap	Defined Episode Length	Criteria	Evidence Required	Evaluation Period	Criteria	Evidence Required	Evaluation Period	Criteria	Evaluation Period
6	**Primary**	ARB	Retain all valid episodes	0 days	14 days	N/A	--	--	--	--	--	--	Heart failure	-183 to 0
7	**Primary**	Sacubitril/ valsartan	Retain all valid episodes	0 days	14 days	N/A	--	--	--	ACEI	Dispensing date	Index date	Heart failure	-183 to 0
8	**Primary**	Sacubitril/ valsartan	Retain all valid episodes	0 days	14 days	N/A	--	--	--	ARB	Dispensing date	Index date	Heart failure	-183 to 0
9	**Primary**	Sacubitril/ valsartan	Retain all valid episodes	0 days	14 days	N/A	--	--	--	--	--	--	Heart failure	-183 to 0
10	**Primary**	Sacubitril/ valsartan	Retain all valid episodes	0 days	14 days	N/A	--	--	--	Sacubitril/ valsartan, ARB, ACEI	Dispensing date or days supply	-183 to -1	Heart failure	-183 to 0
11	**Primary**	Sacubitril/ valsartan	Retain all valid episodes	0 days	14 days	N/A	ACEI	Dispensing date or days supply	-183 to 0	Sacubitril/ valsartan, ARB	Dispensing date or days supply	-183 to -1	Heart failure	-183 to 0
12	**Primary**	Sacubitril/ valsartan	Retain all valid episodes	0 days	14 days	N/A	ARB	Dispensing date or days supply	-183 to 0	Sacubitril/ valsartan, ACEI	Dispensing date or days supply	-183 to -1	Heart failure	-183 to 0
13	**Primary**	Sacubitril/ valsartan	Retain all valid episodes	0 days	14 days	N/A	Sacubitril/ valsartan	Dispensing date or days supply	-183 to -1	ACEI	Dispensing date	Index date	Heart failure	-183 to 0
14	**Primary**	Sacubitril/ valsartan	Retain all valid episodes	0 days	14 days	N/A	Sacubitril/ valsartan	Dispensing date or days supply	-183 to -1	ARB	Dispensing date	Index date	Heart failure	-183 to 0

Appendix F. Specifications Defining Parameters for this Request

This request executed the Cohort Identification and Descriptive Analysis tool, version 9.2.1, to assess utilization of sacubitril/valsartan (SV), angiotensin II receptor blockers (ARB), and angiotensin-converting enzyme inhibitors (ACEI).

		Episode Parameters					Exclusion			Exclusion			Inclusion	
	Multiple Events Episode	Index Exposure	Cohort Definition	Washout Period	Episode Gap	Defined Episode Length	Criteria	Evidence Required	Evaluation Period	Criteria	Evidence Required	Evaluation Period	Criteria	Evaluation Period
15	**Secondary**	ACEI	Retain all valid episodes	0 days	N/A	1 day	--	--	--	--	--	--	--	--
16	**Secondary**	ARB	Retain all valid episodes	0 days	N/A	1 day	--	--	--	--	--	--	--	--

[1] Index start date identifies the date on which patients may begin contribute eligible index exposures. Data prior to the index start date may be used to determine enrollment, washout, and other cohort inclusion criteria.

"--" represent missing information.

International Classification of Diseases, Ninth and Tenth Revisions, Clinical Modification, Healthcare Common Procedure Coding System, and Current Procedural Terminology codes are provided by Optum360. National Drug Codes are checked against First Data Bank's "National Drug Data File (NDDF®) Plus."

Appendix F. Specifications Defining Parameters for this Request

This request executed the Cohort Identification and Descriptive Analysis tool, version 9.2.1, to assess utilization of sacubitril/valsartan (SV), angiotensin II receptor blockers (ARB), and angiotensin-converting enzyme inhibitors (ACEI).

Index start date[1]: 01/01/2015
Index end date: Earliest of follow-up end date or data completeness date
Follow-up End Date: 09/30/2019
Coverage requirement: Medical & Drug
Pre-index enrollment requirement: 183 days
Enrollment gap: 45 days
Age groups: 18-44, 45-54, 55-64, 65+
Stratifications: Age group, race, sex, year, year-month
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Data Partners: Same data version as cder_mpl1p_wp036

		Inclusion			Multiple Events Assessment			Multiple Events Assessment		
	Multiple Events Episode	Criteria	Evidence Required	Evaluation Period	Secondary Episode	Observation Anchor	Observation Window	Secondary Episode	Observation Anchor	Observation Window
1	**Primary**	--	--	--	--	--	--	--	--	--
2	**Primary**	--	--	--	--	--	--	--	--	--
3	**Primary**	--	--	--	--	--	--	--	--	--
4	**Primary**	--	--	--	--	--	--	--	--	--
5	**Primary**	--	--	--	--	--	--	--	--	--

Appendix F. Specifications Defining Parameters for this Request

This request executed the Cohort Identification and Descriptive Analysis tool, version 9.2.1, to assess utilization of sacubitril/valsartan (SV), angiotensin II receptor blockers (ARB), and angiotensin-converting enzyme inhibitors (ACEI).

		Inclusion			Multiple Events Assessment			Multiple Events Assessment		
	Multiple Events Episode	Criteria	Evidence Required	Evaluation Period	Secondary Episode	Observation Anchor	Observation Window	Secondary Episode	Observation Anchor	Observation Window
6	**Primary**	--	--	--	--	--	--	--	--	--
7	**Primary**	ACEI	Dispensing date or days supply	-183 to -1	ACEI	Primary episode index date	-183 to -1	ARB	Primary episode index date	-183 to -1
8	**Primary**	ARB	Dispensing date or days supply	-183 to -1	ACEI	Primary episode index date	-183 to -1	ARB	Primary episode index date	-183 to -1
9	**Primary**	--	--	--	ACEI	Primary episode index date	-183 to -1	ARB	Primary episode index date	-183 to -1
10	**Primary**	--	--	--	--	--	--	--	--	--
11	**Primary**	--	--	--	--	--	--	--	--	--
12	**Primary**	--	--	--	--	--	--	--	--	--
13	**Primary**	ACEI	Dispensing date or days supply	-183 to -1	ACEI	Primary episode index date	-183 to -1	ARB	Primary episode index date	-183 to -1
14	**Primary**	ARB	Dispensing date or days supply	-183 to -1	ACEI	Primary episode index date	-183 to -1	ARB	Primary episode index date	-183 to -1

Appendix F. Specifications Defining Parameters for this Request

This request executed the Cohort Identification and Descriptive Analysis tool, version 9.2.1, to assess utilization of sacubitril/valsartan (SV), angiotensin II receptor blockers (ARB), and angiotensin-converting enzyme inhibitors (ACEI).

		Inclusion			Multiple Events Assessment			Multiple Events Assessment		
	Multiple Events Episode	Criteria	Evidence Required	Evaluation Period	Secondary Episode	Observation Anchor	Observation Window	Secondary Episode	Observation Anchor	Observation Window
15	**Secondary**	--	--	--	N/A	N/A	N/A	N/A	N/A	N/A
16	**Secondary**	--	--	--	N/A	N/A	N/A	N/A	N/A	N/A

[1] Index start date identifies the date on which patients may begin contribute eligible index exposures. Data prior to the index start date may be used to determine enrollment, washout, and other cohort inclusion criteria.

"--" represent missing information.

International Classification of Diseases, Ninth and Tenth Revisions, Clinical Modification, Healthcare Common Procedure Coding System, and Current Procedural Terminology codes are provided by Optum360. National Drug Codes are checked against First Data Bank's "National Drug Data File (NDDF®) Plus."